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γ-gamma 
g – gram(s) 
GC – gas chromatography 
GCMS – gas chromatography-mass spectrometry 
h – hour(s) 
hex. - hexane 
15 
 
HPLC – high performance liquid chromatography 
HRMS – high resolution mass spectrometry 
HSQC – heteronuclear single quantum correlation 
Hz – hertz 
i – iso 
IPA – isopropyl alcohol 
IR – infrared spectroscopy 
J – coupling constant 
KI- potassium iodide 
L/Ln/Ln – ligand 
LiHMDs- lithium hexamethyldisilazide 
m – multiplet or meta 
μ – micro 
M – metal  
mAU – milli arbitrary units 
Me – methyl 
MHz – megahertz 
min. – minute(s) 
mAU – milli arbitrary units 
mL – milliliter(s) 
μL – microliter(s) 
μm – micrometer(s) 
mm – millimeter(s) 
mmol – millimole(s) 
mol – mole(s) or molar 
m.p. – melting point 
MS – mass spectrometry 
m/z – mass to charge ratio 
M – multiplet 
MW – molecular weight 
m/z – mass to charge ratio 
n- number of unints 
n.d. – not determined 
nm – nanometer 
NMR – nuclear magnetic resonance 
Nu / Nu- – nucleophile (neutral / anionic) 
N-xantphos – 4,6-bis(diphenylphosphino)-10H-phenoxazine  
o – ortho 
OMe – methoxy 
p – para 
Pd G2 – Buchwald’s second generation  palladium (II) precatalysts 
Pd G3- Buchwald’s third generation palladium (II) precatalysts 
Ph – phenyl 
pKa = acid dissociation constant 
PPh3 triphenylphosphine 
ppm – parts per million 
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Pr – propyl 
psi – pounds per square inch  
Pyox – pyridine-oxazoline 
q – quartet 
Quinox - 2-(4,5-dihydro-2-oxazolyl)quinoline 
R – alkyl group 
R- rectus 
rac - racemic 
Rf – retention factor 
r.t. – room temperature 
rxn - reaction 
s – singlet or secondary 
S- solvent 
t – tert 
t – triplet 
td – triplet of doublets 
OTf – triflate (trifluoromethanesulfonate) 
TFA- trifluoroacetic acid 
THF – tetrahydrofuran 
TLC – thin layer chromatography 
TMS – tetramethylsilane 
tR – retention time 
UV – ultra violet 
vacuo – vacuum via rotary evaporation and rotary vane pump 
v/v – volume per volume  
VWD – variable wavelength detector 
X / X-– halide or pseudohalide / halide or pseudohalide anion 
Xantphos – 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 






 Palladium catalysis is a common synthetic tool utilized by organic chemists to create 
carbon-carbon bonds. We utilized palladium to catalyze the γ-arylation of α, β-unsaturated 
ketones, and esters. This work expands on palladium-catalyzed α-arylation chemistry and 
extends it to the vinylogous variation at the γ-position. We report the regioselective synthesis of 
mono-γ-arylated 7-methoxy-4-methylcoumarin. We also report efforts towards applying our 
reaction conditions to other α,β-unsaturated ketones and esters to expand the scope of our 
reaction conditions.  
In addition, we utilized palladium to catalyze the enantioselective asymmetric 
intramolecular Mizoroki-Heck reaction to produce potentially bioactive phenanthridinone 
analogs. We achieve this through the Birch-Heck sequence, a 4-step sequence that includes Birch 
reduction/alkylation of benzoic acid, acid chloride formation/amide formation, triflation, and 
then the enantioselective Mizoroki-Heck reaction.  In this process, we report N-H and N-Me 
phenanthridinone analogs' synthesis. A protection/deprotection protocol was found to be the key 
to accessing phenanthridinone derivatives with N-H.  
Besides palladium catalysis, we also explored conducting the enantioselective Mizoroki-
Heck reaction with nickel. Nickel catalysis is a relatively new research area that has recently 
demonstrated success with the enantioselective intramolecular Mizoroki-Heck reaction under 
mild conditions with high yields and ee values. We proposed that we may access a pathway that 
could increase our enantioselectivity under relatively mild conditions by using nickel. We report 
efforts to optimize the nickel catalyzed Heck reaction to minimize side products and to improve 
the yield of the desired 1,3-diene. In the synthesis of phenanthridinone analogs, we have 
demonstrated that the Birch-Heck sequence is a simple way of synthesizing chiral 
phenanthridinone derivatives with quaternary centers.  
In total, three areas of transition metal-catalyzed reactions were explored. This involved 
cross-coupling between enolates and aryl halides and between aryl halides and alkenes. 
Strategies for enantioselective synthesis were developed, and potentially bioactive 
phenanthridinone structures were constructed. Finally, the cross-coupling studies looked at both 












Background and Introduction 
Around 1700, miners in Brazil had found a metal that was an alloy of gold and palladium, 
which they named “ouro podre” or worthless gold. It was not until 1803 that palladium was 
isolated when William Wollaston discovered an impurity during platinum purification. He called 
his newly found metal “palladium” after the recently discovered asteroid, “Pallas,” named after 
the Goddess of Wisdom. Wollaston announced palladium’s properties; however, he did not 
reveal the refining process until right before his death because of its potential commercial value. 
Palladium was not desirable on the market until the 1930’s when a German company developed 
and patented uses of alloys of palladium with gold or silver for use in dentistry. Since then, 
palladium has become an essential tool for chemists to synthesize compounds and has become a 
staple in forming carbon-carbon bonds.1 
There are two types of carbon-carbon bond formations presented in this dissertation: an 
enolate/aryl halide coupling using a palladium precatalyst and an aryl halide/alkene coupling 
using palladium and a chiral ligand. In both cases, a variety of substrates and reaction conditions 
were explored to develop new, more efficient procedures to construct valuable complex 
molecular architectures.  
1.1 Palladium as a precatalyst 
Organic/organometallic chemists commonly use palladium-catalyzed cross-coupling 
reactions to quickly piece together two different molecules that would otherwise not combine. 
For these reactions, palladium is in its 0 or +2 oxidation state, its most active forms.3 Palladium 
precatalysts have been created to make the use of palladium even more convenient and efficient 
by storing palladium in its more stable state (Pd(II)) with the desired ligand coordinated. These 
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precatalysts are typically a reductive elimination away from being active as Pd(0) in catalytic 
cycles. Bruno, Tudge, and Buchwald have created a third generation of phosphine-ligated 
palladium precatalysts based upon a 2-aminobiphenyl scaffold. Scheme 1 shows the differences 
in generation two (G2) and generation three (G3) scaffolds.  In the G2 precatalyst, monodentate 
ligands (L in Scheme 1) are used since there are no empty coordination sites for a bidentate ligand 
to bind due to chlorine being bound to palladium. The G3 scaffold contains a weakly associated 
mesylate group, which creates a cationic complex leaving two vacant coordination sites available 
for bidentate ligand binding. The G3 precatalyst can be prepared from a broader range of 
phosphine ligands due to the two vacant coordination sites.2  In addition, exchanging chloride for 
mesylate improves solution stability. These catalysts are easy to synthesize, activate quickly 
under mild conditions, and can lead to high yields. The palladium precatalysts used in the 
research presented are xantphos G3 and N-xantphos G3. These catalysts were readily available in 















1.2 γ-Arylation  
During my time in the Schmink Lab, we were initially investigating α-arylation chemistry 
and desired to expand our investigations to arylation of the vinylogous γ-position to illustrate 
new applications.3–7  Over the past two decades, α-arylation chemistry has been extensively 
studied and analyzed.8–12 Recent research has shifted to the investigation of γ-arylation of 
enolates due to the challenges of obtaining regioselective arylation at the γ-position: avoiding 
polyarylation products; avoiding α-arylation; preventing β-arylation via Heck reaction; and 
minimizing condensation side products.13 α,β-Unsaturated ketones and esters are challenging to 
selectively mono-γ-arylate due to the dienolate intermediate as shown in Scheme 2, which can 
lead to multiple unwanted side products from two different nucleophilic carbons formed by 
deprotonation of the γ-position. Compared to α-arylation, up to five different products may be 















Scheme 2: Challenges of α-arylation compared to the challenges of γ-arylation 
In contrast, the alkylation of α,β-unsaturated ketone and ester enolates has been 
thoroughly studied and analyzed. In the past, regioselectivity for the -position was controlled by 
using various metals such as copper3,4 and tin.5 For example, Yamamoto and coworkers cross-
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coupled tin dienolates, using palladium, at the γ-position with aryl bromides. A significant 
drawback to using tin dienolates is their limited availability and the toxicity of tin.6,7   
An important discovery was made by Terao and coworkers in 1998 when they utilized 
palladium and aryl bromides to selectively γ-arylate α,β-unsaturated ketones, and aldehydes.14 
Their procedure eliminated the use of toxic metals and expanded the scope of the reaction due to 
widely available aryl bromides and α,β-unsaturated ketones and aldehydes. This lead to a surge 
of papers from 2005 to 2021 being published on utilizing palladium for γ-arylation, which 













Scheme 3: γ-arylation examples from 1998 to this work 
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Expanding on the various examples of γ-arylated species as shown in Scheme 3, we 
began our study to mono-γ-arylate 7-methoxy-4-methylcoumarin. Coumarins are well known for 
their antibiotic, antifungal, anti-inflammatory, and antiviral activities.19 More specifically, 4-
benzyl-7-methoxycoumarin has been reported by Stefanachi and coworkers to inhibit CYP19, 
(AR) a key enzyme in the biosynthesis of estrogens that would potentially limit or block 
pathological activity in ER+ cancer. In addition, it has been found to inhibit CYP17, which is a 
cytochrome P450-dependent enzyme that is involved in the development of prostatic cancer.20 
Coumarins have also been utilized as additives in food and cosmetics to prepare optical 
brighteners, dispersed fluorescent, and laser dyes.19 Chemically the α,β – unsaturated lactone 
allows for interesting reactivity due to increased acidity of the protons at the α- and γ- positions, 
which can lead to further functionalization. The vast array of applications for these types of 
compounds make them valuable structures.  
γ-Arylation should be favorable with 7-methoxy-4-methyl coumarin due to the protons in 
the γ-position being the most acidic and sterically unhindered. Resonance within the α,β-
unsaturated ester promotes arylation at either the α- or γ-position, which can make it challenging 
to achieve mono-arylation at the desired position. Literature precedents have examples of metal-
catalyzed approaches to γ-arylate coumarins; however, these approaches utilized Suzuki-Miyaura 
and Negishi cross-coupling approaches.21–24 To the best of our knowledge, the synthesis depicted 
in our article “Palladium-catalyzed mono-γ-arylation of 7-methoxy-4-methylcoumarin” was the 
first report of an enolate arylation approach to γ-arylate coumarins.25 
The catalytic cycle for the γ-arylation of 7-methoxy-4-methylcoumarin, the process 
developed in our research, is shown in Scheme 4. First, the aryl bromide oxidatively adds to the 
palladium. Next, 7-methoxy-4-methylcoumarin is deprotonated at the γ-position and exchanges 
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with bromine on palladium. Finally, reductive elimination occurs to produce the desired product. 
This generalized procedure follows a similar catalytic cycle for the γ-arylation of α,β-unsaturated 











Scheme 4: Mechanism of γ-arylation 
Application of our reaction conditions to other various α,β-unsaturated ketones and esters 
was the next logical step to ensure that our reaction conditions were not just specific to 7-
methoxy-4-methylcoumarin. Some of the compounds we tried were isophorone, 3-methyl-2-
cyclohexen-1-one, ethyl crotonate, 1-acetyl-1-cyclohexane, and methyl-1-cyclohexene-1-
carboxylate. 
 Isophorone was chosen as an example of an α,β-unsaturated ketone due to its importance 
in industry and medicinal chemistry.26  Shown in Scheme 5 are some examples of derivatives of 
isophorone and their potential uses. A vast array of possible transformations highlights their 







Scheme 5: Isophorone derivatives and their potential applications27 
Terao et al. had attempted γ-arylation of isophorone as well as 3-methyl-2-cyclohexen-1-
one (Scheme 6-A).14 However, they could not avoid polyarylation using their reaction conditions 
even though it was minimal, 6-8%. We hoped to improve upon their work by preventing 
polyarylation using our reaction conditions from Chapter 2 for both isophorone and 3-methyl-2-
cyclohexen-1-one. Unfortunately, the research presented in this dissertation never achieved total 
conversion to the desired mono-arylated product; however, a recent article published in 2020 by 
Yuen and So achieved complete conversion in their study of controlling α- and γ-arylation 
through ligand control (Scheme 6-B).27 Their impressive research used less reactive aryl 
chlorides to make isophorone derivatives in good to excellent yields (63-90%).  
 Hyde and Buchwald reported on the palladium-catalyzed γ-arylation of 4‐
methylcyclohex‐2‐en‐1‐one (Scheme 6-C).16  In addition to achieving mono-γ-arylation, they 
were able to synthesize ketoindolines in one pot by using ortho‐bromoaniline derivatives. The 
ability to create cyclohexanone-fused indolines in one step was novel. These types of 
heterocycles are precursors in the synthesis of some of the Aspidosperma alkaloids, including 
vindoline28–32, aspidophytine33, and the “Büchi ketone” intermediate.34 We report our attempts at 



















Scheme 6: Examples of γ-arylation of isophorone and 3-methyl-2-cyclohexen-1-one.  
In 2010, Huang and Hartwig published the palladium-catalyzed γ‐arylation of α,β‐
unsaturated esters from silyl ketene acetals (Scheme 6-D). Their successful reactions prompted 
us to test ethyl crotonate using our reaction conditions. Ethyl (E)-4-phenylbut-2-enoate has been 
synthesized by a variety of different reactions35–42; however, enolate arylation of the γ-position 
has not been achieved to our knowledge.43 Regarding the utility of ethyl (E)-4-phenylbut-2-
enoate, it is a precursor to bestatin hydrochloride, an anticancer agent44, it is a precursor to 1,3-
diaminoalcohol, an amprenavir intermediate, which is a therapeutic agent for the treatment of 
26 
 
HIV infection45, and it is a precursor to a syn-4-hydroxy-5-phenyl-γ-lactam, which is an 









Scheme 7: Ethyl (E)-4-phenylbut-2-enoate as a precursor42 
1-Acetyl-1-cyclohexane and methyl-1-cyclohexene-1-carboxylate do not have any 
examples of γ-arylation to our knowledge.54,55 1-Acetyl-1-cyclohexane was used to prove that if 
α̍-protons and γ-protons were available for deprotonation, then α-arylation would be preferred 
due to the increased acidity of the protons in the α-position as well as the position being 
sterically unhindered. We also decided to analyze methyl-1-cyclohexene-1-carboxylate, an α,β-
unsaturated ester with a similar structure to 1-acetyl-1-cyclohexane. The γ-position should have 
the most acidic protons in this case, with no α-protons available.  
Our work on the γ-arylation of 7-methoxy-4-methylcoumarin was published in 2019.25 
The rest of the compounds described were investigated to expand the scope of our reaction 
conditions to other α,β-unsaturated ketones and esters and to improve upon the results of certain 




1.3 Enantioselective synthesis of phenanthridinone analogs with quaternary carbons using 
the Birch-Heck Sequence 
 Due to challenges with expanding the scope of our reaction conditions to other α,β-
unsaturated carbonyl compounds and lack of funding on the γ-arylation project, our focus 
switched to the synthesis of chiral phenanthridinone analogs using the enantioselective 
intramolecular Mizoroki-Heck reaction. Creating chiral bioactive compounds, improving 
enantioselectivity, and synthesizing chiral phenanthridinone analogs from secondary and tertiary 
benzamides were the main goals of this research. 
Phenanthridinone is an example of a flat structure with a rich history of bioactivity. They 
have been utilized as a critical scaffold in inhibitors of poly ADP ribose polymerase (PARP) and 
tankyrase56–59, which are targets in the treatment of cancer. In addition, phenanthridinone analogs 
were the top inhibitor of DNA topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 
(TDP1), which are also targets in the treatment of cancer. Inhibition of ADP ribosyltransferase in 
the anthrax-like toxin Bacillus cereus prompts phenanthridinone’s use as an antibacterial.60,61 
Due to their effectiveness as progesterone receptor antagonists, phenanthridinone analogs can be 
used as contraceptive agents, abortifacients, and in the treatment of hormone-dependent cancers 
and endometriosis.62 Bioactivity has also been shown for N-substituted tertiary benzamides.63–65 
This information makes our research all the more valuable since we have provided access to 
chiral phenathridinone derivatives from secondary and tertiary benzamides.66–73 
Unfortunately, the broad range of phenanthridinone bioactivity undermines therapeutic 
selectivity and success in clinical settings.56–58 Lovering and coworkers in their analysis of drug 
development candidates since 1980, found that most natural compounds and synthetically made 
drugs that became successful therapeutics had three-dimensional structures and higher 
proportions of sp3 centers and chiral carbons.74,75 Unfortunately, it is fairly challenging to 
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synthesize these compounds.  Indeed, the three most commonly used medicinal chemists’ 
reactions are amide bond formations, the Suzuki-Miyaura reaction, and nucleophilic aromatic 
substitution, which all synthesize flat sp2 structures.76 Synthetic chemist’s affinity for these 
reactions is due primarily to their efficiency and generalizability, but as sp2 focused 
methodologies, they have likely contributed to the creation of structurally limited compound 
libraries with flat molecular structures. These flat structures have low aqueous solubility, can 
engage in more promiscuous binding behavior, and often do not completely fill the space in 
binding pockets, which decreases their binding energy and potency.77 Non-planar molecules are 
more soluble and have the potential to improve the interaction between the drug and the target 
protein, allowing for more potency and selectivity.74,75,77  
A Scifinder search conducted in 2021 failed to show any closely related quaternary 
carbon analogs of phenanthridinone. Considering Lovering and coworker’s data on sp3 carbon 
centers and the lack of quaternary phenanthridinone analogs, several projects have been explored 
to fill those gaps. Most importantly, we report use of the Birch-Heck sequence (Scheme 13), 
which stems from our past published work on the Birch reduction-alkylation along with the 
Mizoroki-Heck reaction78, to synthesize chiral phenanthridinone analogs. Three different 
projects will be discussed using the Birch-Heck sequence: (1) synthesizing chiral quaternary 
phenanthridinone analogs using palladium as the catalyst; (2) providing a pathway to the 
secondary benzamide phenanthridinone derivates; and (3) optimization of a nickel catalyst, 
instead of palladium, for the enantioselective intramolecular Heck reaction. All have utilized the 
same four steps: (1) the Birch reduction-alkylation to install the quaternary carbon center; (2) an 
amide formation reaction; (3) a triflation procedure for the phenol derivatives; and (4) the 
29 
 
enantioselective intramolecular Mizoroki-Heck reaction to close the ring setting the 
configuration of the all-carbon quaternary stereocenter.  
This process has been proven to rapidly access quaternary phenanthridinone analogs in 
the research reported. The compounds created could lead to more discriminant binding to 
produce more potent drugs with fewer side effects due to the greater three-dimensional 










Scheme 8: Development of the phenanthridinone Birch-Heck sequence 
 
1.3.1 Birch reduction – alkylation  
One of the critical reactions, as well as the first step, in our sequence is the Birch-
reduction-alkylation, which installs the all-important quaternary center quickly and works well to 
produce alkylated products in high yields with a wide variety of alkyl R-groups. This reaction 
was discovered in 1944 by Arthur Birch and involves reducing aromatic systems by dissolving 
metals (Li, Na or K) in liquid ammonia to form 1,4-diene anions.79 In the final step of the 
reaction with electron-deficient benzene derivatives, the enolate anion intermediate is quenched 







Scheme 9: Generalized Birch reduction-alkylation reaction 
1.3.2 Mizoroki-Heck Reaction 
The second crucial reaction in our sequence is the Mizoroki-Heck reaction. In 1971, 
Mizoroki and coworkers initially reported this reaction in their discussion of the arylation of 
olefin with aryl iodide, which is catalyzed by palladium.82 This reaction was later improved by 
Heck and Nolley in 1972.  Palladium catalyzes a cross-coupling reaction in which an aryl or 
vinyl halide or pseudohalide is coupled with an olefin, Scheme 9.  
 
 
Scheme 10: Mizoroki-Heck general reaction scheme 
Since 1971, Mizoroki-Heck reactions have demonstrated success using intermolecular 
and intramolecular processes. Shibasaki and Overman independently reported the first examples 
of intramolecular asymmetric Heck reactions in 1989.83,84 Shibasaki and coworkers reported the 
asymmetric synthesis of cis-decalin derivatives by palladium-catalyzed cyclization of prochiral 
alkenyl iodides, Scheme 10-A. Their work utilized BINAP, one of the most generally reliable 
and effective ligands for asymmetric Heck reactions, which provided the best 
enantioselectivity.85 Shibasaki and coworkers’ research demonstrated for the first time that an 
intramolecular Heck reaction could be used for enantioselective construction of tertiary carbon 
stereocenters, although their enantioselectivities were low. Overman and coworkers reported the 
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asymmetric Heck cyclization for the direct formation of a quaternary carbon stereocenter in 
1989.84 They synthesized spirotricyclic dienones by palladium-catalyzed cyclizations of enol 
triflate derivatives of 2-dienyl-1,3-cyclohexanediones, Scheme 10-B. Unfortunately, their 
enantioselectivities were also low. Since 1989, the enantioselective asymmetric Mizoroki-Heck 
reaction has been improved to yield products with enantioselectivities up to 99%. In 1992, 
Shibasaki, Sato, and Watanabe improved the ee of previously analyzed cis-decalin derivatives to 
91% when they used an alkenyl triflate instead of an alkenyl iodide to promote a cationic Heck 
mechanism, Scheme 10-A.86 This swap also allowed for the omission of expensive silver salts 
and the use of hydrocarbon solvents such as toluene or benzene. Shibasaki and worker’s studies 
in 1992 claimed that acetate, from Pd(OAc)2, was replacing the dissociated Pd-I inhibiting the 
cationic pathway, which led to low ee values. Using the alkenyl triflate in 1992, eliminated this 
deleterious effect from Pd(OAc)2 and promoted a cationic Heck mechanism, which was 
determined to contribute to the improved enantioselectivity. 
Continuing the development of the asymmetric intramolecular Heck reaction, Ozeki and 
coworkers in 2013 reported on the first asymmetric total synthesis of (+)-taiwaniaquinol D and 
(−)-taiwaniaquinone D by using an intramolecular Heck reaction in a key step (Scheme 10-C).87 
In 2015, Shen and coworkers reported on the enantioselective arylative dearomatization of 
indoles using palladium-catalyzed intramolecular reductive Heck reactions (Scheme 10-D).88 In 
2016, Joshi and Pigge reported on the asymmetric construction of 3,3-disubstituted oxindoles 
and isoindolinones, which demonstrated the use of reactive pyridine anhydrobases in metal-
catalyzed transformations as well as providing a new approach to heterocyclic ring systems 
(Scheme 10-E).89 All of these examples provided methods to form 5-membered rings, which 
























Scheme 11:Enantioselective Asymmetric Mizoroki-Heck Reactions 
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In 2019, Cheng and coworkers reported on the enantioselective synthesis of quaternary 
3,4-dihydroisoquinolinones via Heck carbonylation reactions in their synthesis of minalrestat 
analogs (Scheme 10-F).90 They demonstrated high ee values for their enantioselective 6-
membered ring cyclization. Although the list reported in Scheme 10 is not exhaustive, it 
represents a variety of reaction conditions for the enantioselective asymmetric palladium-
catalyzed Mizoroki Heck reaction that afforded good to excellent yields with good to excellent 
ee values. 91–93 Interestingly, although many ring sizes have been formed in intramolecular Heck 
reactions85,91–96, most literature examples report the synthesis of 5-membered ring products. We, 
therefore, anticipated that our desired Heck reaction forming a 6-member ring in an 
enantioselective intramolecular Mizoroki-Heck reaction may be more challenging.   
Our research focused on the enantioselective intramolecular Mizoroki-Heck reaction to 
create chiral phenanthridinone analogs using palladium and nickel as catalysts (Scheme 11). The 
enantioselective intramolecular Mizoroki-Heck reaction had been used previously in our lab to 
create tricarbocyclic structures with all-carbon quaternary stereocenters.78 We sought to expand 
this reaction to the synthesis of triheterocyclic structures, like phenanthridinone, using the 
analogous  enantioselective92,97  desymmetrizing process.95,98–103 In the process, we create a 6-
member ring which has relatively few highly enantioselective examples reported in the literature 
as discussed prior. 85,94–96 The palladium research became the major focus of my thesis research, 
while the nickel project made important progress but is still undergoing optimization.  The 
enantioselectivities achieved in this dissertation from the palladium-catalyzed Heck reactions 
were low for most compounds, so we began investigations into optimization of a nickel 
catalyzed Heck procedure due to promising results in the literature indicating that high 











Scheme 12: Chiral Mizoroki-Heck reactions using palladium and nickel  
Several variations of the Pd-catalyzed Mizoroki-Heck reaction exist; however, our 
research focused on the cationic mechanism, as shown in Scheme 12. The cationic pathway is 
identified by the cationic Pd complex in the mechanism. Cabri104 and Hayashi105 proposed the 
first examples of the cationic reaction mechanism to describe Heck reactions of aryl triflates in 
the presence of palladium-diphosphine catalysts. In asymmetric synthesis, the cationic pathway 
has been the most successful.92 This has been the case in our past research78 as well, and was true 
for the asymmetric synthesis of phenanthridinone analogs reported here.  Using the aryl triflate 
substrate promoted the cationic pathway and enhanced stereochemical control.  
The mechanism of the Mizoroki-Heck reaction begins with oxidative addition of the aryl 
halide or pseudohalide (OTf) with palladium (0) forming complex II.  Triflate dissociation due 
to a weak association with palladium creates the cationic palladium complex III. Ligand 
exchange allows for coordination of the alkene to palladium, complex IV. This step requires 
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equilibration for the alkene and aryl group to be cis- to one another in order for insertion to occur 
and may hinder enantioselectivity if a prolonged equilibration time is required. The alkene then 
undergoes a syn-1,2-insertion to form V, which sets the stereochemistry of the two newly formed 
stereocenters and is the rate-determining step. β-Hydride elimination with the syn-β-hydrogen 
(left of palladium in Scheme 12) is possible due to the hydrogen and palladium being syn-
coplanar, producing the 1,3-diene product, complex VII. The base can either be used to 
deprotonate the β-hydrogen, as shown in the mechanism, or it can be used to deprotonate 
palladium after β-hydride elimination. Palladium (0) can then dissociate and enter into the 
catalytic cycle.106 As evidenced through past literature references85,92,107–109 and witnessed in our 















Scheme 13: Cationic Mizoroki-Heck Mechanism 
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1.4 Nickel-Catalyzed Mizoroki-Heck Reactions 
 Due to the high palladium cost, chemists are interested in utilizing cheaper transition 
metals such as Co110–112, Cu113, and Ni114–121. Nickel is found in group 10 of the periodic table, is 
more affordable than palladium due to its abundance in nature, is non-toxic, and has some 
similar properties to palladium, which makes it attractive to study. Research utilizing palladium 
catalysts for Mizoroki-Heck reactions is extensive; however, research into the enantioselective 
intramolecular Mizoroki-Heck reaction using nickel catalysts is minimal.114–121 Nickel can access 
a range of oxidation states like palladium; however, in mechanistic cycles, it is known to 
potentially go through multiple oxidation states anywhere from Ni(0) to Ni(III), which can make 
it difficult to discern the mechanism and may lead to unwanted side reactions. Palladium, for the 
most part, involves a two-electron pathway in catalytic cycles (Pd(0)/Pd(II) pathway), although it 
can access a range of oxidation states.  
Nickel’s other properties also cause varying reactivity when compared to palladium. 
Nickel is less electronegative, has a lower reduction potential, and its atomic radius is smaller 
than palladium. Oxidative addition occurs quickly compared to palladium due to nickel’s low 
reduction potential; however, the reduction of nickel is hindered and usually requires an 
additional reductant such as manganese or zinc. Unfortunately, for the Mizoroki-Heck reaction, 
the lower electronegativity of nickel results in a weaker agostic interaction with the β-hydrogen 
relative to palladium. In addition, nickel’s smaller radius results in a more strained geometry in 
the transition state leading to slower β-hydride eliminations.116 Another drawback to utilizing 
nickel is the harsh conditions that often need to be used, such as high temperatures, very polar 
solvents, metal additives, and prolonged reaction times to help overcome the barriers to 
mechanistic steps in the Heck reaction.  
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Desrosiers and coworkers reported amongst the first examples of an enantioselective 
intramolecular nickel-catalyzed Mizoroki-Heck cyclization to generate quaternary centers using 
a chiral nickel precatalyst with ee values up to 96% (Scheme 14-A).115 They were also able to 
demonstrate that a β-hydride elimination could be achieved when nickel was used as the catalyst. 
Due to nickel’s small atomic radius and low electronegativity, β-hydride eliminations are 
typically slow; therefore, some type of reductive Heck product may be favorable for nickel 
reactions.  
Qin, Lee, and Zhou reported the first example of a nickel-catalyzed asymmetric reductive 
Heck reaction in their research synthesizing indolines (Scheme 14-B).122 The reductive Heck’s 
mechanism goes through a reductive elimination as the final step in the mechanistic cycle instead 
of a β-hydride elimination. Several years later in 2019, Yang, Jin, and Wang reported the nickel-
catalyzed asymmetric intramolecular reductive Heck reaction of unactivated alkenes using mild 
reaction conditions (Scheme 14-C).119 Their conditions promoted an increased reaction rate at a 
lower temperature than reported by Qin et. al.. Proton sources, to promote the reductive Heck 
product, in their reaction came from the nickel salt hydrate, Ni(BF4)2·6H2O, and the polar protic 
solvent, isopropyl alcohol. Protodebromination was not reported in their results, and they had 
good to excellent yields of the desired compounds with enantioselectivities up to 98%. Other 
examples of successful reductive Heck reactions are reported in Schemes 14-D and 14-E.117,120 
Indeed, reductive Heck products are common in the literature for nickel-catalyzed Heck 
reactions potentially due to the challenges discussed prior with β-hydride eliminations catalyzed 






















Scheme 14: Advances in Nickel-catalyzed Mizoroki-Heck Reaction. 
We envisioned that we could use the work of Desrosiers et. al. to produce the 1,3-diene 
compounds that we desired due to their success at overcoming the barrier to β-hydride 
elimination to access their desired compound. Understanding that β-hydride eliminations are 
39 
 
typically slow for nickel and that the reductive Heck product may be favorable prompted us to 
attempt the reaction conditions reported by Yang, Jin, and Wang in the hopes of utilizing mild 
reaction conditions to achieve the reductive Heck product for our chiral phenanthridinone 
analogs. Ultimately, the published work in Scheme 14 provided the basis for our initial studies 
by providing valuable information on the optimization of the nickel catalyzed enantioselective 
intramolecular Heck reaction.   
Prior examples in the literature (Scheme 14) suggested several important considerations 
as we approached our studies. First, a reductant such as zinc or manganese is almost always 
required to reduce nickel to a lower oxidation state due to nickel’s low reduction potential.116 
Other additives in the nickel-catalyzed reaction have also been reported to help reduce nickel, 
such as B2Pin2, (Scheme 14-E).
114 Second, adding exogeneous halide sources, such as LiI, has 
been found to improve the enantioselectivity of the Heck reaction by helping to favor the neutral 
pathway.112 Third, oxazoline-based ligands were abundant in the literature for nickel catalyzed 
Heck reactions as demonstrated in Scheme 14, which were found to work better than phosphine 
based ligands. These important concepts helped guide our decisions on the optimization of 
reaction conditions using nickel to synthesize chiral phenanthridinone analogs.   
The impressive work already achieved in nickel catalysis led us to investigate the use of 
nickel in our enantioselective asymmetric intramolecular Mizoroki-Heck reactions. All but one 
of the examples presented in Scheme 14 formed five-membered rings. A similar pattern was 
noted for palladium. Circumstantial evidence suggests that, like the Pd-catalyzed intramolecular 
Heck reaction, five-member ring formation is more efficient and enantioselective than six-
member ring formation. If we can build on the work listed in Scheme 14, we could potentially 
reduce the time, reduce the temperature, and promote higher yields without loss of 
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enantioselectivity. Some of the challenges that we faced were 1) avoiding protodehalogenation, 
2) limiting or eliminating the reductive Heck product, 3) and enhancing enantioselectivity using 
chiral ligands.  
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– CHAPTER 2 – 
γ-Arylation of α,β-unsaturated ketones and esters 
 7-Methoxy-4-methylcoumarin was chosen to investigate the γ-arylation of an α,β-
unsaturated ester due to the protons in the γ-position being the most acidic as well as being 
electronically and sterically unhindered. The challenges we faced were regioselectively arylating 
the γ-position (versus the alpha-position), avoiding polyarylation, and avoiding condensation 
side products.1 Overall, we overcame these challenges to selectively mono-γ-arylate 7-methoxy-
4-methylcoumarin in good to excellent yields and this work has been reported in the scientific 
literature.2 
Our research’s next logical step was to apply our reaction conditions to other α,β-
unsaturated ketones and esters to ensure that our reaction conditions were not just specific to 7-
methoxy-4-methylcoumarin. Other α,β-unsaturated ketones and esters that we investigated are 
isophorone, 3-methyl-2-cyclohexen-1-one. ethyl crotonate, 1-acetyl-1-cyclohexane, and methyl-
1-cyclohexene-1-carboxylate.  
2.1 Synthesis of γ-arylated 7-methoxy-4-methylcoumarin: 
The substrate for our studies was generated from the commercially available 4-
methylumbelliferone via protection of the phenol, thereby eliminating an acidic proton that 
would complicate our efforts at γ-arylation. In that event, deprotonation of the phenol proton 
may lead to a coupling or aromatic substitution reaction to occur with the Ar-Br.3 Therefore, the 
phenol needed to be protected to allow efficient γ-arylated products without unwanted side 
reactions. A Williamson ether synthesis was utilized to install a methyl group onto the hydroxyl 










Scheme 15: Williamson Ether Synthesis of 7-methoxy-4-methylcoumarin 
 
 Dr. Jason R. Schmink achieved the optimization of the γ-arylation of 7-methoxy-4-
methylcoumarin.2 The research presented here is the contribution that I had to explore the scope 
of these reaction conditions. When xantphos G3 was used in our reaction, it afforded the best 
reactivity with total consumption of the starting material and suppression of diarylated products. 
N-Xantphos G3 had similar reactivity but is more expensive, so xantphos was chosen as the 
ligand in the G3 scaffold.5  DPEPhos, DPPF, and MorDalPhos ligands in a G3 complex, and PA-
PPh ligand in a G2 complex were also attempted. However, none were as efficient as xantphos at 
producing mono-arylated product. Next, various bases were attempted to deprotonate the γ-
position. LiHMDS, a strong base that is soluble in THF, was found to be the optimal base. It’s 
strength stems from the fact that nitrogen is less electronegative than oxygen, which means that it 
does not stabilize a negative charge as well as oxygen making it more reactive as a base.  The 
bulky groups on the nitrogen minimize nucleophilic side reactions that would impede the 
compound’s ability to function as a base. Although carbonate bases were found to be the best 
base in γ-arylation procedures in the literature6–9, they did not work for our reaction conditions.  
Carbonate bases (pKa~10)10 do not solubilize completely in THF and they are weaker bases than 
LiHMDS (pKa ~26).11 Out of all of the polar aprotic solvents screened, THF heated at 70˚C 
worked the best. Pressure buildup in the vial due to evaporated THF, b.p.= 66˚C, may have 
increased the reaction rate due to more collisions of the molecules in solution. While toluene, a 
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Scheme 16: Optimized reaction conditions 
 
2.1.2 Aryl bromides 
 The synthesis of 7-methoxy-4-methylcoumarin followed the optimized reaction 
conditions as shown in Table 1. First, attempts were made with aryl bromides due to their 
widespread availability and good reactivity in the literature.  




Entry Compound Ar-X Yield (%)a 
1 1 bromobenzene 90 
2 2 2-bromoanisole 98 
3 3 3-bromoanisole 93 
4 4 4-bromoanisole 88 
5 5 4-bromoveratrole 90 
6 6 4-bromo-N,N-dimethylaniline 66 
7 7 2-bromomesitylene 81 
8 8 2-bromonapthalene 74 
9 9 3-bromotoluene 70 
10 10 4-bromotoluene 65 
11 11 2-bromo-4-tert-butyltoluene 68 
12 12 4-bromo-tert-butylbenzene 75 
13 13 4-chlorobromobenzene 70 
14 14 4-bromobenzotrifluoride 30 
15 15 4-bromobenzonitrile 95 
16 16 5-bromobenzofuran 92 
17 17 2-bromopyridineb 57 
18 18 3-bromopyridineb 32 




Electron-rich aryl bromides and sterically diverse aryl bromides worked well in entries 1-
11. When we attempted 4-chlorobromobenzene, oxidative addition into the Ar-Br bond occurred, 
yielding 4-Cl-Ar on the product. This confirms that Br derivatives react faster in the oxidative 
addition step than Cl derivatives under the reported reaction conditions. Electronegative CF3 in 
entry 13 had only 30% of the product isolated. Electronegative aryl groups can help to weaken 
the Ar-Br bond, which makes oxidative addition easier; however, they may hinder reductive 
elimination. 4-Bromobenzonitrile is a lot less electron-withdrawing than 4-
bromobenzotrifluoride, which in turn provided better reactivity in entry 14. Heterocycle 5-
bromobenzofuran, entry 16, yielded 92% of the desired product.  Derivatives made from 2- and 
3-bromopyridine had incomplete reactions with low isolated yields, entries 17-18. Pyridine rings 
have been known to coordinate via their nitrogen atom to palladium12–14, which may be why the 
reaction is being impeded.2 Attempts were made in Table 2 to increase the yield of 3-
bromopyridine; however, none successfully improved the GC yield.  
 An extended reaction time of 48 hours was thought to allow for equilibration in the 
reaction yielding more product; however, less product was produced, entry 2. Lowering the 
amount of aryl halide to 1.00 equivalent was thought to potentially reduce the amount of pyridine 
that could associate with the palladium at the nitrogen, increasing the ability of the palladium to 
oxidatively add into the Ar-Br bond; unfortunately, the yield was even worse, entry 3. Having 
1.05 eq. of 7-methoxy-4-methylcoumarin only yielded 20% of the product in the GC, with the 
major species being the starting material, entry 4. Lower temperatures were thought to slow the 
reaction, leading to less product, which was consistent with the data obtained. Raising the 
temperature to 80°C could have accelerated the reaction leading to pyridine’s association and 
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dissociation from palladium promoting the desired product; unfortunately, the product formation 
was lower than the standard conditions listed in entry 1 on Table 2.    



















1b 1.05 1.00 standard 24 65/35 
2 1.05 1.00 standard 48 50/50 
3 1.00 1.00 standard 24 40/60 
4 1.00 1.05 standard 24 20/80 
5 1.05 1.00 Standard, 60°C 24 10/90 
6 1.00 1.00 Standard, 60°C 48 30/70 
7 1.05 1.00 Standard, 80°C 24 50/50 
 a Values reported are GC yields. b Standard conditions 
 
 Not all aryl bromides worked well with our chemistry, Figure 3. Vinyl bromide 1 had 
only one peak in the GC attributed to 7-methoxy-4-methylcoumarin; however, there may have 
been a peak hidden in the 7-methoxy-4-methylcoumarin peak due to compound 1 in Figure 3 
dimerizing via cross-coupling. Aryl bromide 2 contained a messy GC potentially due to the 
sulfur coordinating to the palladium.  
 
 




2.1.3 – Aryl chlorides 
 Next, we wanted to see if our reaction conditions would work with the less reactive aryl 
chlorides to expand our scope even further.15 When the standard conditions were attempted with 
4-chloroanisole, no product peak was found in the GC, Table 3, entry 1. In entry 2, the 
precatalyst was switched to the more electron-rich N-xantphos, the heat was increased to 90°C, 
and 48 hours later, by GCMS, 84% of the desired product was formed. Xantphos G3 at 90°C was 
attempted with chlorobenzene for 24 hours; however, the reaction was incomplete, with 55% of 
the product being produced. Using the conditions listed in the reaction scheme in Table 3, we 
were finally able to isolate 70% of pure product, entry 4. 









1a,b - 4-chloroanisole - n/a 
2a,d - 4-chloroanisole 84 n/a 
3a,c - chlorobenzene 55 n/a 
4e 19 chlorobenzene 100 70 




It is well known that aryl chlorides using bidentate phosphine ligands require a high-
energy Pd-L2 pathway, which is why higher temperatures are typically required.
15 Aryl chlorides 
are electron-rich, which hinders oxidative addition. Mao, Walsh, and coworkers reported15 N-
xantphos to have an acidic phenoxazine N-H (pKa ~ 21 in DMSO).
16 In basic reaction conditions, 
the phenoxazine N-H deprotonates and associates with a main group metal, in our case lithium, 
and the ligand pi-system.17 Mao and coworkers argue that the main group metal, lithium, 
cooperates with the palladium center to lower the barrier for the oxidative addition of aryl 
chlorides, making N-xantphos superior to xantphos. Their explanation for cooperativity between 
palladium and the main group metal stemmed from Zhang and coworkers' research. Zhang et al. 
analyzed protonated and deprotonated N-xantphos via 31P{1H} NMR, where there was a slight 
shift of the PPh2 moiety after deprotonation. They also completed DFT calculations to compare 
the natural charges of protonated N-xantphos to deprotonated N-xantphos. Only slight changes in 
those charges, qP = 0.926 to 0.9231 and qO = -0.501 to -0.5172 suggest that the electronic 
structure at the phosphorous and oxygen atoms is mostly unchanged upon deprotonation of N-
xantphos.17 Our results were consistent with their results when we used N-xantphos and 
LiHMDS in our reaction sequence; however, the mechanism of this process is unknown.18  
With the promising results of γ-arylation using 7-methoxy-4-methylcoumarin, we moved 
onto the exploration of using our optimized reaction conditions on other α,β-unsaturated ketones 
and esters in attempts to flex the utility of these conditions.  
2.2 Optimization of the γ-arylation of isophorone 
 Next, we investigated the synthesis of γ-arylated isophorone based upon the promising 
work from Terao and coworkers6 and Hyde and Buchwald.8 Our goals were to expand the scope 
 
1 qP = atomic partial charge of Phosphorous 
2 qO = atomic partial charge of Oxygen 
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of our reaction conditions to other α,β-unsaturated ketones and esters and improve upon Terao 
and coworkers’ research by eliminating polyarylation. First, we attempted to optimize γ-arylation 
of isophorone using the previously optimized reaction conditions from 7-methoxy-4-
methylcoumarin (Table 4, entry 1). Unfortunately, only starting material remained after 24 hours 
under those conditions, so we undertook a  reevaluation of the reaction conditions.  
Our study took a systematic look at the reaction conditions, in particular, the nature of the 
base, the choice of catalyst, the reaction temperature, and solubilizing the base with water.  
Switching the base to cesium carbonate, which is commonly used in both α- and γ-arylation 
chemistry6–9  produced 3% of compound C (Table 4, entry 2). Lowering the temperature to 50˚C 
lowered the amount of energy that was available to overcome the activation barrier to 
diarylation, which should lead to a higher yield of mono-arylated product. The reaction was 
incomplete; however, 53% of compound C was made (entry 3). Switching the precatalyst from 
xantphos G3 to N-xantphos G3 decreased compound C, but it eliminated side products D-G 
(entry 4). A longer reaction time of 48 hours increased the amount of compound C without 
introduction of any side products (entry 5). Raising the temperature to 70˚C with N-xantphos G3 
consumed all of compound A and increased compound C; however, side products E and F were 
still present albeit in low yields (entry 6). Ultimately, N-xantphos significantly suppressed 
diarylation compared to xantphos using the same reaction conditions. Deprotonation of the 































1 THF 3eq LiHMDS (4%)Xantphos Pd G3 70 24 90 8 1 - - - - 
2 THF 3 eq Cs2CO3 (4%)Xantphos Pd G3 70 24 3 - 3 1 89 - 1 
3 THF 3 eq Cs2CO3 (4%)Xantphos Pd G3 50 24 32 10 53 - 5 - - 
4 THF 3 eq Cs2CO3 (4%)N-Xantphos Pd G3 50 24 66 11 22 - - - - 
5 THF 3 eq Cs2CO3 (4%)N-Xantphos Pd G3 50 48 31 7 61 - - - - 
6c THF 3 eq Cs2CO3 (4%)N-Xantphos Pd G3 70 24 - 1 70 - 16 11 - 
7 99% THF 
1% H2O 
3 eq Cs2CO3 (4%)N-Xantphos Pd G3 50 24 57 35 8 - - - - 
8 98% THF 
2% H2O 
3 eq Cs2CO3 (4%)N-Xantphos Pd G3 50 24 58 34 7 - - - - 
9 THF 3 eq Cs2CO3 (4%) dppf Pd G3 50 24 58 33 - - - - - 
10 THF 3 eq Cs2CO3 (4%) dppf Pd G3 70 24 51 31 trace - - 8 - 
11 THF 3 eq K2CO3 (4%)N-Xantphos Pd G3 50 24 60 40 - - - - - 
12 THF 3 eq K2CO3 (4%)N-Xantphos Pd G3 70 24 60 38 trace - - - - 
13b THF 3 eq K2CO3 (4%)N-Xantphos Pd G3 50 24 59 31 - - - - - 
14 THF 3 eq KOtBu (4%)N-Xantphos Pd G3 50 24 49 34 - trace - - - 
15 THF 3 eq KOtBu (4%)N-Xantphos Pd G3 70 24 51 29 4 trace - - - 
a Values reported are GC yields b 0.2 eq 18-crown-6. c Best reaction conditions 
Cesium carbonate was slightly soluble in THF, so a small percentage of water in entries 
7-8 was added to help solubilize the base; unfortunately, compound C was found in small 
amounts. Switching the precatalyst to dppf G3 did not improve the reaction, entry 9. As a ligand, 
dppf has been previously shown to be reactive in arylation reactions2,19–21 and has a smaller bite 
angle (99˚) than xantphos, (108˚) and N-xantphos (114˚). A slightly smaller bite angle in 
combination with the phenyl rings attached to the phosphines was thought to potentially cause 
steric hindrance around the palladium, making it more difficult for diarylation to occur; however, 
the reaction failed both at 50˚C and 70 ˚C. Potassium carbonate instead of cesium carbonate did 
not improve the reaction even while using 18-crown-6 to sequester potassium to make the base 
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more reactive (entries 11-13). Potassium tert-butoxide, another common base in α-arylation 
chemistry22–25, was attempted in entries 14-15 but only afforded a trace of C at 70 ˚C.  
Next, the equivalents of base, temperature, and time were explored in Table 5. Lower 
than three equivalents of cesium carbonate and lower temperatures lead to less C produced, 
entries 1-8. Lower temperatures and more equivalents of cesium carbonate in entries 9,10, and 
11 had promising results; however, the yields of C were low. To achieve mono-γ-arylation at 
low temperatures, long reaction times greater than 48 hours would be required. Higher 
temperatures, higher equivalents of base, and longer reaction times were the most favorable 
conditions since only small amounts of the polyarylated species were produced in entry 13 vs. 
higher amounts in entries 12.  



























1 0.5 50 48 50 3 47 - - - - 
2 0.5 55 48 36 17 47 - trace trace - 
3 0.6 50 48 32 20 48 - trace trace - 
4 0.7 50 48 33 18 50 - trace trace - 
5 0.8 50 48 29 17 54 - trace trace - 
6 1 50 24 46 29 25 - - - - 
7 1 50 48 31 20 49 - - - - 
8 2 50 24 46 29 25 - - - - 
9 2 50 48 28 16 56 - - - - 
10 3 50 24 42 28 28 - - - - 
11 4 50 24 52 38 7 - - - - 
12 3 70 24 - 1 70 - 16 11 - 
13 4 70 48 24 13 63 - trace trace - 
aValues reported are GC yields. 
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2.3 Examples of other γ-arylated α,β-unsaturated ketones and esters 
 Shown in Table 6 are the results of coupling various aryl bromides with isophorone 
(A),3-methyl-2-cyclohexen-1-one (A1), and ethyl crotonate (A2). These substrates had similar 
results with incomplete reactions and minimal amounts of polyarylated products. The positions 
that we attempted to γ-arylate are circled in the image in Table 6. 




























1 A 3-bromoanisole L2 72 50 24 19 58 - n/a n/a 35 (20b) 
2 A 3-bromoanisole L2 72 55 10 4 86 trace n/a n/a n/a 
3 A1 4-bromoanisole L2 24 50 12 78 10 - n/a n/a n/a 
4 A1 4-bromoanisole L2 48 50 9 72 14 5 n/a n/a n/a 
5 A 4-bromo-N,N-dimethylaniline L2 72 50 29 68 3 - n/a n/a n/a 
6 A 4-bromo-N,N-dimethylaniline L2 72 55 27 66 6 - n/a n/a n/a 
7 A bromobenzene L2 72 50 17 trace 83 - n/a n/a 34 (21b) 
8 A 4-bromobenzotrifluoride L2 72 50 trace - 19 81 n/a n/a n/a 
9 A 1,2-dibromobenzene L2 24 70 24 47 29 - n/a n/a n/a 
10 A1 1,2-dibromobenzene L2 24 70 3 90 8 - n/a trace n/a 
11 A1 1,2-dibromobenzene L1 24 70 trace 90 trace - n/a 10 n/a 
12d A2 4-bromoanisole L1 24 70 - - - 8 84 n/a n/a 
13d A2 4-bromoanisole L1 24 23 trace - - 67 27 n/a n/a 
a Values reported are GC yields. b Incomplete reaction. c Isolated yield after column chromatography. Compound numbers shown in parentheses. d 
2 mol% Xantphos Pd G3, 3 eq LiHMDS. 
While the results of using various aryl bromides were promising, the reactivity greatly 
varied. These results were disappointing since one of the project's goals would be to apply the 
optimized reaction conditions to various aryl halides that could produce the desired mono γ-
arylated products in good to excellent yields. When bromoanisole derivatives were examined, 
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isophorone in entry 2 had a higher yield than entry 1 with using an elevated temperature of 55˚C. 
In addition, 3-methyl-2-cyclohexen-1-one (A1), which is similar in structure to isophorone, with 
4-bromoanisole had half of (A1) remaining and half of mono-arylated product produced, entry 3. 
Through resonance, the methoxy group is electron-donating to the ortho- and para- positions, 
strengthening the Ar-Br bond hindering oxidative addition. Polyarylated species were not 
apparent in the GC; however, when the reaction was run for 48 hours, diarylated product was 
present. Without the methyl groups at the β-position in A1 vs. A, the α-protons are sterically 
unhindered. α-Arylation might have been the preferred mono-arylated species; however, this was 
never confirmed via NMR analysis. When another electron-rich aryl halide, 4-bromo-N,N-
dimethylaniline, was used with isophorone in entries 5 and 6, small amounts of γ-arylated 
product were present. Bromobenzene had the best reaction results with the most amount of γ-
arylated species in the GC at 50˚C for 72 hours, entry 7. These results were comparable to entry 
2, which required a slightly higher temperature. More electron density in the aryl ring might 
hinder oxidative addition, so we attempted 4-bromobenzotrifluoride, which contained the very 
electron-withdrawing trifluoromethyl group. 4-Bromobenzotrifluoride coupled with isophorone 
yielded the diarylated product as the major product, entry 8. The CF3 group is electron-
withdrawing, which weakens the Ar-Br bond, making oxidative addition faster. The acidity of 
the proton in the γ -position, once mono-arylation is achieved, is even more acidic, which 
promotes diarylation. 1,2-Dibromobenzene did not work well for isophorone or 3-methyl-2-
cyclohexen-1-one, entries 9-11. At 70˚C, a peak in the GC corresponding to cyclized product F 
formed, entry 11. This may occur through a sequential γ-arylation and then a Mizoroki Heck 
reaction to form the cyclized product.  
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During optimization of isophorone, compounds 20, entry 1, and 21, entry 7 in Table 6 
were isolated under initial reaction conditions before complete optimization to confirm the final 
product’s configuration. The low isolated yields compared to the GC yields may be attributed to 
loss of product from using the high vacuum system to dry the compounds, which were oils. As 
an example, the NMR of 3-(3-methoxybenzyl)-5,5-dimethylcyclohex-2-en-1-one is shown in 
Figure 1. The protons are labeled as proof of the γ-arylated product, C, which were compared to 












Figure 1: NMR of 3-(3-methoxybenzyl)-5,5-dimethylcyclohex-2-en-1-one 
Previous work by Dr. Jason R. Schmink proved that ethyl crotonate might be a viable 
compound for our proposed γ-arylation reaction conditions due to diarylated and triarylated 
compounds being present in the GC.27 The reaction conditions initially explored by Dr. Jason 
Schmink are reported in Table 6, entry 12. When the reaction was attempted at room 
temperature for 24 hours, the diarylated product was the primary product with significantly less 




























the GC, entry 13.  The reaction quickly forms the diarylated species even at room temperature, 
making it challenging to produce mono-arylated product. Unfortunately, incomplete reactions 
that produced polyarylated species for compounds A, A1, and A2 prompted us to stop the 
investigation and move onto other more promising compounds.  
2.4 α'-Arylation of 1-acetyl-1-cyclohexane 
Applying our reaction conditions from 7-methoxy-4-methylcoumarin to the arylation of 
1-acetyl-1-cyclohexane proved successful. Only one peak in the GC was present for entries 1 and 
2 in Table 7. Unfortunately, when we isolated the product and analyzed it via NMR 
spectroscopy, we found that we produced the α'-arylated product F. α'-Arylated product was 
expected due to the increased acidity of the protons at the α'-position compared to the γ-position. 
In addition, that position is sterically unhindered compared to the methylene protons at the γ-
position. 















1 22 bromobenzene - 85 
2 23 3-bromoanisole - 90 
a Values reported are GC yields 
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 As proof of α'-arylated product, shown in Figure 2 is the 1H NMR spectrum for 1-
(cyclohex-1-en-1-yl)-2-(3-methoxyphenyl)ethan-1-one. The spectrum was compared to the 










Figure 2: NMR of 1-(cyclohex-1-en-1-yl)-2-(3-methoxyphenyl)ethan-1-one 
 Due to the α'-arylated product being produced in excellent yields at 50˚C, it was apparent 
that the γ-arylated product was not favored and that the α' protons are the most acidic. Our 
interest in γ-arylated products led us to investigate other substrates. The site of arylation has a 
preference for the least hindered carbanion position, which is supported by both data obtained 
from 1-(cyclohex-1-en-1-yl)-2-(3-methoxyphenyl)ethan-1-one and isophorone.  
2.5 γ-Arylation of methyl-1-cyclohexene-1-carboxylate 
 α,β-unsaturated ketones are prone to α-arylation, so our focus shifted to another α,β-




















happens primarily at methyl carbons or if this process could be applied to methylene carbons. 
Cesium carbonate was screened as a potential base due to the promising results from isophorone. 
Only peaks correlating to starting materials A, B, and other impurities were found in the GC, 
Table 8.   




















1 bromobenzene 34 56 - - - 9 
2 4-bromobenzotrifluoride 51 34 - - - 15 
3 4-bromoanisole 39 61 - - - trace 
a Values reported are GC yields 
 Due to the disappointing results from cesium carbonate, we switched the base to lithium 
hexamethyldisilazide due to its reactivity in our 7-methoxy-4-methylcoumarin research.2 
Switching the base led to 31 % of the mono-arylated product being produced and other side 
products being present in the GC in Table 9,  entry 1. Lowering the temperature from 70˚C to 
50˚C proved beneficial to eliminate side products and produced only mono-arylated product in 
the GC (entries 1-4). Using 5% or 3% of the precatalyst in entries 3 and 4, respectively, did not 
significantly affect the reaction. With those conditions in mind, various aryl bromides were 
explored in entries 5-15; however, meager yields of the product were obtained due to problems 
in the purification process.  These results confirm that we can arylate methylene carbons in good 
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crude yields with aryl bromides with electron-withdrawing groups, neutral, and electron-
donating groups; however, we still had to confirm what mono-arylated species we made.  






























1 bromobenzene 70 - - 31 - - 69 n/a - 
2 bromobenzene 50 - - 100 - - - 63 24 
3c bromobenzene 50 - - 100 - - - 60 - 
4d bromobenzene 50 - - 100 - - - n/a - 
5a 4-bromobenzotrifluoride 70 trace trace 17 - - 83 n/a - 
6a 4-bromobenzotrifluoride 50 19 - - - - 81 n/a - 
7e 4-bromoanisole 50 - - 100 - - - 40 25 
8 4-bromoanisole 70 - - 95 - - 5 n/a  
9 3-bromoanisole 50 - - 100 - - - 45 26 
10 3-bromoanisole 60 - - 100 - - - 30 - 
11 5-bromobenzofuran 50 - - 100 - - - 47 27 
12e 4-bromo-n,n-
dimethylaniline 
50 - - 100 - - trace 37e 
 
28 
13 3-bromopyridine 50 - - 100 - - - 59 29 
14 1-bromo-4-fluorobenzene 50 - - 100 - - - 41 30 
15 4-bromotoluene 50 - - 97 - - 3 n/a - 
a Incomplete Reaction b Values reported are GC yields c 5% Xantphos Pd G3 d 3% Xantphos Pd G3 e Impure isolated product`    
Determining what mono-arylated product we produced proved challenging. COSY NMR 
analysis of the benzene derivative indicated that the γ-arylated product was the most likely 
structure; however, we think that we made a γ-arylated β,γ-unsaturated ester. Since we are 
starting with an α,β-unsaturated ester, the γ-arylated product may form and then isomerize via 
palladium to the β,γ-unsaturated ketone to be in conjugation with the aryl ring. We compared our 
proton NMR (Chapter 6.2.4, Figure 63) to examples in the literature. We were able to rule out 
the αˈ product29 and γˈ product30 based upon a comparison of our proton NMR to the literature. 
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The β-product was not a good fit either due to the coupling between H5 and H6. Since both 
protons are coupled to the same methylene protons, we propose that H6 and H5 are being coupled 





















Figure 3:  COSY NMR of compound 24 
The most important information we received from this experiment was that we were able 
to γ-arylate a methylene carbon using our reaction conditions at low temperatures. We propose 
















2.6 Consecutive amide formation/ Heck cyclization of methyl-1-cyclohexene-1-carboxylate 
 Application of the standard reaction conditions to 2-bromoaniline yielded no product (A) 
in the GC; however, two side products were detected corresponding to B and C in Table 10. We 
found these to be very interesting products of presumably a tandem reaction sequence, acylation 
and Heck cross-coupling or vice versa; consequently, we decided to explore this event further.  
Table 10:  Consecutive amide formation/ Heck cyclization of methyl-1-cyclohexene-1-



















1 THF LiHMDS 24 50 - Trace 100 
2 THF LiHMDS 24 70 - 18 82 
3 THF LiHMDS 24 100 - 63 37 
4 Toluene LiHMDS 24 110 - 25 75 
5c THF LiHMDS 24 100 - 32 68 
6 THF LiHMDS 48 100 - 69 31 
7 THF Cs2CO3 24 100 - - - 
8d THF LiHMDS 48 100 - 62 36 
9 CPME KOtBu 24 100 - - 83 
10e THF LiHMDS 48 100 - 38 62 
11f THF LiHMDS 48 100 - 44 56 
12g THF LiHMDS 48 100 - 74 26 
13i THF LiHMDS 24 100 - 88 12 
14h THF LiHMDS 24 100 - 100 - 
a Incomplete Reaction b Values reported are GC yields c 4% N-Xantphos Pd G3 d 4eq LiHMDS e 5% Xantphos Pd G3  f 3% Xantphos Pd G3 g 
Conditions the same as Entry 3, but after 24 hours, 1% Xantphos Pd G3 was added and the reaction was left for an additional 24 h at 100˚C. h 
Conditions the same as Entry 3, but after 8 hours, 10% Xantphos Pd G3 was added and the reaction was left for an additional 18 h at 100˚C. i 
Conditions the same as Entry 3, but after 6 hours, 5% Xantphos Pd G3 was added and the reaction was left for an additional 18 h at 100˚C. 
Compound C was selectively produced when the reaction was run at 50˚C, Table 10, 
entry 1. Raising the temperature promoted a Mizoroki-Heck product to be made in increasing 
yields in entries 1-3. Switching the solvent to toluene to attempt the reaction at a higher 
temperature slowed the cyclization process (entry 4). When the precatalyst was switched to N-
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xantphos G3, entry 5,  the cyclization process was hindered. Leaving the reaction for 48 hours 
with the conditions listed in entry 2 had minimal effect on B’s production. Switching the base to 
cesium carbonate shut down the reaction entirely (entry 7). Increasing the amount of LiHMDS 
and increasing the reaction time to 48 hours did not increase B. Switching the solvent to CPME 
and switching the base to potassium tert-butoxide generated product C selectively. Increasing the 
amount of xantphos G3 decreased the amount of B produced, entry 10. Lowering the amount of 
precatalyst also reduced the amount of B, entry 11.  
Due to changes in the reaction conditions not increasing the amount of B produced, we 
began to wonder if the reaction was stalling. To probe if the reaction was stalling, 1% of 
precatalyst was added after 24 hours. The reaction was placed back on the pie reactor for an 
additional 24 hours. This increased the amount of B produced significantly in entry 12, which 
confirmed our suspicions that the reaction was stalling. With these extremely promising results 
in mind, we repeated the reaction conditions; however, we amended our procedure. We added in 
5% xantphos G3 after 6 hours, in addition to the 4% catalyst that was initially added, and left the 
reaction for an additional 18 hours at 100˚C, entry 13. This amendment increased the amount of 
product but did not fully convert C to B. Finally, we added 10% xantphos G3 after 6 hours and 
left the reaction for an additional 18 hours at 100˚C (entry 14). This selectively produced 
cyclized product B. We isolated 88% of cyclized product B; however, we could not separate the 

















Figure 4: NMR of compounds B1 and B2 
While exploring various reaction conditions, we isolated both the cyclized product B and 
the amide product C to confirm our hypothesis of what was being produced. When analyzing the 
cyclized product’s NMR, it was discovered that two different alkene constitutional isomers had 
formed, Table 10, compound B. There should have only been one peak due to one proton at 
around 8.50 ppm to 9.00 ppm where an amide N-H proton would appear; however, there were 
two peaks. Also, there should have only been 2 protons in the vinylic region when there were 4 
protons. The proton NMR was compared to England’s, Merey’s, and Padwa’s work, where they 
isolated compound B1.31 The peaks for B1 were assigned accordingly. Other peak assignments 








































































used to confirm our suspicions (Chapter 6.2.4.1, compound 31). Only one peak due to the 
cyclized product was present in the GC, which did not confirm nor deny our suspicions.  
2.7 Conclusions: 
 We were able to successfully regioselectively mono-γ-arylate 7-methoxy-4-
methylcoumarin utilizing the optimized reaction conditions. Also, we were able to use less 
reactive aryl chlorides with slight modifications to our reaction. The less expensive xantphos G3 
precatalyst could be utilized for most of the substrates except for aryl chlorides, which required 
more electron-rich N-xantphos G3.  
 Expanding our reaction conditions to isophorone, 3-methyl-2-cyclohexen-1-one, ethyl 
crotonate, and methyl-1-cyclohexene-1-carboxylate proved challenging. We were unable to 
achieve mono-γ-arylated products in good to excellent yields. 1-acetyl-1-cyclohexane yielded 
only mono-α'-arylated product due to the most acidic protons on the α'-carbon, which was 
confirmed by comparing the 1H NMR spectrum to literature values. Methyl-1-cyclohexene-1-
carboxylate had the best results that eliminated polyarylation, consumed the starting material, 
produced γ-arylated product, and demonstrated that γ-arylation could successfully occur on a 
more hindered methylene carbon using our reaction conditions. Unfortunately, the yields were 
low due to issues in the purification process and removing carbazole, which is reductively 
eliminated from the precatalyst before palladium enters the catalytic cycle, from the products. In 
addition, the sequential amide formation/Mizoroki-Heck reaction of methyl-1-cyclohexene-1-
carboxylate had some promising results; however, the reaction produced constitutional isomers, 
which could not be separated. The utility of this reaction sequence was not enough to continue 
with this research. Due to the lack of funding and publishable results, we decided to end our 
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– CHAPTER 3 – 
The Birch-Heck Sequence utilizing Palladium: 
Creating Phenanthridinone Analogs  
Moving on from the γ-arylation project, we decided to shift our focus to the synthesis of 
chiral phenanthridinone analogs, which had initial success in the Malachowski Lab. We desired 
to combine the significant bioactivity of phenanthridinone, as noted in the introduction, with the 
demonstrated success of drugs with sp3 carbons and quaternary stereocenters through use of the 
Birch-Heck sequence. The initial goal of this project was to synthesize phenanthridinone analogs 
with a secondary benzamide; however, we did find literature examples proving the bioactivity of 
phenanthridinone analogs with tertiary benzamides.1–5 In the research presented, the Mizoroki-
Heck reaction of triflates with secondary benzamides failed to give the desired products. Several 
methods were attempted to 1) use triflate compounds with secondary benzamides in the Heck 
reaction, 2) remove the methyl group from the tertiary benzamide in the Heck product, and 3) 
use a protection/deprotection protocol to achieve the Heck product with a secondary benzamide. 
The tools developed in the process have enabled a range of analogs to be synthesized and have 
laid a foundation for the efficient and enantioselective synthesis of a variety of phenanthridinone 
structures in the future.  
3.1 The Birch Reduction-Alkylation: 
 Previous work in our lab, accomplished by Dr. Andrew Krasley6, optimized the Birch 





Scheme 17: Optimized reaction conditions for the Birch reduction-alkylation 
One of the best solvents for nucleophilic substitution is ammonia.7 Besides providing a 
medium for the alkali metal electrons to reduce the aromatic ring, the ammonia solvent improves 
the efficiency of the alkylation reactions, particularly with secondary alkyl halides. Initial studies 
of benzoic acid in the Birch reaction, by past members of the Malachoski Lab, found that certain 
alkyl bromides and iodides were not producing the desired products and only benzoic acid 
remained after working up the reaction. Dr. Andrew Krasley completed a thorough analysis of 
the Birch reduction-alkylation conditions to rule out potential issues due to technique, chemical 
quality, and other variables in this complex reaction.6 The reduction of benzoic acid was 
observed due to the dark blue color of the reaction when lithium metal was added to the round 
bottom flask containing benzoic acid dissolved in ammonia. Alkylation of the benzoic acid 
dianion was not occurring, Scheme 18-A. The most likely explanation that we came to was the 
formation of a stable carbanion from alkylating agents that underwent nucleophilic attack by the 
benzoic acid dianion to form a cyclic tertiary halide via α-halogenation, Scheme 18-B. The 
cyclic tertiary halide can then be deprotonated at the γ-position to rearomatize the ring to 
regenerate benzoic acid. We found that alkyl chlorides significantly enhanced the yield for alkyl 
halides, which were capable of forming stable carbanions from reductive loss of halide in 
benzoic acid substrates. More specifically, it was proposed that the use of chloride reduces a 
competing ring oxidation process with less electronegative bromides that lead to recovered 














Scheme 18: enolate α-halogenation side reaction 
 The Birch reduction-alkylation is one of the critical reactions in our sequence because it 
installs a quaternary center and creates a symmetrical 1,4-cyclohexadiene structure. Therefore, it 
sets the stage for the key enantioselective Heck desymmetrization and cyclization reaction.  
Table 11 shows all of the Birch products that were synthesized. Most Birch reactions 
worked well with little to no benzoic acid remaining in the 1H NMR, entries 1-9, and 15; 
however, not all arylic halides produced the Birch products in high yields. 2-Chloroacetamide 
formed the Birch product, an impurity, and had remaining benzoic acid, entry 10. 1,1,1-
Trifluoro-2-iodoethane yielded only a trace of the product, with the primary species being 
benzoic acid, entry 11. The trifluoroalkyl moiety forms a stable carbanion due to reductive loss 
of the iodine, promoting α-iodination of the 1,4-cyclohexadiene enolate. The CF3 group is very 
electron-withdrawing due to electronegative fluorine, which stabilizes the carbanion via the polar 
effect. 1-(Chloromethyl)-1-H-benzotriazole did yield some Birch product; however, mainly 
benzoic acid and 1-(chloromethyl)-1-H-benzotriazole remained in the GC, entry 12. Part of the 
problem was that the alkylating reagent was not solubilizing in ammonia. 1-(Chloromethyl)-1-H-
benzotriazole did not dissolve well in THF either, so the solid alkylating agent was added slowly 
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to solubilize the alkylating agent in small amounts. This increased the amount of Birch product 
produced; however, there was still too much benzoic acid in the NMR for us to continue with 
this crude product.  
 2-Bromoacetophenone, entry 13, and 2-(chloromethyl)anthraquinone, entry 14, had 
messy GCs with no product peak and very impure NMRs. 2-Bromoacetophenone may form a 
stable carbanion due to reductive loss of the bromine, promoting α-bromination of the 1,4-
cyclohexadiene enolate. 2-(Chloromethyl)anthraquinone may also promote the enolate α-
halogenation side reaction. Since we had other very successful alkyl halides that worked 
exceptionally well, we did not attempt further optimization for these alkyl halides.  
Table 11: Birch Products 
 
Entry R-X Yield (%) Compound 
1 benzyl chloride 94 32 
2 chloroacetonitrile 80 33 
3 iodocyclohexane 96a 34 
4 1-iodo-2-methylpropane 94a 35 
5 methyl chloromethyl ether 90a 36 
6 1-(chloromethyl)napthalene 90 37 
7 4-bromo-1-butene 89a 38 
8 4-bromo-1-butyne 97 39 
9 2-bromobutane 93a 40 
10 2-chloroacetamide 55b 41 
11 1,1,1-trifluoro-2-iodoethane Traceb 42 
12 1-(chloromethyl)-1-H-benzotriazole >100c,d 43 
13 2-bromoacetophenone 0e - 
14 2-(chloromethyl)anthraquinone 0e - 
15 iodomethane 92a 44 
a Trace amount of benzoic acid in NMR b Significant amount of benzoic acid in NMR c NMR very impure. d No workup done. e GC is a mess 
 
3.2 Heck precursor synthesis 
 Both the cationic and neutral catalytic cycles of the Heck reaction were explored. The 
cationic cycle was promoted with both secondary and tertiary benzamides using an aryl triflate 
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electrophile. The neutral catalytic cycle was studied with an aryl bromide electrophile. Our 
synthetic pathway allowed either aryl triflate or aryl bromide groups to be connected to the 
symmetrical Birch products through an amide linker, which was formed in a nucleophilic acyl 
substitution reaction.   
The reaction sequence to synthesize the triflate Heck substrate on the path to 
phenanthridinone analogs, which past members of the Malachowski Lab optimized, is listed in 
Scheme 19.6,9 In the sequence, the Birch product is converted to an acid chloride (A) and is 
immediately coupled with 2-(methylamino)phenol or 2-bromoaniline to form benzamide (B). 
This process is efficient and produces high yields. Triflation of the benzamide formed from 2-
(methylamino)phenol gives compound (C), which can then be utilized in the Mizoroki-Heck 








 Scheme 19: Acid Chloride/Amide formation then Triflation to form Compound C. 
Atropisomers were found to form when we analyzed both the tertiary benzamide 
compounds and their triflated products using NMR spectroscopy. The signals were broad in the 
proton NMR at room temperature and coalesced when heated to produce peaks that could be 
properly analyzed. Atropisomerism occurs when there is hindered rotation about a single bond 
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due to steric or electronic constraints, causing two or more conformers to experience slow 
interconversion.10 Atropisomerism can lead to kinetic resolution in the Heck reaction11, potential 
for temperature control of the isomer interconversion equilibrium, and might have an impact on 
the enantioselectivity.12  The tertiary benzamide has restricted rotation around the N-Ar or N-
(C=O) bond. Slow interconversion of the atropisomers at room temperature causes signal 
broadening in the NMR. Heating the NMR sample in DMSO-d6 at 100˚C caused the peaks to 
coalesce due to increasing the rate at which the atropisomers interconvert by overcoming the 







Figure 5: Rotational features of anilides 
In the Heck reaction, heating to 80˚C likely equilibrates the atropisomers leading to easy 
interconversion. Nevertheless, one atropisomer may react faster in the Heck reaction than 
another, either during oxidative addition or the critical enantiodifferentiating 1,2-migratory 
insertion. The chiral ligand controls the enantioselectivity, but there might be a rate difference 
between atropisomers that helps to improve the enantioselectivity.  
Results for the amide formations are listed in Table 12. Since the acyl chlorides were 
immediately reacted in the amide formation, their yields and characterization are not reported.  
The yields in entries 1-10 were high for all of the different compounds. When taken in deuterated 
chloroform, analysis of the tertiary benzamide compounds via NMR proved difficult due to 
atropisomer formation and the restricted rotation around the N-Ar or N-(C=O) bond most likely 
due to steric interactions with the methyl group. Secondary benzamides have free rotation around 
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the N-Ar or N-(C=O) bond due to hydrogen being small. Therefore, the secondary benzamides 
do not have the same issues with steric interactions allowing for NMRs to be taken at room 
temperature in deuterated chloroform.  
Table 12: Secondary and tertiary amide formation using 2-aminophenol or 2-




Entry R1 -R Yield (%)a Compound 
1 -H -CH2Ph 90 45 
2 -H -CH2CN 84 46 
3b -H -CH2Ph 94 47 
4 -CH3 -CH2Ph >100 48 
5 -CH3 -CH2CN 96 49 
6 -CH3 -cyclohexane 97 50 
7 -CH3 -isobutyl 99 51 
8 -CH3 -CH2OCH3 90 52 
9 -CH3 -1-methylnapthalene 94 53 
10 -CH3 -CH2CH2CH=CH2 99 54 
11 -CH3 -CH2CH2C C >100 55 
12 -CH3 -sec-butyl 99 56 
13 -CH3 -CH3 94 57 
a Values from GC b 2-bromoaniline was used.  
3.3 Synthesis of Triflate compounds  
Triflation of the benzamide is necessary for the compounds made from 2-
(methylamino)phenol to be reactive in the Heck reaction. Past research determined that triflates 
had the best reactivity and enantioselectivity in the Heck reaction when compared to I >Br > Cl.94  
The triflation reaction has the lowest yields in our reaction sequence. Impurities in the amide 
compounds and potential degradation of the compounds on the silica gel column could 






Table 13: Triflate yields 
 
Entry R1 -R Yield (%)a Compound 
1 -H -CH2Ph 70 58 
2 -H -CH2CN 57 59 
3 -CH3 -CH2Ph 84 60 
4 -CH3 -CH2CN 64 61 
5 -CH3 -cyclohexane 56 62 
6 -CH3 -isobutyl 60 63 
7 -CH3 -CH2OCH3 52 64 
8 -CH3 -1-methylnapthalene 62 65 
9 -CH3 -CH2CH2CH=CH2 80 66 
10b -CH3 -sec-butyl 38 67 
11 -CH3 -CH2CH2C C 12 68 
12 -CH3 -CH3 88 69 
a Isolated Yield b Column Chromatography of amide before Triflation  
3.4 The Mizoroki-Heck Reaction 
 As indicated in Chapter 1, the cationic pathway for the Mizoroki-Heck reaction has had 
massive success in palladium-catalyzed research15–20. The enantiomeric selectivity is attributed 
to the alkene-coordination step or the alkene-insertion step. Cationic complex (III, Scheme 20) 
is generated by dissociation of the triflate anion. The alkene substrate can then complex with 
palladium at the vacant coordination site (IV). Alkene-insertion into the palladium-Ar bond then 
affords intermediate (V) where a new chiral carbon center is generated, Scheme 20. A cationic 
complex makes palladium more electron-deficient and is proposed to promote faster insertion 
into the alkene. β-Hydride elimination affords compound VI, which dissociates from palladium 
to yield the Heck product (VII).  
 The stereochemistry is ultimately controlled by chiral bidentate ligand (BINAP), 
coordinated to palladium to maintain the rigid chiral surroundings. Aryl bidentate phosphorous 
ligands were previously found to be successful in the Mizoroki-Heck reaction.19,20 Previous 
Malachowski lab members discovered that BINAP was the best ligand for our reaction 


















Scheme 20: Cationic Pathway for the Mizoroki-Heck Reaction 
Our original focus was to create phenanthridinone analogs from secondary benzamides 
due to examples in the literature presenting bioactivity.22–28 We repeated the work of Dr. Andrew 
Krasley6 in Table 14, entry 1, and received the same inconclusive results. The original reaction 
conditions yielded protodehalogenated product, C, as the major species. A small percentage of 
the desired Heck product was present in the GC; however, only 25% of B was produced after 48 
hours. Optimization of this reaction occurred by changing the temperature, solvent, and 
palladium source in attempts to suppress protodehalogenation as well as promote the formation 
of Heck product B.  
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1 Pd(OAc)2 DMF 80 48 h - 25 62 trace 14 
2b Pd(OAc)2 DMF 80 71 h 37 13 30 trace 25 
3b Pd(OAc)2 DMF 100 22h 32 min - - 30 - 72 
4 Pd(OAc)2 Toluene 80 22 h 15 min 100 - - - - 
5 Pd(TFA)2 DMF 80 24 h 98 - 2 - - 
a Crude yield in GC. b GC a complex mixture. 
 We repeated the reaction conditions from entry 1 but allowed the reaction to go for 72 
hours. This yielded a messy GC with multiple side products, entry 2. Next, the temperature was 
raised to 100˚C in attempts to force the Heck reaction to occur; however, this had the opposite 
effect, and no Heck product was present in the GC (entry 3). All of the starting material was 
consumed to create undesired side products. When the solvent was changed to toluene, the 
reaction was completely shut down, and only starting material remained, entry 4. Finally, the 
palladium source was changed to palladium (II) trifluoroacetate in attempts to promote the 
cationic Heck mechanism. Sabrina Tran had success using this palladium source in the N-Me 
phenanthridinone Heck reaction conditions around the same time that this optimization work was 
occurring.21 Unfortunately, this change did not consume much of the starting material, and the 
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only product present in the GC was compound C. Due to the lack of Heck product B being 
produced and the production of multiple unwanted side products, our focus shifted to different 
reaction conditions to synthesize the desired phenanthridinone analogs.  
Our past work on the γ-arylation of methyl-1-cyclohexene-1-carboxylate, where a tandem 
amide formation / Heck cyclization occurred, proved that a secondary benzamide could be 
utilized in the Heck reaction. Inspired by that work, we analyzed different bases and their 
equivalents in Table 15 due to rearomatized product D being the major product in entry 1 when 
our past reaction conditions were attempted. Application of our reaction conditions to compound 
A in Table 15 did not produce Heck product B. Changes to the amount of base added, entries 1-
3, did not limit the amount of D produced. Switching the base to potassium tert-butoxide 
(conjugate acid pKa ≈ 17)
29, a weaker base than LiHMDS (conjugate acid pKa ~26)
30, in entry 4 
did not make the desired product and lead to an incomplete reaction with undesired side 
products. Cesium carbonate, in entry 5, was attempted due to its marginal solubility in THF, 
which would limit reactivity; however, none of compound B was produced. Raising the 
precatalyst amount consumed all of the starting material and led to exclusively the rearomatized 
product, entry 6. Based upon these results, rearomatization is likely facilitated by palladium. This 
may occur at high temperatures via oxidative addition into the PhCH2-C(quaternary) bond 
(Scheme 21, Pathway A) or a C-H insertion into the bis-allylic position (Scheme 21, Pathway 
B). In pathway A, the base may be deprotonating the amide nitrogen forming an amide anion, 
which can assist in directing palladium to insert into the PhCH2-C(quaternary) bond. Both 

























Scheme 21: Pathways to rearomatized product 
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1 4 LiHMDS 3 28 h 29 min 80 - 1 - 99 - 
2 4 LiHMDS 2 24 80 - trace - 100 - 
3 4 LiHMDS 1 48 80 41 - - 1 58 
4 4 KOtBu 1 48 80 5 - - 50 45 
5 4 Cs2CO3 3 48 80 21 - - 2 77 
6 10 LiHMDS 2 88 h 35 min 80 - - - 100 - 
a Crude yield in GC  
 The synthesis of phenanthridinone analogs from secondary benzamides was not possible 
in our hands; therefore, our focus changed to working with N-Me tertiary benzamide derivatives 
in the construction of phenanthridinone analogs.   
 Past members of the Malachowski lab had already optimized reaction conditions for 
triflated tertiary benzamides in the Heck reaction.6,21 We were able to synthesize 
phenanthridinone analogs in good to excellent yields using their conditions; however, the 
reaction times sometimes took longer than 24 hours to react and the e.r. values were low for 
some substrates, Table 16. 6,21 Using lower temperatures is a standard method to improve 
enantioselectivities; however, when past members of the Malachowski Lab had attempted 
temperatures lower than 80˚C, enantioselectivities were not improved.21  We attributed this to the 
kinetic resolution of the atropisomers of the triflate starting material. We think that one of the 
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atropisomers is more favorable to proceed through the Heck reaction, which is why elevated 
temperatures are necessary for equilibration of those isomers. 
Table 16: Mizoroki-Heck products for N-Me phenanthridinone derivatives 
 





1 -CH2Ph 42 h 42 min 84 9:1 80 69 
2a -CH2CN 24 h 97 8:1 81 71 
3 -C6H11 Cyclohexane 103 h 5 min 24 3:1 55 73 
4 -CH2H10H7 Napthalene 48 h 31 7:1 74 75 
5b -CH2CH2CH=CH2  21 h 27 min 7 8:1 79 76 
6 Cyclized butene product 21 h 27 min 54 42:1d 95 77 
7c -sec-butyl 72 h 26 3:1 51 78 
a No LiOAc was used b 10 mol % Pd(OAc)2, 14 mol % R-BINAP 
c HPLC has three peaks. d The peaks in the HPLC were not entirely resolved 
which is why this number may be elevated. 
In addition to the products, we detected a compound in the GC of the Heck reaction with 
a mass that corresponded to an acetate group, from the reduction of Pd(OAc)2, attached to the 
cyclized product at either C9 or C10, Figure 6. The acetate compound was thought to be a key 
intermediate in our reaction based on its growth and disappearance during the reaction process. 
During the purification of the cyclohexane derivative using column chromatography, we were 
able to isolate the acetate intermediate and we characterized it using proton and COSY NMR, 
Figures 7 and 8. From the proton NMR (Figure 7), it is not clear where the acetate group was 
added. A COSY NMR (Figure 8) was taken to confirm the configuration of the acetate 
compound. The two most important couplings are shown in Figure 8. These couplings should 
occur if the acetate group is attached at C9 (C, Figure 6). H11 is only coupled to the H10 and H10 
is coupled to both H11and H9, so compound C (Figure 6) is the actual structure of the acetate 
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Figure 8: COSY NMR of the acetate intermediate 
Next, we wanted to confirm if compound C was an intermediate in the synthesis of the 
1,3-diene. The cyclohexane derivative was chosen to monitor disappearance of the acetate 
intermediate with time due to an analyzable amount of compound C (Table 17) in the GC under 
standard conditions. A lower palladium and ligand loading than the standard conditions were 
utilized to slow the reaction further to be able to monitor the reaction. The acetate compound 
forms quickly within half an hour into the reaction, entry 1. This means that the 1,3-diene forms 
and is immediately reacted with acetate to create the acetate compound, which we can monitor 
through entries 1-3. In Table 17, we also witnessed compound C’s disappearance with extended 
















Table 17: Reaction Monitoring experiment for acetate intermediate 
 






 30 min 3 31 
2
b
 60 min 4 44 
3
b
 90 min 5 52 
4 19 h 52 min 38 62 
5 24 h 45 55 
6 43 h 43 min 62 36 
7 59 h 39 min 76 21 
8 83 h 48 min 93 7 
9 102 h 19 min 97 3 
a Values are GC yields b Incomplete reaction 
With the acetate intermediate (C) being the major product after 30 minutes, we believe 
that the 1,3-diene, complex III (Scheme 22), is being formed, then the palladium reinserts via 
Pd-H 1,2-insertion to create the allylic complex, IV (Scheme 22). A potential explanation is the 
hydrogen attached to the palladium after β-hydride elimination is not being removed from 
complex III (Scheme 22), and therefore promotes a 1,2 insertion into the double bond to create 
complex IV (Scheme 22).  We speculate that the palladium-allylic complex is a resting state, 
which may be an energy minimum. Extra electron density from the allylic complex may stabilize 
cationic palladium better than association with the alkene. The allylic complex that forms is 
electrophilic, which is prone to nucleophilic addition.31 Acetate, as the nucleophile, may help to 
push or extract palladium out of the energy low and to move the cycle forward. Acetate is a soft 
nucleophile, so it will attack the allylic complex instead of palladium, proceeding via the 
mechanism shown in Scheme 23. Literature examples were in agreement with our hypothesis 
due to numerous reports discussing the interception of a palladium allylic complex by 
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nucleophiles.31–34  Palladium dissociation from the double bond and deprotonation by the base to 
yield the 1,3-diene is slowed by this process. The cationic Heck mechanism may promote 
reinsertion into the double bond to yield allylic complex IV (Scheme 22) due to the weakly 
associated triflate making palladium electron deficient. The allylic complex allows for more 
electron density to be shared with palladium stabilizing the cationic complex. Also, the weakly 
associated triflate allows palladium to have an empty coordination site (III), which allows for the 
















Scheme 22: Cyclohexane acetate intermediate formation 
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Adding another acetate source was hypothesized to increase compound VI (Scheme 22 
)31; however,  we35 found that the addition of lithium acetate to the reaction accelerated the 
reaction to produce the 1,3-diene (III, Scheme 23) as the major product.31,35 We proposed that 
palladium was reinserting into the freshly formed double bond in compound III, formed by the 
Heck cycle, to make the allylic complex IV. Acetate, from lithium acetate, can attack the allylic 
complex forming the acetate intermediate (VI). We hypothesized that, after the acetate 
intermediate forms (VI, Scheme 23), the re-insertion of palladium into the allylic C-OAc bond 
was happening quickly, promoting β-hydride elimination (Scheme 23, VI-->VIII). After β-
hydride elimination, the acetate group remains as a ligand on palladium (X, Scheme 23) and the 
palladium complex is no longer cationic. As a neutral Pd complex, it has less affinity for the 
newly created double bond, which in turn prevents a Pd-H 1,2-insertion from occurring to reform 
the stable allylic complex IV. Electron-poor metal centers bearing electron donating groups, such 
as compound X, react rapidly in the reductive elimination reaction (X->XI, Scheme 23), since 
the ligands lose electron density as the reaction proceeds.36,37 Ultimately this should produce 
acetic acid (XI) in our reaction.  
Another proposed mechanism from complex VI to produce the 1,3-diene product is that 
palladium may associate with the double bond on the top face of complex VI, acetate leaves, and 
the allylic complex can reform. Palladium may then complete a β-hydride elimination to make 
complex III and then dissociate from the product. We are currently unsure which mechanism 
dominates to reform the 1,3-diene from the acetate intermediate based upon our prior 
mechanistic study in Table 17 where it appears that the acetate intermediate forms quickly and 































Scheme 23: Acetate intermediate reaction sequence.  
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Using similar conditions to Table 16, with the addition of lithium acetate, good to 
excellent yields were obtained for compounds 69 to 77. Enantiomeric ratios improved with the 
addition of lithium acetate from Table 16.  This contradicts our past research6,9 and the 
literature38, which hinted that the cationic cycle could lead to the best e.r. values for our 
compounds. While we do not have a definitive reason as to why enantiomeric ratios were 
improved, a theory is that additional acetate in solution may promote an anionic Heck 
mechanism. Amatore and Jutand were the first to report an anionic Heck mechanism promoted 
by acetate in 2000.39 They proposed that an anionic palladium complex required less 
equilibration before the 1,2-insertion step than the cationic palladium complex to make the aryl 
group and the alkene cis- to one another for insertion to occur. This increased the rate of 
insertion and improved enantioselectivities, which prompted us to consider an anionic 
mechanism for our new set of reaction conditions. 
When the benzyl derivative was run with Pd(TFA)2 to eliminate acetate from the reaction 
and to ensure a cationic palladium complex in the reaction, 65% of the product was isolated 
which had an e.r. value of 10:1, entry 1. The difference between using Pd(TFA)2 and Pd(OAc)2 
was minimal for the benzyl derivative (entry 2), which had an e.r. value of 9:1 without lithium 
acetate added. This indicates that the cationic complex may not have as much of an effect on the 
enantioselectivity as we originally proposed. When lithium acetate was added to the reaction, the 
enantioselectivity of the benzyl derivative was increased to 11:1 in entry 2, which also indicates 
that the cationic complex may not be the key to higher enantioselectivities.  
Continuing our analysis, benzyl derivatives 69 and 70 had the same e.r. values; however, 
the yield of compound 70 was low in Table 18 compared to compound 69. Potentially cyanide 
could coordinate to palladium, which could hinder the reaction leading to a lower yield. This is 
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not the case with the acetonitrile derivative in entry 4; however, the enantiomeric ratio is lower. 
Cyanide coordination to the palladium directly participating in the Heck reaction could affect the 
enantioselectivity versus compound 70. The isobutyl derivative unsurprisingly had a lower e.r. 
due to the group’s bulkiness interfering with PdL2 from accessing the appropriate configuration, 
entry 5. Similar results for the cyclohexane derivative (entry 6) and the naphthalene derivative 
(Entry 8) occurred. Ultimately, the size of the R-group could have an impact on the 
enantioselectivity. For example, the methyl derivate had an e.r. of 12:121 and the ethyl derivative 
had an e.r. of 10:1 (not shown)35, which are much higher than entries 4,5, and 7. Using MOM as 
an R group proved beneficial for the Heck reaction due to a high e.r. of 20:1, which is one of the 
highest e.r. values achieved using our reaction conditions. The results in the table indicate that 
both size of the compound and functionalized groups may have an impact on the 
enantioselectivity of the Heck reaction. R groups that were sterically hindered lead to lower e.r. 
values while relatively unhindered R-groups lead to higher e.r. values. R-groups that could 
competitively bind to palladium also hindered the e.r. values. Interesting reactivity was found 
when we analyzed the butene derivatives Heck products. When 3-butene as an R-group was 
subjected to Heck reaction conditions, two different products were found in the GC. The first 
peak, at 13.8 min, was due to the 1,3-diene product (compound 76) and the second peak, at 14.8 
min, was due to an unusual cyclized product (77). When the Heck reaction was run without 
lithium acetate, the cyclized product was the major product (54% isolated product). When 
lithium acetate was used, the 1,3-diene product was the major product (55% isolated product). 
When these products were analyzed using chiral HPLC, the 1,3-diene, in entry 8, had a 
significantly lower e.r. value than the cyclized product, entry 9. The additional cyclization traps 
the ring in a specific formation, which likely increases the enantioselectivity.  
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Table 18: Mizoroki-Heck reaction conditions to make N-Me phenanthridinone derivatives with 














1a,e -CH2Ph 65 n/a n/a 10:1 - 
2 -CH2Ph 92 11:1 83 9:1 69 
3 -CH2Ph(3-CN)  57 11:1 83 n/a 70 
4a -CH2CN 97 8:1 81 8:1 71 
5 Isobutyl 83 7:1 76 n/a 72 
6 -C6H11 Cyclohexane 59 6:1 70 3:1 73 
7b -CH2OCH3 88 20:1 91 n/a 74 
8 -CH2H10H7 Napthalene 65 8:1 79 7:1 75 
9b -CH2CH2CH=CH2  55 12:1 62 8:1 76 
10 Cyclized butene product 14 14:1 87 42:1d 77 
a No LiOAc was used b 10 mol % Pd(OAc)2, 14 mol % R-BINAP 
c HPLC has three peaks. dThe peaks in the HPLC were not entirely resolved 







Figure 10: Butene Heck products 
NMR data such as proton, C13APT, COSY, and HSQC were run in attempts to 
determine the structure of the isolated cyclized product; however, we were unable to elucidate 
the structure. Fortunately, we were able to grow crystals of the cyclized product and an x-ray 
crystal structure was obtained, which confirmed the product’s configuration and stereochemistry 




Figure 11: X-ray crystallography data for cyclized product  
 
The proposed mechanism for the cyclization process is shown in Scheme 25. There are 
various potential reaction pathways for this transformation; however, we believe an allylic 
complex might be the key to the cyclized product based upon our lithium acetate studies. 
Nonetheless, the mechanism of this reaction is complex due to the proton on C13 (Figure 11) 
coming forward. This indicates that palladium would have to be on the backside of the complex 
in order for this to happen. When palladium forms the allylic complex, it should remain on the 
top face of our compound. This is demonstrated by the addition of acetate to the opposite face of 
our compounds, which was confirmed by Dr. Malachowski using NOESY NMR, which did not 
have a coupling between the proton attached to the same carbon as the acetate and the benzylic 
hydrogen (VI, Scheme 23). This is in agreement with Larock and Han’s31 work where they 
indicated that acetate, as a soft nucleophile, should add to the opposite face of the molecule to 
where palladium is attached.  
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After helpful conversations with Dr. Patrick Walsh at the University of Pennsylvania, we 
propose that the cyclized product is forming via the complex mechanism reported in Scheme 25. 
When lithium acetate is present in solution, acetate attacks the allylic complex to form the 
acetate intermediate (XI, Scheme 25) via the pathway marked in dark blue. Then, palladium can 
insert into the C-O bond and proceed via the mechanism reported in Scheme 23 to generate the 
1,3-diene. There is not a vacant site on palladium, when acetate is attached, to coordinate with 
the alkene leading to more 1,3-diene (77) being produced. In addition, this process makes 
palladium uninterested in the less electron-donating alkene from butene. Without lithium acetate, 
the 5-membered ring forms as the major product (VIII, Scheme 25). This occurs using many 
ligand exchanges for palladium to be guided to the back-side of the complex by the butenyl 
group’s alkene. Then, another series of ligand exchanges allows for palladium to be in position 
to reinsert into the olefin in complex IV (Scheme 25) to create the allylic complex. 
Carbocyclization33 of the allylic complex with the alkene bond forms a 5-membered ring, 
complex VI. Finally, β-hydride elimination, then dissociation of the compound from palladium 
produces compound VIII. These results support the hypothesis that the allylic complex is a 
resting state in the reaction due to the cyclized product forming selectively when lithium acetate 






























Scheme 24: Butene Derivative Cyclized Product Mechanism 
3.5 Removal of methyl group from amide nitrogen on Heck product 
Since we could not directly use a secondary amide in the Heck reaction, we decided to 
take our tertiary amide Heck products and remove the methyl group to provide the desired NH 
phenanthridinone analogs. Aluminum chloride has been used as a mild reagent to remove methyl 
groups from ethers and aryl methyl ethers.40–42 However, our attempts to remove the methyl 
group using aluminum chloride failed to produce the desired phenanthridinone (N-H) analogs.  
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Table 19: Removal of methyl group using aluminum chloride 
 






1b Toluene 23 20 h 30 min - - 100 
2 THF 85 18 h 22 min 100 - - 
3 CPME 23 20 h 30 min 100 - - 
4 CPME 85 22h 30 min 100 - - 
5 Toluene 85 24 h 11 min - - 100 
6 N,N-dimethylaniline 85 76 h 24 min - - 100 
7 Anisole 85 48 h 43 min - - 100 
a Values reported are GC yields b Inconclusive Results 
  In all of the reaction conditions, either no reaction occurred, or undesired side products 
were formed. Due to minimal examples of demethylation of tertiary amides in the literature43–45, 
failed alternative methods by other group members6,35, and these disappointing results, we 
decided to attempt a protection/deprotection protocol of the amide to produce the desired 
phenanthridinone analogs.  
3.6 MOM protection/deprotection protocol to produce (N-H) phenanthridinone analogs 
 Qin et al. had published a paper on structurally simple phenanthridine analogs in which 
they synthesized both N-MOM (methoxymethyl) and N-PMB (p-methoxybenzyl) protected 
phenanthridinone derivatives as intermediates in their reaction sequence.46 They provided 
examples of the deprotection of a PMB group and a lithium aluminum hydride (LAH) reduction 
of the N-MOM benzamides of phenanthridinones on the path to phenanthridine derivatives. This 
publication proved that benzamides could undergo a protection/deprotection protocol 
successfully. This prompted us to investigate our secondary benzamides’ MOM 
protection/deprotection protocol to produce the desired N-H phenanthridinone analogs using the 







Figure 12: Protection of secondary benzamide 
In the reaction, sodium hydride was used to deprotonate the secondary benzamide and 
then the resulting amide anion was treated with methyl chloromethyl ether (MOM-Cl). Good 
yields of compounds 79 and 80 were isolated by column chromatography. When these 
compounds were subjected to the standard Mizoroki-Heck reaction conditions, the yields and 
enantiomeric ratios were similar to the N(Me) derivatives, Table 20. Lithium acetate was 
utilized for the benzyl derivative 81 because it decreased reaction time to 24 hours rather than 48 
hours. The acetonitrile derivative 82 did not use lithium acetate because it was found to hinder 
the Mizoroki-Heck reaction and led to the production of the rearomatized side product with the 
triflate group reductively cleaved in addition to the desired product.   
Table 20: Mom protected phenanthridinone derivatives 
 
Entry R Yield 
 
e.r. ee (%) Compound 
1a -CH2Ph 81% 12:1 84% 81 
2 -CH2CN 73% 10:1 81% 82 
a 2.0 eq LiOAc  
 With the desired MOM protected products in hand, we then attempted various reaction 
conditions to try to remove the MOM group. First, we attempted to use various concentrations of 
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hydrochloric acid in methanol, which is a common method for deprotecting MOM groups.47,48 
Concentrated hydrochloric acid was attempted by stirring at room temperature overnight, and 
only starting material remained. Heating the solutions to 62˚C for 4 hours did not change the 
reactivity. Another method was attempted by slowly adding trifluoroacetic acid (TFA) to the 
Heck product and heating the reaction to 70˚C overnight.46 This also failed to promote MOM 
group deprotection.  
Since the other deprotection strategies did not work, we attempted conditions reported by 
Fukuyama and Liu in their work on the stereocontrolled total synthesis of (±)-gelsemine.49  Their 
deprotection protocol worked well for the benzyl derivative producing the secondary benzamide 
product with a matching enantiomeric ratio to the N-Me phenanthridinone analog. The 
deprotection of the acetonitrile derivative was not attempted due to time constraints on finishing 
this research. Finally, we were able to access secondary benzamides, which were previously 





Figure 13: MOM deprotection using Fukuyama and Liu’s procedure 
3.7 Conclusions 
 In conclusion, we were able to synthesize chiral phenanthridinone analogs using the 
Birch-Heck sequence. The Birch reduction/alkylation is a facile way of producing quaternary 
centers in high yields. Tertiary amide triflates (60-69) formed atropisomers which were 
characterized using high-temperature NMR to equilibrate the isomers and coalesce the NMR 
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proton, carbon and fluorine signals.  As stated previously, atropisomers introduce the potential 
for kinetic resolution in the Heck reaction11, but we overcame that complication by heating the 
reactions at elevated temperatures to allow for atrompisomer equilibration during the reaction.12 
The Mizoroki-Heck reaction was accomplished with good to excellent yields and good to 
excellent enantiomeric ratios when lithium acetate was used. We discovered that an allylic 
complex forms when the palladium reinserts into the olefin after β-hydride elimination in our 
reaction. This allylic complex is proposed to be a resting state, which can then undergo 
nucleophilic addition or a 1,2-insertion. Nucleophilic addition of an acetate group leads to the 
1,3-diene being produced at a faster rate and with higher e.r. values. Acetate, as the nucleophile, 
may help to push or extract palladium out of the energy low and to move the cycle forward. 
Acetate may also contribute to an anionic Heck cycle, which was found in the literature to 
increase the rate at the 1,2-insertion step and increase enantioselectivities when compared to the 
cationic cycle.39 
Further analyzation of the various compounds synthesized indicated that R groups that 
were sterically hindered led to lower e.r. values while relatively unhindered R-groups led to 
higher e.r. values. R-groups that could competitively bind to palladium also hindered the e.r. 
values. An important discovery of a tandem Mizoroki-Heck reaction/cyclization via a 1,2-
insertion led to an increase in the e.r. value for the butene derivative. This proves that additional 
functionalization of the 1,3-diene is possible and may lead to future endeavors.  
 Several important conclusions about the (N-H) phenanthridinone derivative were 
discovered in this research. First, secondary benzamides will not produce the desired 
phenanthridinone products under similar reaction conditions used for the tertiary benzamides. 
Second, using xantphos G3 as a precatalyst like the research presented in Chapter 2, section 6 
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did not produce the Heck product. Third, removing the methyl group from the nitrogen on the 
Heck product proved challenging, and aluminum chloride yielded none of the desired product. 
Finally, the MOM protection/deprotection protocol successfully produced the N-H 
phenanthridinone analog for the benzyl derivative with a matching enantiomeric ratio to the N-
Me analog. Deprotection procedures using standard conditions in the literature such as using 
concentrated HCl in methanol or TFA did not deprotect the MOM group, which is why we had 
to use a more involved procedure reported by Fukuyama and Liu.49 
 Future research using this work should explore other derivatives using the MOM 
protection/deprotection on a larger scale. The acetonitrile derivative should also be deprotected. 
This opens doors in our research in both the palladium Heck project and the nickel Heck project 
to produce potentially bioactive compounds. The bioactivity of both the N-H and N-Me 
phenanthridinone analogs will be explored with our biological collaborators at Lankenau 
Institute of Medical Research.  
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– CHAPTER 4 – 
The Birch-Heck Sequence Catalyzed by Nickel 
 Desrosiers and coworkers presented the first enantioselective intramolecular nickel-
catalyzed Mizoroki-Heck coupling to generate quaternary stereocenters using a nickel 
precatalyst.1 They were able to successfully synthesize 3,3’-disubstituted oxindoles with 
quaternary stereocenters in good to excellent yields. However, Yang, Jin, and Wang’s work on 
synthesizing a variety of benzene-fused cyclic compounds bearing a quaternary stereogenic 
center in a highly enantioselective manner inspired us to investigate nickel as a catalyst.2 Both of 
these examples utilize an enantioselective Heck reaction with internal alkenes to form bicyclic 
structures with high enantioselectivities using relatively mild conditions. Switching to nickel 
from palladium could have several benefits such as making our research more cost-effective, 
increasing the rate of the reaction, and allowing for more mild reaction conditions to be utilized. 
In addition, we had hoped that our enantioselectivities would improve based upon the promising 
research on the enantioselective intramolecular Mizoroki-Heck reactions presented in the 
literature and in Chapter 3.1–11 
 Srydstrup et al. 12, Watson et al. 13, and Jamison et al. 14 reported on the use of Ni(0) 
catalyst precursors combined with aryl triflates or pivalates in the Mizoroki-Heck reaction using 
a cationic mechanism. Their conditions were limited due to Ni(0) complex’s high sensitivity to 
air and moisture and the need for electron-rich alkenes. As reported, the most successful reaction 
conditions required a combination of a Ni(II) catalyst precursor with an external reductant such 
as zinc or manganese.13,15,16 This procedure allowed for milder reaction conditions and facilitated 
the cross-coupling of both electron-rich and poor alkenes, which we desired for our compounds.  
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 Due to the success with our palladium research using a cationic Heck mechanism, we 
began to wonder if the same was true for nickel. Desrosiers and coworkers investigated both the 
cationic and neutral pathways for the nickel-catalyzed Mizoroki Heck reaction, Figure 14.1,17 
When they attempted reaction conditions that promoted a cationic pathway, only a 17% yield of 
the desired oxindole was produced with poor enantioselectivity. Neutral pathway conditions 
significantly improved the yield and enantioselectivity. Having an exogeneous halide source, 50 
mol % of LiI, was found to maintain the high level of conversion while also improving the 
enantioselectivity at 60˚C. Overman and coworkers also observed improved selectivity in the 
neutral pathway when halide salts were added.18 For these reasons, the focus of our research 
utilized Ar-Br rather than Ar-OTf to promote a neutral pathway. In addition, we explored the use 
of halide salts to improve the reactivity of our reported conditions.   
 
Figure 14: Comparison of cationic and neutral nickel-catalyed Mizoroki-Heck reaction17 
4.1 Nickel as a precatalyst 
Using Desrosiers and coworker’s studies1 as a starting point, we set out to investigate 
nickel precatalysts in the Mizoroki-Heck reaction to form the desired phenanthridinone analogs. 
We began by using the reaction conditions from Desrosiers and coworkers; however, we ran the 
reaction at 55˚C (Table 21, entry 1). To our delight, there was a peak with the corresponding 
mass of the 1,3-diene. Unfortunately, many side products constituted the majority of material in 
the crude product’s GC. With the promising results of forming the 1,3-diene, we decided to 
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optimize the nickel-catalyzed Heck reaction. If successful, then it would represent, to our 
knowledge, the first example of an intramolecular enantioselective Heck reaction to generate 
tricyclic structures using nickel catalysis.1–11 



























1b NiCl2(R,R-QuinoxP*) 0.5 44 h 26 min 8 12 37 38 13 - 
2 NiCl2(R,R-QuinoxP*) 0.5 15 h 26 min 52 11 8 13 17 trace 
3 (DPEPhos)Ni(o-tolyl)Cl 0.5 16h 39 min 89 - - - 5 - 
4 (XantPhos)Ni(o-tolyl)Cl 0.5 23h 44 min 65 14 11 - - 4 
6 (dppe)Ni(o-tolyl)Cl 0.5 16 h 8 min 93 - - 2 - 7 
7 (dppf)Ni(o-tolyl)Cl 0.5 21 h 16 min - 36 25 trace - 40 
8c (dppf)Ni(o-tolyl)Cl 0.5 21 h 45 min - 32 25 23 21 trace 
9 (dppf)Ni(o-tolyl)Cl 1 21 h 45 min - 37 26 trace 37 trace 
10c,d (dppf)Ni(o-tolyl)Cl 1 96 h 25 min 83 3 2 2 2 7 
11e (dppf)Ni(o-tolyl)Cl 1 24 hr 35 min 95 4 - - - - 
a Values from GC b Reaction run at 55˚C c No base used. d Zn used instead of Mn as reducing agent. e NH instead of N(Me) 
 Repeating the reaction conditions from entry 1 at 80˚C for less time yielded about the 
same amount of B as entry 1 with less side products C-F; however, there was an abundance of 
starting material left. The R, R-QuinoxP* ligand was expensive (100 mg = $141 from Sigma-
Aldrich, 4/8/2021); therefore, we only had a small amount of synthesized precatalyst to use. We 
decided to explore non-chiral nickel precatalysts that were available in our lab in entries 3-11. At 
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the time, we wanted to ensure the production of 1,3-diene Heck product while also gaining 
insight into the types of ligands that should be investigated using nickel precatalysts without 
using up the expensive chiral precatalyst. Out of the various precatalysts explored in entries 3-6, 
(dppf)Ni(o-tolyl)Cl had the best results producing minimal side products and 36% of the 1,3-
diene, entry 7. Analysis of the precatalysts showed that flexible ligands were unsuccessful, which 
is why DPEPhos and dppe failed. R,R-QuinoxP* has bulky tert-butyl groups attached to the 
phosphines, which may block the substrate from getting close to nickel versus sterically 
unhindered dppf. Most importantly, from these reactions, we discovered that ridged ligands, such 
as R,R-QuinoxP*, xantphos, and dppf, showed a small formation of compound C. Ultimately 
with the high cost of the chiral ligand and no conditions that ultimately improved the synthesis of 
the 1,3 diene, we chose to explore other reaction conditions. 
4.2 Heck reaction using a nickel salt and pyox ligand 
 Yang, Jin, and Wang reported on the nickel-catalyzed asymmetric intramolecular 
reductive Heck reaction of unactivated alkenes.2 As discussed prior, reductive Heck reactions 
may be favorable for nickel due to nickel’s affinity for slow β-hydride eliminations. From their 
research, we learned the importance of using pyox ligands with nickel.19 The nitrogen atom of 
the pyridine ring is electron-poor, increasing the rate of the reduction of nickel. The nitrogen of 
the oxazoline ring is electron-rich, which can help promote oxidative addition.19 This balance is 
optimal for the Heck reaction where some steps require the metal to be electron-rich, and others 
need the metal to be electron-poor. In addition, 100 mg of (S)-tert-Butyl-2-(2-pyridyl)oxazoline 
is eight times less expensive than R,R-QuinoxP*. We attempted to utilize Yin, Jin, and Wang’s 
reaction conditions2 with our substrates; however, we had disappointing results. The poor results 
were attributed to either the polar protic solvent or water in the nickel salt acting in polar aprotic 
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solvents as proton sources, which promoted protodehalogenation of the starting material.20 Wang 
et. al. had proposed that the isopropanol in their reaction protonates the Ni-alkyl complex after 
1,2-insertion; however, in our reaction, aryl-nickel protonation was faster than the 1,2-insertion. 
Both polar protic and polar aprotic solvents were investigated using the nickel salt in Table 22. 
Out of all of the reaction conditions screened in Table 22, none of them produced cyclized 
product. Either the reaction returned unreacted starting material or produced compounds E and 
F.  






















1 0.15 0.15 iPrOH 22 55 - - - - 100 - 
2 0.05 0.05 iPrOH 17 55 - - - - 100 - 
3 0.15 0.15 DMF 17 55 - - - - 100 - 
4 0.15 0.15 DMF 27 80 - - - - 92 8 
5 0.15 0.15 DMSO 17 55 - - - - 99 1 
6 0.15 0.15 iPrOH 27 80 - - - - 95 5 
7 0.15 0.15 CPME 49 55 83 - - - 2 3 
 a Values from GC 
Eliminating proton sources was our logical next step. We switched to using NiCl2, which 
was readily available, is cheap, and has shown reactivity in catalyzing reactions.21–23 Shown in 
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Table 23 are the reaction conditions screened for the benzyl derivative using NiCl2 and the pyox 
ligand. Lower temperatures were initially attempted due to Desrosiers and coworker's studies 
which showed great reactivity at 60˚C.1 When the reaction was run at 55 ˚C, the reaction went to 
completion; however, primarily protodebrominated product E was present with small amounts of 
B and C in the GC. The low amounts of compound B indicate that the amount of energy in the 
reaction is not enough to overcome the barrier for 1,2-insertion to close the ring and to overcome 
the barrier to β-hydride elimination. Compared to palladium, nickel is known to be faster at 
oxidative additions24 and 1,2-insertions24, but is significantly slower at β-hydride eliminations.24 
Nickel has a low reduction potential and electronegativity; consequently, oxidative addition 
occurs readily and reduction of the metal is hindered.25 Also, β-hydride eliminations are slower 
due to nickel being smaller than palladium, which leads to poor orbital overlap with the σ* of the 
C-H bond.24 Higher temperatures should help overcome the activation energy necessary for these 
reactions to occur; however, this does not help to explain the high amount of protodebrominated 
product at low temperatures.26–28  
Without an outside proton source in the reaction, we proposed that Ni-H, formed from β-
hydride elimination, could be used to produce compounds C and E. Nickel should complete the 
catalytic cycle; however, it may not be reduced to Ni(0) by zinc. Instead, it can oxidatively add 
into another Ar-Br bond and then reductively eliminate to produce compound E. Due to the high 
amount of protodebrominated product, Ni-H could not be the only path to produce E. Another 
possibility is that nickel is inserting into the Ar-Br bond, and then compound E is being 
generated in the standard workup conditions. Higher temperatures should help overcome the 
activation energy necessary for the 1,2-insertion and the β-hydride elimination to occur, which 
should decrease the amounts of E and F produced.26–28  By increasing the temperature in entries 
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2-5, we were able to limit the amount of protodebrominated product formed, improve the yield 
of compound B, and decrease the reaction time to 10 minutes. This the fastest reaction time that 
we have to date of running Heck reactions.29,30 When the temperature was raised to 150˚C, the 
reaction stalled potentially due to the temperature being too close to the boiling point of DMF. 
The best reaction conditions are listed in entry 4, where the reaction was run at 120 ˚C for 10 
minutes.  
Table 23: NiCl2 in the Mizoroki-Heck reaction. Initial conditions.  
 
 
















1d LiI  1 23h 47 min 55 - 11 16 - 61 12 
2d LiI  1 15 h 80 - 41 48 - 11 trace 
3 LiI  1 10  min 100 - 47 49 - 4 - 
4 LiI  1 10 min 120 - 48 49 - 3 - 
5 LiI  1 21 h 9 min 150 77 3 1 14 5 - 
6 b,d LiI  0.5 23 h 45 min 55 59 4 5 - 15 17 
7 c LiI  1 18 h 26 min 120 50 20 24 - 5 - 
8 LiI  - 10 min 120 - 40 49 - 11 - 
9 LiI  1 10 min 120 - 48 49 - 3 - 
10 LiBr  1 18 h 45 min 120 91 3 3 - 3 - 
11 KI  1 10 min 120 - 43 56 - 1 - 
12e KI  1 10 min 120 - 29 50 - - - 
a Values from GC b Manganese is the reducing agent c 3.0 eq Na2CO3 
d 1 hour ligand association occurred before placing the vial in the pie reactor 
e 1.0 eq. 18-crown-6  
 
Next, we moved onto the investigation of additives to improve reactivity. When we were 
still exploring lower temperatures, manganese was used instead of zinc to reduce nickel, entry 6. 
Starting material was the major species in the GC, which indicated that manganese was inferior 
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to zinc, entry 1, as a reductant for our reaction. Sodium carbonate, a weak base,  was added in 
entry 7 to sequester protons in solution, limiting protodehalogenation, and to participate in the β-
hydride elimination if nickel could not access the β-hydrogen. However, the reaction stalled, and 
equal amounts of compounds B and C were produced.  
Desrosiers et. al. and Overman et. al. both reported on the addition of exogenous halides 
to improve yields and enantioselectivity of their products through the promotion of a neutral 
Heck mechanism.1,18 The necessity of adding LiI was probed in entries 8 and 9. When LiI was 
not present in the reaction, entry 8, there was about four times more of the protodebrominated 
product present than in the reaction with LiI added, entry 9. Our results made us question the 
purpose of the halide salt in our reaction because prior literature explanations of keeping a 
neutral cycle did not explain why protodehalogenation was hindered. Another function of 
exogeneous halide sources was discussed by Wang and coworkers when they also experienced 
increased reactivity when iodide sources were added into their nickel catalyzed reactions.9  They 
cited Colon and Kelsey’s investigation into the kinetic effect of the added halide salts on nickel-
catalyzed coupling of aryl chlorides with excess reducing metal.31 Colon and Kelsey’s studies 
showed that halide salts accelerated the reduction of NiCl2 to active catalyst in the sequence 
I>Br>Cl> no salt31 They proposed that the added halide associates to nickel to make a 
pentacoordinate nickelate complex, which can form a bridged Zn complex to facilitate electron 
transfer. In addition, halogen exchange was not supported by their data because neither 
bromobenzene nor iodobenzene were detected in the presence of added halide salts. Added 
halogens that act as bridging ligands in the reduction of nickel by zinc could explain the role of 
lithium iodide in our reaction, since halogen exchanged starting material was not present in our 





Figure 15: Formation of nickelate intermediate, bridging ligand complex, and reduced nickel  
Based on the success of lithium iodide in minimizing the protodehalogenation side 
reaction, we decided to explore different metal halide additives. Lithium bromide, entry 2, 
hindered the reaction, with starting material being the major species in the GC. Excess bromide 
in solution might force equilibration of the reaction towards the starting material. Potassium 
iodide, the most ionic halide salt, was the best additive to limit the amount of protodehalogenated 
product (E), entry 3. To make the iodide more reactive, we used 1.0 eq of 18-crown-6 in entry 4 
to sequester the potassium. This change to the conditions eliminated the protodehalogenated 
product; however, it led to more over-reduced product C.  While it is not clear how the halide 
improves our reaction, we can confirm that the iodide interferes with the production of the 
protodehalogenated product. With the optimized temperature and halide additive in hand, we 
decided to explore different ligands in attempts to produce the 1,3-diene selectively.  
4.3 Exploration of cationic vs. neutral pathway  
 To confirm our suspicions from Desrosiers et.al.’s work, we also ran experiments with 
Ar-Br and Ar-OTf to probe a neutral vs. cationic pathway. Switching the ligand from pyox to 
2,2’-bipyridine yielded similar results to the pyox ligand with using a neutral pathway, entry 1. 
Although these results were not an improvement on the conditions reported in Table 23, the 
bipyridine ligand had comparable results to the pyox ligand and was more cost-efficient, so it 
was used in subsequent reaction screening. Next, we attempted to use racemic BINAP and the 
triflate precursor due to their success in our palladium research; however, the reaction failed and 
only had starting material and compound F. BINAP may be too bulky with nickel for oxidative 
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addition and the 1,2 insertion to occur. Nickel is smaller than palladium, so more cumbersome 
ligands may shield the substrate from the catalyst. We also attempted to use aryl triflate starting 
material instead of aryl bromide with the pyox ligand; however, the reaction failed to produce 
cyclized product.  
Table 24: Ligand screening: cationic vs. neutral pathway 
 
Entry X Nickel 
Eq. Ligand 
Ligand 













1 Br 0.1 2,2'-bipyridine 0.1 10 min 120 - 41 44 - - trace 
2c -OTf 0.15 rac-BINAP 0.15 19 h 21 min 55 57 - - - - 43 
3b -OTf 0.1 pyox 0.1 10 min 120 93 - - - - 7 
a Values from GC b1 h ligand association c No KI 
These results confirmed that a neutral pathway is required for our precursors to progress 
through the Mizoroki-Heck reaction to produce cyclized products. Research in optimization of 
the ligand is still occurring in our lab. One of the critical parts of our research is to make chiral 
compounds, which requires the use of chiral ligands. Other pyox-type ligands will be explored in 
our lab due to the promising initial results. A major issue with optimization using the benzyl 
derivative specifically was that compounds B and C could not be separated using column 
117 
 
chromatography to be able to produce accurate HPLC data, which explains the absence of yields 
and e.r.’s.  
4.4 Nickel Mizoroki-Heck reactions of the methyl derivative  
 Attempts to isolate the 1,3-diene without the over-reduced side product forming for the 
benzyl derivative proved difficult. We decided to analyze the methyl derivative next due to it 
being sterically unhindered and having great success in the palladium-catalyzed Heck reactions. 
First, attempts were made in entries 1 and 2 (Table 25) to utilize the benzyl derivative reaction 
conditions; however, the reaction was incomplete after 10 minutes. We were able to isolate 
compounds B (compound 84, Chapter 6, 4%) and C (compound 85, Chapter 6, 21%) from 
entry 1 via column chromatography and characterize them using 1H NMR (see experimental data 
in Chapter 6.3.7). Unfortunately, when we took HPLC data, the 1,3-diene had a 1:1 ratio. In the 
interest of further optimizing the reaction conditions for yield and efficiency, we turned to 
analyze the effect of halides in the reaction.  
We switched the halide to iodide to eliminate one type of halide in our reaction sequence 
due to having Br, Cl, and I present and potentially accelerate oxidative addition. The Ar-I bond is 
longer than Ar-Br due to iodide having a larger atom size, which decreases the strength of the 
bond. When we ran the same reaction conditions with the iodide substrate, the results were 
similar to entry 1 with bromine, so we switched to analyzing our reaction conditions using the 
iodide substrate, entry 3. Increasing the amount of potassium iodide limited the amount of 
protodehalogenated product E but lead to an increased yield of compound D, entry 4. The 
reaction is possibly proceeding faster than 10 minutes due to the assisted reduction of nickel 
through the nickelate complex. The extra reaction time could lead to palladium-catalyzed 
isomerization of the alkene to the 1,4-diene, which has been witnessed in palladium-catalyzed 
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Heck reactions that we have conducted.32  Not using any potassium iodide decreased cyclized 
product B’s yield and increased the amount of protodehalogenated product E (entry 5), which 
was consistent with our data from the benzyl derivative. Switching the additive from KI to LiI 
increased protodehalogenated product E, entry 6, which is consistent with our data from the 
benzyl derivative. When we added triethylamine as a proton scavenger, entry 7, there was no 
effect on the reaction versus entry 4. 






Entry X KI A (%)a B (%)a C (%)a D (%)a E (%)a F (%)a 
1 Br 1.0 - 51 32 17 - - 
2b Br 1.0 - 39 22 8 1 - 
3c I 1.0 - 52 32 13 3 - 
4 I 3.0 - 50 34 16 1 - 
5 I - - 43 27 16 14 - 
6 I LiI 2 eq - 47 31 13 9 - 
7d I 3.0 - 54 30 13 2 - 
a Values from GC b 1 eq Zn c Ni(COD)2 
d1.0 eq Et3N  
Next, we explored various ligands that were readily available to screen using a neutral 
Heck cycle. Since Ni(COD)2 and NiCl2 had similar reactivity, this is demonstrated later on in 
Table 28, we used them interchangeably while attempting different reaction conditions, Table 
26, entry 1. When we tried to use racemic BINAP, the reaction yielded mainly starting material, 
entry 2. When we utilized a quinox ligand, entry 3, less Heck product B was produced, and more 
of the protodehalogenated product was present. These reactions confirmed the need for 
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oxazoline-based ligands in our reaction. Other chiral ligands are being explored in our lab to 
improve the enantioselectivity as well as the yield of the 1,3-diene products.  
















1 Ni(COD)2 pybox - 52 32 13 3 - 
2 Ni(COD)2 rac-BINAP 94 0.70 0.7 4 0.10 - 
3 NiCl2 2-(4,5-dihydro-2-oxazolyl)quinoline - 45 24 16 14 - 
a Values from GC   
 With every reaction that yielded protodehalogenated product, we began to question 
whether the zinc was inserting into the Ar-X bond rather than nickel promoting 
protodehalogenation.2 We wanted to study the reaction without the Ni catalyst added to the 
solution and use deuterium as a marker to be able to produce compound B. In entry 1 (Table 27), 
although the reaction was incomplete, the most prominent peak at 10.4 min in the GC had a mass 
of 228 g/mol, which corresponds to deuterated product B. Potassium iodide does not restrict this 
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process as it does with the nickel catalyst present. From this experiment, we conclude that zinc 
functions as a reductant to nickel under our normal reaction conditions,31 but it can also compete 
with nickel to insert into the Ar-I bond and potentially lead to protodehalogenation side 
reactions. Also, a peak at 11.9 min had a mass of 227 g/mol, which may be due to compound D 
or an isomer of D. When manganese was used instead of zinc, only starting material remained, 
entry 3. Manganese does not insert into the aryl-halide bond, which may potentially eliminate the 
protodehalogenated product in our reaction.  More investigation into this process needs to be 
done to potentially limit the zinc-enabled protodehalogenation process and investigate its impact 
on the reaction with nickel.  




Entry D2O Reductant Time A (%)a B (%)a C (%)a D (%)a 
1 0.5 eq Zn 20 min 36 47 - 17 
2 - Zn 16 h 19 min - - 47 53 
3 - Mn 18 h 12 min 100 - - - 
a Values from GC  
A series of optimization conditions are shown in Table 28. The best reaction conditions 
are shown in entry 1, which had the most product and the least amount of side products D and E. 
The reaction was rerun, but no zinc was added in entry 2 to confirm that zinc was necessary in 
the reaction sequence. No reaction occurred, which confirmed that zinc is needed to reduce 
nickel chloride to be active in the reaction. When we attempted to use manganese instead of zinc, 
entry 3, all of the starting material was consumed, there was a minimal amount of 1,3-diene, and 
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the protodehalogenated product was the major product. This contradicts the results in our metal 
insertion study in Table 27, where manganese did not insert into the Ar-I bond to contribute to 
protodehalogenation. This suggests that the major path to protodehalogenation does not involve 
manganese or zinc and can happen with just the Ni/L catalyst. Zinc was the best reductant for our 
reaction sequence. 
Next, we attempted to investigate NiI2, NiBr2, and Ni(COD)2 in comparison to NiCl2, 
Table 28, entries 4-6, which would also further probe the role of halides in the reaction. Nickel 
chloride had the best results in entry 1; however, these reaction conditions were not run with the 
bromine derivative. Nickel bromide, entry 4, and nickel iodide, entry 5 had similar results to 
nickel chloride, so these results are inconclusive. The reaction using Ni(COD)2  had 0.5 eq of 
nickel and 0.5 eq of ligand because Ni(COD)2  is Ni(0) and does not need to be reduced, which 
makes it prone to degradation. Ni(COD)2 had similar reactivity to NiCl2 when bipyridine was 
used as the ligand, entry 6. More reactions need to be done to explore the effect of these nickel 
sources.   
We decided to vary the amounts of reactants when using Ni(COD)2 and bipyridine to 
optimize reactants’ quantities since entry 6 had similar reactivity to NiCl2 and the pyox ligand in 
entry 1. We raised the amounts of Ni(COD)2 and ligand in entries 7 and 8 and found that the 
conditions that were the most similar to entry 1 was when one equivalent of nickel and base was 
used. Next, we added zinc to the Ni(COD)2 reactions to see if it was needed to reduce nickel after 
β-hydride elimination, to hinder protodehalogenation, and increase the reactivity of nickel. 
However, it increased the amount of protodehalogenated product E, entries 9-10, which is 
consistent with our data on zinc inserting into the aryl-halide bond. That process promotes 
protodehalogenation. More investigation into this process needs to be completed in the future.  
122 
 

































1 I 3 1 NiCl2 0.20 L1 0.26 120 10 min - 50 32 9 9 




1 NiCl2 0.1 L1 0.1 120 26 h 22 min - 11 - 2 37 
4 Br 1.5 1 NiBr2 0.20 L2 0.20 100 10 min - 52 18 9 21 
5 Br 1.5 1 NiI2 0.20 L2 0.20 100 10 min - 53 18 8 21 
6 Br - 1 Ni(COD)2 0.5 L2 0.5 120 10 min - 49 10 9 11 
7 Br - 1 Ni(COD)2 1 L2 1 120 10 min - 57 7 6 29 
8 Br - - Ni(COD)2 1.5 L2 1.5 120 10 min - 44 7 18 30 
9 Br 0.5 - Ni(COD)2 1 L2 1 120 10 min - 48 9 13 30 
10 Br 1.5 1 Ni(COD)2 1 L2 1 120 10 min - 41 8 12 23 
11c Br - - Ni(COD)2 1 L2 1 120 10 min - 55 9 9 28 
12d Br - - Ni(COD)2 1 L2 1 120 10 min - 52 9 - 39 
13e Br 1.5 1 NiCl2 0.10 L2 0.1 120 10 min 15 16 25 21 13 
     a Values from GC b 3 eq of zinc added after 10 minutes of stirring c 1 eq K2CO3 
d 1 eq Cy2NMe 
e 2 eq NaH 
 In entries 11-12, we added 1 eq K2CO3 and 1 eq Cy2NMe, respectively, to eliminate any 
protons in the reaction that could potentially lead to protodehalogenation. Unfortunately, the 
addition of base did not affect the outcome of the reaction significantly. Sodium hydride as a 
stronger base or potential proton source in entry 13 gave a messy GC with lots of side products 
present. Excess protons in our reaction can cause unwanted side products to form.  Since we 
were unable to limit the amount of protodehalogenated product through variations on the 
components in our reaction, we investigated other sources to help limit protodehalogenation. 
As discussed prior, we hypothesized that Ni-H was not getting reduced after the β-hydride 
elimination in the Heck sequence and was then involved in creating unwanted side products, the 
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over-reduced product (Table 28, C), the alkene product (Table 28, D) and the 
protodehalogenated material (Table 28, E). A search in the literature about this particular 
problem led us to Lv and coworkers work where they utilized a sacrificial alkene in their Heck 
reaction to sequester H2 from nickel in the last step of their synthesis of arylated γ,δ- and δ,ε-
unsaturated carboxamides to regenerate Ni(0), Scheme 26.33 We hoped that by adding a 
sacrificial alkene into our reactions, we could limit, or eliminate, the over-reduced product and 











Scheme 25: Lv and coworkers oxidative Heck cycle with sacrificial alkene (S.A.) 
We attempted to utilize cyclohex-2-en-1-one (S.A.1) as a sacrificial alkene to eliminate 
side products C and E. At 80˚C after 10 minutes with Ni(COD)2 (1 eq.) and bipyridine, all of the 
starting material was consumed and 53% of the 1,3-diene was present in the GC, entry 1. 
Cyclohex-2-en-1-one is sterically unhindered where the alkene is located and is polarized 
towards the carbonyl group, which may contribute to it acting as a good sacrificial alkene. In 
addition, we also analyzed 1,1-diphenyl ethylene (S.A.2) and trans-cinnamaldehyde (S.A.3) as 
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sacrificial alkenes in entries 2-3.  1,1-diphenyl ethylene, entry 2, yielded mostly 
protodehalogenated product (E), possibly due to the steric hindrance around the alkene. Trans-
cinnamaldehyde had similar results to entry 1, which may indicate that polarized alkenes are 
better sacrificial alkenes for our reaction.   
We then probed the reactivity of  S.A.1 versus S.A.3 with nickel chloride and zinc; 
however, after 10 minutes, mainly starting material was present in the GC, so the temperature 
was increased to 100 ˚C, and the reaction was resumed for another 10 minutes. The reaction 
using S.A.1 ran to completion; however, S.A.3 did not. To analyze the sacrificial alkenes 
properly, we decided to run both of the reactions at 150 ˚C in entries 6-7. S.A.1 was the superior 
sacrificial alkene that limited protodehalogenation and had a high amount of compound B.  
Next, we wanted to explore the best temperature for our reaction to run with (S.A.1) and 
KI to minimize protodehalogenation, entries 8-10. Entry 9 contained the best results achieved 
during this research which had the most compound B and limited side products.  After 
optimizing the sacrificial alkene additive’s reaction conditions, we returned to explore the effect 
of the halide additive. Adding potassium iodide, entry 10, hindered the reaction and there was 
significantly less of the 1,3-diene product (B) at 150˚C. Changing the additive to LiI, entry 11, or 
NaI, entry 12, also hindered the reaction with less of the 1,3-diene product (B) being produced 
than in entry 9. Raising the temperature to 150˚C, near the boiling point of DMF, was not 
favorable for our reactions. The optimal temperature determined was 120˚C that limited side 





































NiCl2 0.2 0.20 2 80 10 - 48 8 1 44 
3 - - Ni(COD)2 1 1 3 80 10 - 52 22 23 5 
4 1.5 - NiCl2 0.2 0.20 1 
80 (10min)-
>100(10min) 
20 - 45 20 13 21 
5 1.5 - NiCl2 0.2 0.20 3 
80 (10min)-
>100(10min) 
20 46 16 - 2 35 
6 - - Ni(COD)2 1 1 1 150 10 - 54 28 18 0.20 
7 - - Ni(COD)2 1 1 3 150 10  - 42 22 13 1 
8 - 1 Ni(COD)2 1 1 1 100 10 - 53 21 19 7 
9 - 1 Ni(COD)2 1 1 1 120 10 - 63 18 13 6 








Ni(COD)2 1 1 1 150 10 - 43 16 13 6 
a Values from GC   
Unfortunately, even with the best reaction conditions, there was still a complex mixture of 
products and protodehalogenation. Other members of the Malachowski lab are still investigating 
this project to attempt to understand the mechanism of this reaction.   
4.5 Conclusions 
 In conclusion, the nickel-catalyzed Mizoroki-Heck reaction has had promising results 
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during optimization. We learned several important lessons from the research presented. First, we 
learned that nickel precatalysts do not work well with our substrate. Second, when we attempted 
to use Ni(BF4)2·6H2O, proton sources from the solvent as well as from the salt hydrate 
contributed to making the protodebrominated side product. Even with polar aprotic solvents, the 
major product produced was the protodehalogenated product. Third, pyox ligands were found to 
be the best ligands to use with nickel due to their push-pull nature being favorable for Heck 
reaction conditions. BINAP, a phosphorous based ligand, did not work with nickel; however, it 
was found to be the best ligand for our palladium research. Fourth, various metal halide additives 
were screened to help reduce the amount of protodehalogenated product. Potassium iodide, the 
most ionic halide salt, was found to be the best additive that is predicted to help reduce nickel via 
a nickelate complex. Fifth, bromide and iodide substrates can be used without much change in 
the Heck reaction results. More research needs to be done to investigate reactivity between 
halide substrates. Sixth, zinc can insert into the aryl-halide bond and may contribute to the 
closing of the ring to make the over-reduced product. Ongoing studies of the effect of zinc are 
being investigated by another graduate student in our lab, Diana Rachii.34 Seventh, nickel 
chloride was found to have the best results of all of the nickel sources, although there was not 
much of a difference between using NiCl2, NiI2, or NiBr2 as confirmed by Diana Rachii.
34 
Finally, one of the most important discoveries in our research was the benefit of using a 
sacrificial alkene. Cyclohex-2-en-1-one was found to be the best sacrificial alkene to sequester 
H2 from nickel, which may be attributed to its alkene being sterically unhindered as well as being 
polarized towards the carbonyl.  
 The promising results of this project have inspired our lab to continue research in using 
nickel to catalyze the Mizoroki-Heck reaction to make phenanthridinone analogs. The process is 
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particularly useful because of the speed of the reactions and the significantly lower cost of the 
nickel transition metal catalyst. The research presented in this dissertation attempted to limit the 
amount and yield of side products in the reaction. Next steps in the optimization sequence are to 
explore other ligands and eventually find a chiral ligand to enhance the enantiomeric ratio to a 
level worthy of publication.  
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– CHAPTER 5 – 
Conclusions 
5.1- Conclusions 
 A variety of transition metal catalyzed cross-coupling reactions were explored with both 
palladium and nickel including enolate cross-coupling and the enantioselective Mizoroki-Heck 
reaction. Buchwald G3 palladium precatalysts have been successful in catalyzing the γ-arylation 
of α,β-unsaturated ketones and esters. The γ-arylation of 7-methoxy-4-methylcoumarin worked 
exceptionally well with electron-rich, electron-poor, and sterically diverse aryl bromides. Aryl 
chlorides were also tolerated when higher temperatures and N-xantphos G3 was used.35 
Attempts at expanding our reaction conditions to other α,β-unsaturated ketones and esters 
exhibited the limited scope of our conditions due to a lack of selectivity. Polyarylation products 
could not be avoided in the synthesis of isophorone, 3-methyl-2-cyclohexen-1-one, and ethyl 
crotonate. We were able to confirm that when α'-protons were available, for example, with 1-
acetyl-1-cyclohexane, mono-α'-arylated product was produced. We had more promising results 
when we utilized methyl-1-cyclohexene-1-carboxylate to eliminate α-protons, which should 
allow for γ-arylation to occur.  
The γ-arylation of methyl-1-cyclohexene-1-carboxylate worked well for electron-rich 
aryl halides; however, there were issues with isolating the products, which lead to low yields. 
The γ-arylated product we isolated did not have the double bond in the α, β-position; instead, we 
confirmed that the double bond had shifted to the β, γ-position. This reaction ultimately proved 
that we could arylate methylene carbons selectively. When 2-bromoaniline was attempted in the 
γ-arylation of methyl-1-cyclohexene-1-carboxylate, a sequential amide formation/ Mizoroki 
Heck reaction occurred which formed a 5 membered ring. Unfortunately, this reaction produced 
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constitutional isomers that were inseparable. Due to the lack of funding and the numerous 
problems presented, we made the decision to stop research on this project and continue to the 
Birch-Heck sequence, which is the main research area in the Malachowski Lab.  
 The Birch-Heck sequence is a method developed by the Malachowski lab, which has 
been used to synthesize potentially bioactive drug precursors.29,30 Our focus was to create 
phenanthridinone analogs which have shown bioactivity in the literature.36–53 The Birch 
reduction-alkylation creates quaternary carbon centers in high yields from inexpensive, 
commercially available materials.54,55 A sequential acid chloride/amide formation produces the 
benzamide in high yields. We propose that atropisomers are forming in the tertiary benzamides 
due to the need for high-temperature NMR to resolve the peaks.56–59 The tertiary benzamide has 
restricted rotation around the N-Ar or N-(C=O) bond, which leads to the formation of 2 different 
atropisomers.57 Triflation of the amide phenol products was found to have the lowest yields in 
the reaction sequence. Either the benzamides had impurities or the triflates were degrading in the 
column, which could explain the low yields obtained. Atropisomers were also present in the 
triflate compounds. Finally, the enantioselective Mizoroki-Heck reaction had several important 
discoveries. Atropisomers introduced the potential for kinetic resolution in the Heck reaction.56 
We overcame that complication by heating the reactions at elevated temperatures to allow for 
equilibration of the rotational isomers in the Heck reaction.57 Initial studies using past 
Malachowski Lab members conditions29,32 for the Heck reaction had low yields and low e.r. 
values.  We were able to improve the yields and e.r. values by adding lithium acetate into our 
reaction, which was determined to cause progression of the Heck reaction past a palladium 
allylic complex and was proposed to potentially cause the reaction to proceed through an anionic 
mechanism instead of a cationic mechanism. 
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In our studies, we also discovered that an acetate intermediate was present in our 
reaction. Our lab discovered an acetate intermediate formed quickly after the 1,3-diene was 
produced when excess acetate was added to our reactions. To make the acetate compound we 
isolated, palladium would have to reinsert into the olefin after the 1,3-diene is produced. Our 
current hypothesis as to why palladium would reinsert is that a palladium allylic complex is 
formed, which is a resting state. This was confirmed by two different examples of nucleophilic 
attack of the allylic complex. When excess acetate is added, it can attack the allylic complex, 
which is why we see the acetate intermediate in our reaction. Another example of interception of 
the palladium allylic complex was when we used the butene derivative in the Heck reaction. The 
butene derivative not only yielded the 1,3-diene, but it also formed a product with a 5-membered 
ring. The cyclized product was also made by interception of a palladium allylic complex.  The 
structure of the cyclized product was confirmed using X-ray crystallography. Ultimately, we 
determined that additional functionalization of the allylic complex may help palladium out of the 
energy low, which moves the cycle forward.  
 Another important discovery in our research was applying a protection/deprotection 
protocol to access N-H phenanthridone analogs. Secondary benzamides did not produce the 
desired Heck products using our standard reaction conditions. Attempts at removing the methyl 
group from the tertiary phenanthridinone Heck products proved futile as well. Using a protection 
strategy, we were able to synthesize the MOM-protected Heck products in high yields. Removal 
of the MOM group did not occur when standard acid cleavage protocols were attempted60,61, but 
ether cleavage with TMS-I and hydrolysis of the hydroxymethyl group provided the secondary 
benzamide phenanthridinone product without compromising the enantioselectivity of the Heck 
reaction. Ultimately, this process provides access to N-H phenanthridinone products that could 
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not be accessed using the Heck reaction. This opens doors in both the palladium project and 
nickel project to synthesize potentially bioactive compounds.  
 We also had some success with our attempts at nickel catalyzed Heck reactions. We 
learned several important lessons from the research presented. Both nickel precatalysts and 
Ni(BF4)2·6H2O did not work with our substrate. Proton sources from both the solvent and the 
nickel salt were proposed to promote protodebromination. Pyox ligands were found to have the 
best reactivity with nickel; whereas, BINAP was found to be the best ligand for our palladium 
research. Pyox ligands benefit from the electron-poor nitrogen atom of the pyridine ring and the 
electron-rich nitrogen of the oxazoline ring. Oxidative-addition is promoted by the electron-rich 
oxazoline ring, and the reduction of nickel is promoted by the pyridine ring. This balance is 
optimal for the Heck reaction vs. electron-rich BINAP.19 Metal halide additives were found to 
minimize the amount of protodehalogenated product via a proposed nickelate complex, which 
helps to reduce nickel. Studies to investigate the purpose of the halide salts are ongoing in our 
lab. Zinc, as an additive, was found insert into the aryl-halide bond and could contribute to the 
closing of the ring to make the over-reduced product. Finally, one of the most important 
discoveries in our research was the benefit of using a sacrificial alkene, which was found to limit 
protodebromination. Unfortunately, when we obtained HPLC data using the methyl derivative, 
the e.r. was 1:1 when we used (S)-4-(tert-butyl)-2-(pyridin-2-yl)-4,5-dihydrooxazole as the 
ligand. A screening of chiral ligands will need to be accomplished in future studies on this 
project.  
 We demonstrated the benefit of using palladium to synthesize C-C bonds via γ-aylation 
and in the Mizoroki-Heck reaction. We made significant discoveries in our enantioselective 
Mizoroki-Heck reaction using nickel and palladium, respectively. We improved upon the work 
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of past members of the Malachowski lab and provided a strategy to access N-H phenanthridinone 
analogs. While important discoveries in the optimization of the nickel project were achieved, 
studies are ongoing in our lab.  
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– CHAPTER 6 – 
Experimental 
6.1 General Experimental Details 
General:  Unless otherwise noted, all reagents were purchased from commercial sources and 
used as received without further purification. Solvent was purchased from Sigma-Aldrich 
(anhydrous, sure-seal) or similar vendor and used as received. Anhydrous tetrahydrofuran (THF) 
was obtained by distillation from benzophenone-sodium under argon. Ligands were purchased 
from Strem Chemical, Inc. and the Buchwald G3-precatalysts were prepared in accordance with 
literature procedures1. When performing air sensitive reactions, reagents and solvents were 
transferred using either stainless steel cannulae or plastic syringes equipped with stainless steel 
needles. Air-sensitive reactions were performed under a positive pressure of either nitrogen (N2) 
or argon (Ar) in reaction vessels sealed with rubber septa. 
 Thin layer chromatography was carried out on silica gel plates and eluted plates were 
visualized with UV light (254/365 nm) or basic potassium permanganate (KMnO4).. Flash 
chromatography was carried out on silica gel (60 Å, 230-400 mesh) or with Biotage® Sfär Silica 
- 60 μm 20 g or 10 g columns. All yields refer to isolated yields of analytically pure product 
unless otherwise noted. Melting points were measured on a digital melting point apparatus and 
are uncorrected.  1H and 13C {1H} NMR spectra were recorded at 400 MHz and 100 MHz, 
respectively, on a Bruker 400 MHz instrument. Spectra were recorded in ppm and referenced to 
residual solvent CHCl3 (7.28 ppm) or DMSO (2.50 ppm). 
1H NMR data are presented as 
follows: chemical shift, multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, 
dd=doublet of doublets, etc.), integration, and coupling constant(s) in Hertz (Hz). 13C NMR data 
are reported in ppm relative to the solvent signal, CDCl3 (77.0 ppm) or DMSO (39.5ppm). 13C 
NMR experiments were conducted with either the broad band decoupled (CPD) or the attached 
proton test (APT) pulse sequence. GC analyses were performed with a EI-MS detector fitted with 
a 30 m x 0.25 mm column filled with crosslinked 5% PH ME siloxane (0.25 um film thickness); 
gas pressure 7.63 psi He. Analysis of samples involved heating from 70 to 250oC (10oC / min), 
then hold at 250 oC for 5 minutes. Low resolution, electron impact (EI mass spectral data is 
presented as follows: mass ion peak (relative intensity).  High-resolution mass spectroscopy data 
were collected on the Thermo Q-Exactive Orbitrap, a high resolution mass spectrometer. The 
ionization method was heated electrospray (HESI). Samples were introduced via UHPLC with 
no chromatography. Mobile phase was 80:20 Water (0.1% formic acid): Acetonitrile (0.1% 
formic acid), flow rate of 0.2mL/min. IR data was obtained with an FT-IR spectrometer and all 
were recorded as thin films. HPLC analysis was conducted using an Agilent 1100 fitted with a 











6.2 γ-arylation General Procedures and Data 





Scheme 26: Williamson-ether synthesis of 7-methoxy-4-methylcoumarin 
A similar procedure to Bing Gong et al was used2. A three-necked 1000 mL roundbottom 
flask with a mechanical stir bar was charged with 4-umbelliferone (22.6 g, 128 mmol), 
potassium carbonate (35.5 g, 257mmol), methyl iodide (16mL, 257 mmol), and acetone (500 
mL). The reaction was left to reflux for 6 hours and then was left to cool overnight. The next 
day, a standard extraction was done using ethyl acetate. Magnesium sulfate was used to dry the 
solution and gravity filtration was performed. A white free flowing powder was isolated yielding 
15.6 g (89%) of pure product. 1H NMR (400 MHz, CDCl3): δ 7.43 (d, 1H, J=8.8), 6.78 (m, 2H), 
6.08 (d, 1H, J=1.1), 3.81 (s, 3H), 2.33 (d, J=1.2) ppm. Spectral data were in accordance with the 
literature3. 





Scheme 27: Reaction conditions for aryl bromides 
All reactions were prepared at the 1.0 mmol scale in a glovebox using 8-mL screw cap 
vials with a Teflon-coated stir bar. The vial was charged with 4% Xantphos Pd G3 (0.038 g, 0.04 
mmol), 7-methoxy-4-methylcoumarin (0.190g, 1mmol), and an aryl bromide (1.05 mmol). Next, 
3 mL of a 1.0 M LiHMDS solution was added. Finally, 2 mL of THF was added to the reaction 
vial. The reaction was capped, removed from the glovebox, and allowed to stir on an aluminum 
block preheated to 70 °C for 24 hours. Upon completion, the reaction was allowed to cool. A 
standard workup was completed using about 2.5 mL of a 2.0 M HCl solution and 
dichloromethane to extract. Magnesium sulfate was utilized to dry the sample before gravity 
filtering and removing the solvent under reduced pressure. Completion was checked using TLC 
and GC-MS. The crude reaction mixture was loaded onto a silica gel column using a wet load 






4-benzyl-7-methoxycoumarin: Using the general procedure outlined above with bromobenzene 
(126 μL, 1.2 mmol), the crude reaction mixture was purified using column flash chromatography 
(silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl acetate (Rf = 0.36) and 0.261 
g (98%) of an orange powder was isolated. m.p. 137-139 °C.  IR (neat): 3065, 2921, 2852, 1704, 
1606, 1512, 1277 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.55 (d, 1H, J=8.4 Hz), 7.38-7.23 (m, 6H), 
6.84-6.81 (m, 2H), 6.01 (s, 1H), 4.09 (s, 2H), 3.88 (s, 1H) ppm. 13C (100 MHz, CDCl3): δ 162.6, 
161.4, 155.6, 154.7, 136.2, 129.0, 127.2, 125.7, 112.8, 112.6, 112.4, 101.0, 55.7, 38.2, 29.7 ppm.  
EI MS, m/z: 266 (100), 249 (3), 237 (45), 233 (19), 207 (15), 194 (4), 178 (8), 165 (19), 152 (12), 
139 (3), 128 (2), 115 (7), 105 (2), 91 (8), 76 (6), 65 (6), 51 (4). Spectral data were in accordance 
































Figure 17: 13C NMR of compound 1 
 
 2 
7-methoxy-4-(2-methoxybenzyl)coumarin: Using the general procedure outlined above with 2-
bromoanisole (131 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 60% petroleum  ether / 30% DCM/ 10% ethyl acetate (Rf 
= 0.31) and 0.277 g (93%) of an light yellow powder was isolated. m.p. 131-132 °C. IR (neat): 
3079, 2893, 2836, 1710, 1607, 1237, 1205, 810, 575 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.51 
(d, 1H, J=7.9), 7.17 (t, 1H, J= 7.8), 6.98 (d, 1H, J = 7.8), 6.82-6.79 (m, 2H), 6.75-6.72 (m, 2H), 
5.77 (s, 1H), 3.94 (s, 2H), 3.76 (s, 3H), 3.71 (s, 1H) ppm. 13C (100 MHz, CDCl3): δ 162.5, 161.7, 
157.2, 155.4, 155.1, 130.6, 128.7, 125.6, 124.4, 120.8, 113.2, 112.3, 111.7, 110.6, 100.9, 55.7, 
55.4, 32.0 ppm.  EI MS, m/z: 296 (100), 281 (11), 265 (12), 253 (19), 237 (15), 221 (8), 207 
(16), 190 (52), 177 (5), 162 (37), 151 (12), 131 (6), 115 (7), 91 (10), 77 (8), 65 (6), 51 (4). 





































7-methoxy-4-(3-methoxybenzyl)coumarin: Using the general procedure outlined above with 3-
bromoanisole (133 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl acetate (Rf = 
0.27) and 0.297 g (88%) of an light yellow powder was isolated. m.p. 157-158 °C. IR (neat): 2995, 
2944, 2837, 1708, 1611, 1290, 1148, 1043, 841, 789, 758, 698 cm-1. 1H NMR (400 MHz, CDCl3): 
δ 7.55 (d, 1H, J = 8.7), 7.27 (m, 1H), 6.84 (m, 3H), 6.82 (d, 1H, J= 1.7), 6.77 (m, 1H), 6.03 (s, 
1H), 4.06 (s, 2H), 3.88 (s, 3H), 3.80 (s, 3H) ppm. 13C (100 MHz, CDCl3): δ 162.6, 161.4, 160.0, 
155.6, 154.5, 137.7, 130.0, 125.7, 121.3, 115.0, 112.8, 112.6, 112.4, 112.3, 101.0, 55.7, 55.2, 38.2 
ppm.  EI MS, m/z: 296 (100), 281 (12), 267 (14), 253 (28), 237 (22), 225 (5), 207 (11), 194 (5), 
































Figure 21: 13C NMR of compound 3 
 
 
               4 
7-methoxy-4-(4-methoxybenzyl)coumarin: Using the general procedure outlined above with 4-
bromoanisole (131 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl acetate (Rf = 
0.25) and 0.268 g (90%) of an light yellow powder was isolated. m.p. 161-162 °C. IR (neat): 
3079, 2830, 2836, 1710, 1607, 1237, 1205, 8010, 575 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.56 
(d, 1H, J = 8.8), 7.16 (d, 2H, J = 8.6), 6.89 (dd, 2H, J1 = 6.7, J2= 2), 6.83 (m, 2H), 6.00 (s, 1H), 
4.03 (s, 2H), 3.88 (s, 3H), 3.82 (s, 3H) ppm. 13C (100 MHz, CDCl3): δ 162.5, 161.5, 158.7, 
155.6, 155.1, 130.0, 128.0, 125.6, 114.4, 112.8, 112.4, 112.3, 101.0, 55.7, 55.3, 37.3 ppm. EI 
MS, m/z: 296 (100), 281 (25), 267 (12), 253 (19), 237 (6), 207 (13), 165 (8), 151 (7), 135 (5), 








































                 5 
4-(3,4-dimethoxybenzyl)-7-methoxycoumarin: Using the general procedure outlined above with 
4-bromoveratrole (151μL, 1.05 mmol), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 50% petroleum ether / 30% DCM/ 20% ethyl acetate (Rf = 
0.30) and 0.2925g (90%) of a yellow flake-like powder was isolated. m.p. 179-181°C. IR (neat): 
3074, 2995, 2936, 2838, 1703, 1608, 1509, 1388, 1275, 1132, 1026, 810 cm-1. 1H NMR (400 MHz, 
CDCl3): δ 7.57 (d, 1H, J=8.6), 6.90-6.74 (m, 5H), 6.02 (s, 1H), 2.14 (s, 2H), 3.89-3.87 (m, 9H). 
13C (100 MHz, CDCl3): δ 162.3, 161.5, 155.5, 155.1, 149.3, 148.3, 128.5, 125.6, 121.3, 112.8, 
112.4, 112.3, 112.1, 111.6, 101.0, 56.0, 55.9, 55.7, 37.8 ppm.  EI MS, m/z: 326 (100), 311 (12), 
283 (10), 267 (8), 207 (9), 152 (11), 120 (8). HRMS (ESI): M+1 calculated for C19H19O5, 
































Figure 25: 13C NMR of compound 5 
 
 6 
4-(4-(dimethylamino)benzyl)-7-methoxycoumarin Using the general procedure outlined above 
with 4-bromo-N,N-dimethylaniline (0.221g), the crude reaction mixture was purified using column 
flash chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl acetate 
(Rf  = 0.32) and 0.204 g (66%) of a yellow solid was isolated. Melting point: 206 – 208 °C. IR 
(neat): 3069, 2975, 2897, 2842, 2790, 1712, 1606, 1519, 1342, 1279, 1263, 1132, 985, 873, 847, 
813, 752, 709, 575, 479 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.58 (dd, 1H, J = 9.5, 2.7 Hz), 7.10 
(d, 2H, J = 8.7, 2.8 Hz), 6.81– 6.84 (m, 2H), 6.70– 6.73(dd, 2H, J = 8.7, 2.0 Hz), 6.03 (s, 1H), 3.99 
(s, 2H), 3.87 (s, 3H), 2.95 (s, 6H) ppm. 13C (100 MHz, CDCl3): δ 162.5, 161.6, 155.7, 155.6, 149.7, 
129.7, 125.7, 123.6, 113.0, 112.99, 112.3, 112.2, 101.0, 55.7, 40.6, 37.3 ppm.  EI MS, m/z: 309 
(100), 134 (20), 294 (16), 280 (7), 266 (7), 118 (7). HRMS (ESI): M+1 calculated for C19H20O3N, 



































7-methoxy-4-(2,4,6-trimethylbenzyl)coumarin: Using the general procedure outlined above 
with  2-bromomesitylene (161 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl acetate (Rf = 
0.49) and 0.249 g (81%) of an light yellow powder was isolated. m.p:190-196 °C. IR (neat): 3073, 
2923, 2846, 1711, 1605, 1386, 1277, 988, 844 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.76 (d, 1H, 
J=8.8 Hz), 6.97 (d, 1H, J= 2.5 Hz), 6.95-6.94 (m, 2H), 6.89 (d, 1H, J=2.5 Hz), 5.55 (t, 1H, J=1.4 
Hz), 4.04 (d, 2H, J=1.2 Hz), 3.92 (s, 3H), 2.32 (s, 3H), 2.18 (s, 6H) ppm. 13C (100 MHz, CDCl3): 
δ 162.6, 161.6, 155.3, 154.1, 137.0, 136.9, 129.2, 129.1, 124.8, 113.2, 112.4, 110.1, 101.0, 55.8, 
31.0, 20.9, 19.8 ppm.  EI MS, m/z: 308 (100), 293 (10), 280 (8), 265 (39), 251 (7), 235 (3), 222 
(4), 207 (4), 191 (4), 179 (5), 157 (6), 137 (9), 117 (6), 103 (3), 91 (5), 77(3), 63 (2), 51 (1). HRMS 



































7-methoxy-4-(naphthalene-2-ylmethyl)coumarin: Using the general procedure outlined above 
with 2-bromonapthalene (0.218 g, 1.05 mmol), the crude reaction mixture was purified using 
column flash chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl 
acetate (Rf = 0.32) and 0.234 g (74%) of a dark yellow/orange free-flowing powder was isolated. 
m.p. 137-139 °C. IR (neat): 3014, 2970, 1698, 1606, 1390, 1278, 1124, 1020, 842, 747, 476 cm-1. 
1H NMR (400 MHz, CDCl3): δ 7.83-7.76 (m, 3H), 7.67 (s, 1H), 7.56 (d, 1H, J= 8.8 Hz), 7.50-7.45 
(m, 2H), 7.34 (dd, 1H, J = 8.4, 1.6 Hz), 6.84 (d, 1H, J = 2.5 Hz), 6.79 (dd, 1H, J1= 8.8, 2.5 Hz), 
4.11 (s, 2H), 3.73 (s, 3H) ppm. 13C (100 MHz, CDCl3): δ 162.6, 161.4, 155.6, 154.5, 133.7, 133.6, 
132.5, 128.7, 127.7, 127.6, 126.9, 126.4, 126.0, 125.7, 112.8, 112.7, 112.3, 101, 55.7, 38.4 ppm.  







































7-methoxy-4-(3-methylbenzyl)coumarin: Using the general procedure outlined above with 3-
bromotoluene (127 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl acetate (Rf = 
0.38) and 0.1972 g (70%) of a light yellow free flowing powder was isolated. m.p. 113-115 °C. IR 
(neat): 3003, 2888, 1781, 1713, 1607, 1390, 1277, 1131, 986, 846, 832, 703, 588 cm-1. 1H NMR 
(400 MHz, CDCl3): δ 7.56 (d, 1H, J=9.0 Hz), 7.28-7.22 (m, 1H), 7.24 (t, 1H, J=8.0 Hz), 7.10 (d, 
1H, J=8.0 Hz), 7.04 (d, 2H, J= 8.0 Hz), 6.85-6.82 (m, 2H), 6.02 (s, 1H), 4.04 (s, 2H), 3.88 (s, 3H), 
2.35 (s, 3H) ppm. 13C (100 MHz, CDCl3): δ 162.6, 161.4, 155.6, 154.8, 138.7, 136.1, 129.7, 128.8, 
127.9, 126.0, 125.7, 112.9, 112.6, 112.3, 101.0, 55.7, 38.1, 21.4 ppm.  EI MS, m/z: 280 (100), 265 
(6), 251 (24), 237 (28), 207 (9), 194 (5), 178 (6), 165 (15), 151 (5), 139 (6), 89 (4), 76 (4). HRMS 




































7-methoxy-4-(4-methylbenzyl)coumarin: Using the general procedure outlined above with 4-
bromotoluene (129 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl acetate (Rf = 
0.58) and 0.1823g (65%) of a light yellow/brown free-flowing powder was isolated. m.p. 155-157 
°C. IR (neat): 3090, 3000, 2895, 1702, 1606, 1394, 1274, 1143, 983, 852, 831, 819, 577, 461 cm-
1. 1H NMR (400 MHz, CDCl3): δ 7.56 (d, 1H, J=8.6 Hz), 7.17-7.12 (m, 4H), 6.85-6.82 (m, 2H), 
6.02 (s, 1H), 4.05 (s, 2H), 3.88 (s, 3H), 2.36 (s, 3H) ppm. 13C (100 MHz, CDCl3): δ 162.6, 161.4, 
155.6, 154.9, 136.8, 133.1, 129.6, 128.9, 125.7, 112.9, 112.5, 112.3, 101.0, 55.7, 37.8, 21.0 ppm.  
EI MS, m/z: 280 (100), 265 (7), 251 (28), 237 (26), 221 (5), 178 (7), 165 (15), 151 (6), 139 (10), 





































7-methoxy-4-(5-(tert-butyl)-2-methylbenzyl)-coumarin: Using the general procedure outlined 
above with 2-bromo-4-tert-butyltoluene (199 μL), the crude reaction mixture was purified using 
column flash chromatography (silica gel, 60Å) with 65% petroleum ether / 30% DCM/ 5% ethyl 
acetate (Rf = 0.30) and 0.228 g (68%) of a light yellow free flowing powder was isolated. m.p. 
101-104 °C. IR (neat): 2961, 2867, 1722, 1609, 1505, 1462, 1426, 1387, 1345, 1267, 1206, 1152, 
1132, 1043, 1023, 983, 876, 849, 836, 825, 814, 746, 721, 702, 634, 608, 555, 487 cm-1. 1H NMR 
(400 MHz, CDCl3): δ 7.65 (d, 1H, J=8.7 Hz), 7.28 (dd, 1H, J= 8.0,2.1 Hz), 7.18 (d, 1H, J=8.0 Hz), 
7.13 (d, 1H, J=2.0 Hz), 6.90 (td, 2H, J=8.0, 2.5 Hz), 5.70 (s, 1H), 4.06 (d, 2H, J=0.8 Hz), 3.91 (s, 
3H), 2.21 (s, 3H), 1.30 (s, 9H) ppm. 13C (100 MHz, CDCl3): δ162.6, 161.6, 155.3, 154.8, 149.5, 
133.7, 133.4, 130.4, 127.2, 125.1, 124.6, 113.1, 112.4, 111.5, 101.0, 55.8, 35.8., 34.3, 31.4, 18.8 
ppm.  EI MS, m/z: 336 (50), 321 (100), 308 (1), 293 (2), 279 (4), 265 (1), 251 (2), 235 (1), 219 
(5), 205 (2), 191 (2), 178 (2), 161 (4), 145 (2), 132 (3), 115 (3), 91 (2), 77 (1), 57 (2). HRMS (ESI): 


































4-(4-(tert-butyl)benzyl)-7-methoxy-coumarin: Using the general procedure outlined above 
with 1-bromo-4-tert-butylbenzene (182 μL), the crude reaction mixture was purified using 
column flash chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% 
ethyl acetate (Rf = 0.43) and 0.241 g (75%) of a light yellow free flowing powder was isolated. 
m.p. 158-160 °C. IR (neat): 2965, 1714, 1606, 1512, 1460, 1411, 1385, 1344, 1275, 1261, 1208, 
1152, 1132, 1039, 1020, 984, 891, 847, 811, 790, 708, 599, 579, 485, 476, 452 cm-1. 1H NMR 
(400 MHz, CDCl3): δ 7.56 (dd, 1H, J= 5.8,3.7 Hz), 7.35 (dd, 2H, J= 6.6, 2.0 Hz), 7.15 (d, 2H, 
J=8.3 Hz), 6.82 (m, 2H), 5.98 (s, 1H), 4.03 (s, 2H), 3.86 (s, 3H), 1.31 (s, 9H) ppm. 13C (100 
MHz, CDCl3): δ 162.6, 161.5, 155.5, 155.0, 150.2, 133.0, 128.7, 125.9, 125.6, 112.9, 112.4, 
112.3, 101.0, 55.7, 37.6, 34.5, 31.3 ppm.  EI MS, m/z: 322 (51), 307 (100), 294 (1), 279 (3), 266 
(11), 249 (1), 237 (3), 233 (1), 207 (1), 191 (2), 178 (2), 166 (4), 154 (4), 140 (3), 126 (6), 104 




































4-(4-chlorobenzyl)-7-methoxycoumarin: Using the general procedure outlined above with 1-
bromo-4-chlorobenzene (0.202 g, 1.05 mmol), the crude reaction mixture was purified using 
column flash chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl 
acetate (Rf = 0.32) and 0.210 g (70%) of a light yellow free-flowing powder was isolated. m.p. 
148-150 °C. IR (neat): 3087, 3006, 2935, 1703, 1600, 1395, 1294, 1019, 831, 576, 463 cm-1. 1H 
NMR (400 MHz, CDCl3): δ 7.49 (dd, 1H, J = 5.4, 4.0 Hz), 7.31 (d, 2H, J = 8.4 Hz), 7.17 (d, 2H, 
J = 2 Hz), 6.83-6.81 (m, 2H), 5.97 (s, 1H), 4.05 (s, 2H), 3.87 (s, 3H) ppm. 13C (100 MHz, CDCl3): 
δ 162.7, 161.2, 155.6, 154.1, 134.7, 133.1, 130.3, 129.1, 125.5, 112.6, 112.5, 112.4, 101.1, 55.8, 
37.5 ppm.  EI MS, m/z: 300 (100), 272 (31), 257 (1), 237 (17), 165 (24), 151 (11), 89 (9). HRMS 




































7-methoxy-4-(4-(trifluoromethyl)benzyl)-2H-chromen-2-one: The reaction was prepared 
according to the general procedure outlined above using 4-bromobenzotrifluoride (147 µL). The 
crude mixture was purified using column chromatography (silica gel, 60 Å) with 60% petroleum 
ether / 33% dichloromethane / 7% ethyl acetate (Rf = 0.35) and 0.102 g (30%) of a yellow solid 
was isolated. m.p. = 126-127 °C. IR (neat): 3082, 2922, 1705, 1605, 1326, 1121 cm-1. 1H NMR 
(400 MHz, CDCl3): δ 7.63 (d, 2H, J = 8.1Hz), 7.49 (d, 1H, J = 8.7Hz), 7.38 (d, 2H, J = 8.0Hz), 
7.28 (s, 2H), 6.87-6.83 (m, 2H), 6.00 (s, 1H), 4.15 (s, 2H), 3.89 (s, 3H) ppm. 13C NMR (100 MHz, 
CDCl3): δ 162.8, 161.1, 155.7, 153.5, 140.4, 129.7 (q, J=32 Hz), 129.3, 125.9 (q, J=3.8 Hz), 125.5, 
124.0 (d, J=271 Hz), 112.9, 112.5, 112.4, 101.2, 55.8, 37.9 ppm. 19F (376 MHz, CDCl3): -62.6(s) 
ppm. EI MS, m/z: 334 (100), 306 (45), 291 (30). HRMS (ESI): M+1 calculated for C18H14O3F3, 


















































4-((7-methoxy-2-oxo-2H-chromen-4-yl)methyl)benzonitrile: Using the general procedure 
outlined above with 4-bromobenzonitrile (0.191g, 1.05 mmol), the crude reaction mixture was 
purified using column flash chromatography (silica gel, 60Å) with 50% petroleum ether / 30% 
DCM/ 20% ethyl acetate (Rf = 0.35) and 0.2772g (95%) of an orange powder was isolated. m.p. 
135-137 °C. IR (neat): 2925, 2227, 1702, 1606, 1134, 836, 578 cm-1. 1H NMR (400 MHz, CDCl3): 
δ 7.66 (d, 2H, J=8.2 Hz), 7.44 (d, 1H, J=8.8 Hz), 7.38 (d, 3H, J= 8.1 Hz), 7.28 (s, 1H), 6.85 (m, 
2H), 6.00 (s, 1H), 4.15 (s, 2H), 3.89 (s, 3H). 13C (100 MHz, CDCl3): δ 162.9, 161.0, 155.7, 153.0, 
141.8, 132.8, 129.7, 125.4, 118.4, 113.0, 112.7, 112.3, 111.4, 101.2, 55.8, 38.1 ppm.  EI MS, m/z: 
291 (100), 263 (57), 248 (19), 232 (3), 220 (5), 203 (6), 190 (16), 177 (7), 165 (9), 151 (15), 140 





































4-(benzofuran-5-ylmethyl)-7-methoxycoumarin: Using the general procedure outlined above 
with 5-bromobenzofuran (132 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl acetate (Rf = 
0.25) and 0.2816 g (92%) of a light grey/green free flowing powder was isolated. m.p. 123-126 
°C. IR (neat): 3114, 3078, 2896, 1694, 1604, 1394, 1269, 1202, 1142, 829, 744, 617 cm-1. 1H NMR 
(400 MHz, CDCl3): δ 7.65 (d, 1H, J=2.2 Hz), 7.58 (d, 1H, 8.7 Hz), 7.48 (m, 2H), 7.17 (dd, 1H, 
J=8.4,1.7 Hz), 6.83 (m, 2H), 6.74 (dd,1H, J= 2.14, 0.8 Hz), 6.02 (s, 1H), 4.18 (s, 2H), 3.88 (s, 3H). 
13C (100 MHz, CDCl3): δ 162.6, 161.4, 155.6, 155.1, 154.1, 145.7, 130.6, 128.1, 125.7, 125.2, 
121.4, 112.8, 112.6, 112.4, 111.8, 106.4, 101.0, 55.7, 38.0 ppm.  EI MS, m/z: 306 (100), 289 (3), 
263 (16), 249 (4), 235 (4), 207 (13), 189 (8), 178 (9), 161 (5), 131 (7), 117 (4), 89 (8), 77 (4), 63 



































7-methoxy-4-(pyridin-2-ylmethyl)coumarin: Using the general procedure outlined above with 
2-bromopyridine (100 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 20% petroleum ether / 30% DCM/ 50% ethyl acetate (Rf = 
0.36) and 0.152 g (57 %) of a yellow/brown powder was isolated. m.p. 101-104 °C. IR (neat): 
3094, 2922, 2851, 1713, 1614, 1286, 1144, 839, 581 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.58 (d, 
1H, J=4.2 Hz), 7.66-7.59 (m, 2H), 7.22-7.17 (m, 2H), 6.81-6.78 (m, 2H), 6.07 (s, 1H), 4.25 (s, 
2H), 3.84 (s, 3H) ppm. 13C (100 MHz, CDCl3): δ 162.7, 161.3, 156.9, 155.6, 153.4, 149.8, 137.0, 
126.2, 123.3, 122.2, 112.8, 112.4, 101.0, 55.7, 41.1 ppm.  EI MS, m/z: 267 (54), 239 (100), 224 
(59), 210 (5), 196 (22), 178 (4), 167 (26), 154 (6), 141 (5), 117 (16), 84 (7), 63 (5), 51 (5). HRMS 





































7-methoxy-4-(pyridin-3-ylmethyl)-coumarin: Using the general procedure outlined above with 
3-bromopyridine ( 101 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 10% DCM/ 90% ethyl acetate (Rf = 0.23) and 0.0859 g 
(32%) of a yellow free flowing powder was isolated. m.p. 138-140 °C. IR (neat): 3003, 2908, 1704, 
1608, 1281, 1137, 835, 717 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.88-8.56 (m, 2H), 7.57-7.55 (m, 
1H), 7.51 (d, 1H, J= 8.7 Hz), 7.32-7.28 (m, 1H), 6.87-6.84 (m, 2H), 6.00 (s, 1H), 4.10 (s, 2H), 3.89 
(s, 3H) ppm. 13C (100 MHz, CDCl3): δ 162.9, 161.0, 155.7, 153.3, 150.1, 148.7, 136.4, 132.0, 
125.4, 123.8, 112.8, 112.6, 112.3, 101.2, 55.8, 35.3 ppm. EI MS, m/z: 267 (100), 238 (35), 224 

































Figure 52: 13C NMR of compound 18 
 
6.2.1.2 Aryl Chlorides 
 
All reactions were prepared at the 1.0 mmol scale in a glovebox using 8-mL screw cap 
vials with a Teflon-coated stir bar. The vial was charged with 4% Nixantphos Pd G3 (0.04 
mmol), 7-methoxy-4-methylcoumarin (1mmol), LiHMDS (3 eq) and an aryl chloride (1.05 
mmol). Finally, 5 mL of THF was added to the reaction vial. The reaction was capped, removed 
from the glovebox, and allowed to stir on an aluminum block preheated to 90 °C for 24-48 hours. 
Upon completion, the reaction was allowed to cool. A standard workup was completed using 
about 2.5 mL of a 2.0 M HCl solution and dichloromethane to extract. Magnesium sulfate was 
utilized to dry the sample before gravity filtering and removing the solvent under reduced 
pressure. Completion was checked using TLC and GC-MS. The crude reaction mixture was 
loaded onto a silica gel column using a wet load technique. The yields reported in this thesis are 





4-benzyl-7-methoxycoumarin: Using the general procedure outlined above with chlorobenzene 
(107 μL) for 24 hours, the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl acetate (Rf = 
0.35) and 0.185 g (70%) of a light yellow free-flowing powder was isolated. m.p. 139-142 °C. IR 
(neat): 3064, 3001, 2905, 1705, 1608, 1389, 1277, 1135, 988, 836, 700 576 cm-1. 1H NMR (400 
MHz, CDCl3): δ 7.55 (d, 1H, J=8.6 Hz), 7.38-7.24 (m, 5H), 6.85-6.82 (m, 2H), 6.01 (s, 1H), 4.09 
(s, 2H), 3.88 (s, 3H) ppm. 13C (100 MHz, CDCl3): δ 162.6, 161.4, 155.6, 154.7, 136.2, 129.0, 
128.9, 127.2, 125.6, 112.8, 112.6, 112.4, 101.0, 55.7, 38.1 ppm.  EI MS, m/z: 266 (100), 237 
(49), 207 (18), 165 (19). Spectral data were in accordance with the literature4. HRMS (ESI): 




































6.2.2 γ-arylation of Isophorone General Procedures and Data 
 
Scheme 28: γ-arylation of isophorone general procedure 
All reactions were prepared at the 1.0 mmol scale in a glovebox using 8-mL screw cap 
vials with a Teflon-coated stir bar. The vial was charged with 4% Nixantphos Pd G3 (0.038 g, 
0.04 mmol), cesium carbonate (0.978 g, 3 mmol), isophorone (150μL), and an aryl bromide 
(1.05 mmol). Finally, 5 mL of THF was added to the reaction vial. The reaction was capped, 
removed from the glovebox, and allowed to stir on an aluminum block preheated to 50 °C for 72 
hours. Although incomplete, the reaction was allowed to cool. A standard workup was completed 
using about 2.5 mL of a 2.0 M HCl solution and dichloromethane to extract. Magnesium sulfate 
was utilized to dry the sample before gravity filtering and removing the solvent under reduced 
pressure. Completion was checked using TLC and GC-MS. The crude reaction mixture was 
loaded onto a silica gel column using a wet load technique. The yields reported in this thesis are 
from one trial only.  
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3-(3-methoxybenzyl)-5,5-dimethylcyclohex-2-en-1-one: Using the general procedure outlined 
above with 3-bromoanisole (133 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 60% petroleum ether / 30% DCM/ 10% ethyl acetate (Rf 
= 0.32) and 0.0864 g (35%) of a yellow oil was isolated. IR (neat): 2955, 2835, 1663, 1598, 
1276, 1047, 781, 698 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.25 (t, 1H, J=8.0 Hz), 6.81 (dd, 1H, 
J=8.2, 2.3 Hz), 6.77 (d, 1H, J= 7.5 Hz), 6.71-6.70 (m, 1H), 5.93 (s, 1H), 3.81 (s, 3H), 3.48 (s, 
2H), 2.23 (s, 2H), 2.14 (s, 2H), 0.99 (s, 6H) ppm. 13C (100 MHz, CDCl3): δ 200.1, 161.9, 159.8, 
138.4, 129.7, 125.9, 121.5, 114.9, 112.2, 55.2, 51.1, 44.5, 43.3, 33.6, 28.2 ppm.  EI MS, m/z: 244 
(100), 229 (23), 211 (6), 201 (5), 188 (72), 173 (8), 159 (56), 145 (36), 131 (4), 121 (34), 103 
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3-benzyl-5,5-dimethylcyclohex-2-en-1-one: Using the general procedure outlined above with 
bromobenzene (111 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 63% petroleum ether / 30% DCM/ 7% ethyl acetate (Rf = 
0.38) and 0.0733 g (34%) of a yellow/brown oil was isolated. IR (neat): 3028, 2956, 2868, 1664, 
1453, 1367, 1275, 751, 700, 519 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.34-7.23 (m, 3H), 7.18-
7.16 (m, 2H), 5.91 (s, 1H), 3.49 (s, 2H), 2.21 (s, 2H), 2.13 (s, 2H), 0.98 (s, 6H) ppm. 13C (100 
MHz, CDCl3): δ 200.1, 162.1, 136.9, 129.1, 128.7, 126.9, 125.8, 51.1, 44.5, 43.3, 33.6, 28.2 
ppm.  EI MS, m/z: 214 (45), 199 (8), 181 (3), 171 (4), 158 (100), 141 (4) 129 (41), 115 (23), 102 



































Figure 58: 13C NMR of compound 21 
6.2.3 α-arylation of 1-acetyl-1-cyclohexane General Procedures and Data 
 
 
Scheme 29: α-arylation of 1-acetyl-1-cyclohexane general procedure 
All reactions were prepared at the 1.0 mmol scale in a glovebox using 8-mL screw cap 
vials with a Teflon-coated stir bar. The vial was charged with 4% Nixantphos Pd G3 (0.04 
mmol), LiHMDS (3 eq.), 1-acetyl-1-cyclohexane (1 mmol), and an aryl bromide (1.05 mmol). 
Finally, 5 mL of THF was added to the reaction vial. The reaction was capped, removed from the 
glovebox, and allowed to stir on an aluminum block preheated to 50 °C for 72 hours. A standard 
workup was completed using about 2.5 mL of a 2.0 M HCl solution and dichloromethane to 
extract. Magnesium sulfate was utilized to dry the sample before gravity filtering and removing 
the solvent under reduced pressure. Completion was checked using TLC and GC-MS. The crude 
reaction mixture was loaded onto a silica gel column using a wet load technique. The yields 






1-(cyclohex-1-en-1-yl)-2-phenylethan-1-one: Using the general procedure outlined above with 
bromobenzene (111 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 95% petroleum ether / 5% ethyl acetate (Rf = 0.41) and 
0.172 g (85%) of a yellow free flowing oil was isolated. IR (neat): 3028, 2930, 2858, 1656, 1635, 
1495, 1453, 1434, 1377, 1274, 1247, 1189, 1135, 1074, 992, 921, 792, 738, 702, 626, 612, 542, 
478 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.23-7.20 (m, 2H), 7.16-7.11 (m, 3H), 6.95-6.93 (m, 
1H), 3.86 (s, 2H), 2.19-2.15 (m, 4H), 1.57-1.48 (m, 4H) ppm. 13C (100 MHz, CDCl3): δ 198.6, 
141.1, 139.1, 135.5, 129.3, 128.5, 126.6, 44.0, 26.2, 23.3, 21.9, 21.5 ppm.  Spectral data were in 
accordance with the literature6. EI MS, m/z: 200 (3), 128 (1), 115 (1), 109 (100), 91 (13), 81 










































1-(cyclohex-1-en-1-yl)-2-(3-methoxyphenyl)ethan-1-one: Using the general procedure outlined 
above with 3-bromoanisole (133 μL), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 94% petroleum ether / 6% ethyl acetate with one drop of 
triethylamine (Rf = 0.48) and 0.210 g (90%) of a yellow free flowing oil was isolated. IR (neat): 
2931, 2835, 2859, 1656, 1635, 1597, 1583, 1489, 1452, 1434, 1378, 1257, 1188, 1148, 1045, 
993, 921, 872, 764, 703, 689, 618, 581, 546, 478cm-1. 1H NMR (400 MHz, CDCl3): δ 7.08 (t, 
1H, J = 7.6 Hz), 6.89 (t, 1H, J = 3.6 Hz), 6.67-6.63 (m, 3H), 3.79 (s, 2H), 3.65 (s, 3H), 2.11 (t, 4 
H, J = 3.2 Hz), 1.51-1.46 (m, 4H) ppm. 13C (100 MHz, CDCl3): δ 198.5, 159.7, 141.2, 139.0, 
137.0, 129.5, 121.6, 114.9, 112.1, 5.2, 44.1, 26.2, 23.3, 21.9, 21.5 ppm.  EI MS, m/z: 230 (13), 




































6.2.4 γ-arylation of methyl-1-cyclohexene-1-carboxylate General Procedures and Data 
 
 
All reactions were prepared at the 1.0 mmol scale in a glovebox using 8-mL screw cap 
vials with a Teflon-coated stir bar. The vial was charged with 4% Xantphos Pd G3 (0.04 mmol), 
LiHMDS (3 eq.), methyl-1-cyclohexene-1-carboxylate (1 mmol), and an aryl bromide (1.05 
mmol). Finally, 5 mL of THF was added to the reaction vial. The reaction was capped, removed 
from the glovebox, and allowed to stir on an aluminum block preheated to 50 °C for 24 hours. A 
standard workup was completed using about 2.5 mL of a 2.0 M HCl solution and 
dichloromethane to extract. Magnesium sulfate was utilized to dry the sample before gravity 
filtering and removing the solvent under reduced pressure. Completion was checked using TLC 
and GC-MS. The crude reaction mixture was loaded onto a silica gel column using a wet load 
technique. The yields reported in this thesis are from one trial only. 
 
  
methyl 3,4,5,6-tetrahydro-[1,1'-biphenyl]-3-carboxylate: Using the general procedure 
outlined above with bromobenzene (111 μL), the crude reaction mixture was purified using 
column flash chromatography (silica gel, 60Å) with 94% petroleum ether / 6% ethyl acetate with 
one drop of triethylamine (Rf = 0.31) and 0.135 g (63%) of a yellow free flowing oil was 
isolated. IR (neat): 3023, 2946, 2863, 173, 1598, 1494, 1444, 1433, 1256, 1208, 1155, 1035, 
1024, 934, 905, 848, 830, 759, 744, 694 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.27-7.25 (m, 2H), 
7.20-7.16 (m, 2H), 7.13-7.09 (m, 1H), 6.02 (dt, 1H, J = 3.3, 1.6 Hz), 3.58 (s, 3H), 3.19-3.13 (m, 
1H), 2.37-2.23 (m, 2H), 1.86-1.73 (m, 3H), 1.65-1.59 (m, 1H) ppm. 13C (100 MHz, CDCl3): δ 
174.8, 141.9, 139.1, 128.3, 127.2, 125.3, 121.4, 51.9, 41.9, 27.2, 24.9, 21.4 ppm.  EI MS, m/z: 
216 (36), 201 (1), 184 (10), 157 (100), 141 (13), 129 (28), 115 (21), 102 (3), 91 (57), 77 (10), 65 
(2), 51 (3). 






































methyl 4'-methoxy-3,4,5,6-tetrahydro-[1,1'-biphenyl]-3-carboxylate: Using the general 
procedure outlined above with 4-bromoanisole (131 μL), the crude reaction mixture was purified 
using column flash chromatography (silica gel, 60Å) with 85% petroleum ether / 15% diethyl 
ether (Rf = 0.31) and 0.0979 g (40%) of a light yellow solid was isolated. 1H NMR (400 MHz, 
CDCl3): δ 7.28-7.24 (m, 2H), 6.79-6.76 (m, 2H), 5.99 (dt, 1H, J = 3.4, 1.6 Hz), 3.72 (s, 3H), 3.63 
(s, 3H), 3.21-3.18 (m, 1H), 2.36-2.27 (m, 2H), 1.92-1.75 (m, 3H), 1.71-1.60 (m, 1H) ppm. EI 
MS, m/z: 246 (34), 231 (1), 187 (100), 172 (5), 159 (5), 145 (6), 131 (1), 121 (29), 103 (2), 91 
(1), 79 (60), 63 (1), 51 (1). 
 
 





methyl 3'-methoxy-3,4,5,6-tetrahydro-[1,1'-biphenyl]-3-carboxylate: Using the general 
procedure outlined above with 3-bromoanisole ( μL), the crude reaction mixture was purified 
using column flash chromatography (silica gel, 60Å) with 85% petroleum ether / 10% 
dichloromethane / 5% EtOAc (Rf = 0.26) and  0.133 g (45%) of a light yellow solid was isolated. 
1H NMR (400 Hz, CDCl3): δ 7.10 (t, 1H, J = 8.0 Hz), 6.86 (d, 1H, J = 7.8 Hz), 6.80 (t, 1H, J = 
2.0 Hz), 6.67 (dd, 1H, J = 8.2, 2.0 Hz), 6.02 (dt, 1H, J = 3.4, 1.7 Hz), 3.68 (s, 3H), 3.58 (s, 3H), 
3.17-3.13 (m, 1H), 2.36-2.23 (m, 2H), 1.86-1.73 (m, 3H), 1.66-1.56 (m, 1H) ppm. 13C (100 MHz, 
CDCl3): δ 174.8, 159.6, 143.5, 139.0, 129.2, 121.7, 117.9, 112.5, 111.3, 55.2, 51.9, 41.9, 27.2, 
24.8, 21.4 ppm.  EI MS, m/z: 246 (60), 231 (1), 214 (1), 187 (100), 172 (8), 159 (13), 145 (10), 
131 (3), 121 (47), 103 (3), 91 (7), 79 (19), 59 (2), 50 (1). 







































methyl 3-(benzofuran-5-yl)cyclohex-1-ene-1-carboxylate: Using the general procedure 
outlined above with 5-bromobenzofuran (132 μL), the crude reaction mixture was purified using 
column flash chromatography (silica gel, 60Å) with 85% petroleum ether / 10% dichloromethane 
/ 5% ethyl acetate (Rf = 0.28) and 0.120 g (47%) of a solid was isolated. 1H NMR (400 MHz, 
CDCl3): δ 7.45 (s, 2H), 7.29 (d, 1H, J = 8.6 Hz), 7.21 (dd, 1H, J = 8.6, 1.4 Hz), 6.59 (d, 1H, J = 
1.2 Hz), 5.99 (t, 1H, J= 1.6 Hz), 3.58 (s, 3H), 3.18-3.16 (m, 1H), 2.38-2.28 (m, 2H), 1.90- 1.73 
(m, 3H), 1.65-1.56 (m, 1H) ppm. EI MS, m/z: 256 (44), 241 (1), 197 (100), 181 (5), 169 (10), 

























methyl 4'-(dimethylamino)-3,4,5,6-tetrahydro-[1,1'-biphenyl]-3-carboxylate: Using the 
general procedure outlined above with 4-bromo-n,n-dimethylaniline (0.211 g), the crude reaction 
mixture was purified using column flash chromatography (silica gel, 60Å) with 80% petroleum 
ether / 20% ethyl acetate / one drop of triethylamine (Rf = 0.69) and 0. 0.0949g (37%) of an 
yellow solid was isolated. 1H NMR (400 MHz, CDCl3): δ 7.24 (d, 2H, J = 8.9 Hz), 6.62 (d, 2H, J 
= 8.8 Hz), 5.96 (dt, 1H, J = 3.3, 1.7 Hz), 3.64 (s, 2H), 3.23-3.17 (m, 1H), 2.87 (s, 6H), 2.38-2.28 
(m, 2H), 1.89-1.77 (m, 3H), 1.69-1.60 (m, 1H) ppm. 13C (100 MHz, CDCl3): δ 175.2, 149.9, 
138.5, 130.0, 125.9, 118.1, 112.3, 51.8, 41.9, 40.6, 27.0, 25.0, 21.5 ppm. EI MS, m/z: 259 (100), 
244 (3), 228 (5), 200 (71), 184 (10), 172 (28), 158 (10), 144 (5), 134 (11), 115 (6), 100 (4), 89 





































methyl 3-(pyridin-3-yl)cyclohex-1-ene-1-carboxylate: Using the general procedure outlined 
above with 3-bromopyridine (101 μL), the crude reaction mixture was purified using column 
flash chromatography (silica gel, 60Å) with 80% ethyl acetate / 10% petroleum ether / one drop 
of triethylamine (Rf = 0.36) and 0.128g (59%) of an yellow viscous oil was isolated. IR (neat): 
3030, 2946, 2863, 1729, 1567, 1433, 1413, 1209, 1190, 1157, 1059, 1022, 929, 906, 858, 832, 
801, 753, 709, 621, 540, 515, 458 cm-1. 1H NMR (400 MHz, CDCl3): δ 8.66 (d, J = 1.8 Hz), 8.49 
(dd, 1H J = 4.7, 1.3 Hz), 7.68 (dt, 1H, J = 8.0, 2.0 Hz), 7.24 (ddd, 1H, J = 7.9, 4.8, 0.4 Hz), 6.21 
(dt, 2H, J = 3.5, 1.8 Hz), 3.74 (s, 3H), 3.34-3.29 (m, 1H), 2.51-2.36 (m, 2H), 2.05-1.86 (m, 3H), 
1.83-1.73 (m, 1H) ppm. 13C (100 MHz, CDCl3): 174.4, 148.3, 146.9, 137.1, 136.4, 132.5, 123.2, 
123.1, 52.0, 41.8, 26.9, 24.7, 21.2 ppm. EI MS, m/z: 217 (22), 202 (2), 185 (17), 158 (100), 143 

































Figure 72: 13C NMR of compound 29 
 
 
methyl 4'-fluoro-3,4,5,6-tetrahydro-[1,1'-biphenyl]-3-carboxylate: Using the general 
procedure outlined above with 1-bromo-4-fluorobenzene (115 μL), the crude reaction mixture 
was purified using column flash chromatography (silica gel, 60Å) with 94% petroleum ether / 
6% ethyl acetate / one drop of triethylamine (Rf = 0.29) and 0.0964 g (41%) of an oil was 
isolated. 1H NMR (400 MHz, CDCl3): δ 7.25-7.20 (m, 2H), 6.89-6.83 (m, 2H), 5.96 (dt, 1H, J = 
3.4, 1.7 Hz), 3.59 (s, 3H), 3.17-3.12 (m, 1H), 2.33-2.20 (m, 2H), 1.87-1.70 (m, 3H), 1.67-1.55 
(m, 1H) ppm. 13C (100 MHz, CDCl3): 174.7. 162.1 (d, J = 244 Hz), 138.1, 137.9 (d, J = 3.4 Hz), 
126.9, 126.8, 121.3, 115.1, 114.9, 51.9, 41.8, 27.3, 24.8, 21.4 ppm. 19F NMR (376 MHz, DMSO) 
δ -115.69 (s) ppm. EI MS, m/z: 234 (28), 219 (1), 202 (5), 175 (100), 159 (10), 147 (22), 133 


















































Figure 75:  19F NMR of compound 30 
6.2.4.1 Consecutive amide formation/ Heck cyclization of methyl-1-cyclohexene-1-
carboxylate 
 
Scheme 30:  Reaction conditions for the consecutive amide formation/ Heck cyclization of 
methyl-1-cyclohexene-1-carboxylate 
The reaction was prepared at the 1.0 mmol scale in a glovebox using 8-mL screw cap 
vials with a Teflon-coated stir bar. The vial was charged with 4% Xantphos Pd G3 (0.04 mmol), 
LiHMDS (3 eq.), methyl-1-cyclohexene-1-carboxylate (1 mmol), and 2-bromoaniline (1.05 
mmol). Finally, 5 mL of THF was added to the reaction vial. The reaction was capped, removed 
from the glovebox, and allowed to stir on an aluminum block preheated to 100 °C for 6 hours. 




and 10% Xantphos Pd G3 was added. The vial was placed back on the aluminum block set to 
100 °C for 18 hours. A standard workup was completed using a 2.0 M HCl solution and 
dichloromethane to extract. Magnesium sulfate was utilized to dry the sample before gravity 
filtering and removing the solvent under reduced pressure. Completion was checked using TLC 
and GC-MS. The crude reaction mixture was loaded onto a silica gel column using a wet load 
technique. The yields reported in this thesis are from one trial only. 
 
 
spiro[cyclohexane-1,3'-indolin]-3-en-2'-one + spiro[cyclohexane-1,3'-indolin]-2-en-2'-one: 
Using the general procedure outlined above with 2-bromoaniline (119 μL), the crude reaction 
mixture was purified using column flash chromatography (silica gel, 60Å) with 80% petroleum 
ether / 20% ethyl acetate (Rf = 0.23) and 0.175 g (88%) of a light yellow solid was isolated. EI 
MS, m/z: 199 (100), 182 (28), 170 (54), 159 (1), 152 (7), 145 (81), 130 (12), 117 (38), 103 (4), 
















































































































































































6.3 Mizoroki-Heck Reaction 
6.3.1 Birch reduction/alkylation General Procedures and Data 
 
Scheme 31: Birch/reduction alkylation general reaction sequence 
Procedure:  
A flame dried 3-necked roundbottom flask with a stir bar, connected to a Dewar condenser, 
under argon, was charged with benzoic acid (1.0 eq) which was dissolved in THF (0.43 mL / 
mmol) and cooled to -78˚C. Ammonia (7 mL / mmol) was distilled into the flask and lithium (4.0 
eq) was added in small pieces until a dark blue color was maintained for 30 minutes. Isoprene 
was added dropwise to quench the lithium and produce a bright yellow opaque solution. 
Alkylating agent (2.0 eq) in THF (0.43 mL / mmol) was added slowly dropwise. When the 
addition was complete the reaction was maintained at -78˚C while the color faded to white/off-
white over 1h. The reaction was then warmed to room temperature and the ammonia was 
allowed to evaporate under a stream of argon. Once evaporated the reaction was quenched with 
water, and washed with diethyl ether. The aqueous layer was acidified with 6N HCl (until pH 
~1), and then extracted with diethyl ether. The combined organic layers were washed with 





1-benzylcyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure and workup 
outlined above with benzyl chloride (3.8 mL), 3.3502 g (94%) of a white crystalline solid was 
isolated. m.p. = 71.9-75.0˚C. FTIR-ATR: 3827, 3027, 2861, 2861, 2805, 1692, 1494, 1443, 
1412, 1308, 1287, 1270, 939, 776, 759, 697, 632, 596 527, 500, 469 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 7.28 – 7.14 (m, 3H), 7.17 – 7.09 (m, 2H), 5.91 – 5.77 (m, 4H), 3.03 (s, 2H), 2.56 
(dhept, J = 23.1, 1.2 Hz, 2H), 2.36 (dhept, J = 23.1, 1.6 Hz, 1H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 179.87, 136.25, 130.55, 127.80, 126.55, 126.42, 48.94, 46.06, 26.01 ppm. Spectral data 
were in accordance with the literature.7 EI MS, m/z: 214 (1), 196 (1), 165 (7), 152 (5), 139 (2), 






































1-(cyanomethyl)cyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure and workup 
outlined above with chloroacetonitrile (2.204 g, 18.0 mmol). 2.335 g (80%) of a tan solid was 
isolated. m.p. = 98.3-102.3˚C. FTIR-ATR: 3150, 2937, 2810, 2582, 2269, 1719, 1682, 1452, 
1416, 1405, 1383, 1323, 1288, 1223, 1213, 1085, 1034, 937, 889, 836, 727, 667, 630, 567, 472 
cm-1. 1H NMR (400 MHz, CDCl3): 6.15 (dt, 2H, J = 10.3, 3.4 Hz), 5.76 (dt, 2H, J = 10.4, 2.0 
Hz), 2.81-2.78 (m, 2H), 2.76 (s, 2H) ppm. 13C (100 MHz, CDCl3) 176.6, 129.4, 123.4, 45.8, 
28.2, 26.1 ppm. Spectral data were in accordance with the literature.8 EI MS, m/z: 160 (4), 131 








































[1,1'-bi(cyclohexane)]-2,5-diene-1-carboxylic acid: Using the general procedure and workup 
outlined above with benzoic acid (3.09 g, 25.34 mmol). 5.00 g (96%) of an off-white solid was 
isolated. m.p.= 120.5-125.5˚C. 1H NMR (400 MHz, CDCl3) δ 5.93 (dtd, J = 10.6, 3.3, 1.6 Hz, 
2H), 5.74 (ddt, 2H, J = 19.6, 10.6, 2.0 Hz), 2.62 (tdd, 2H, J = 5.4, 3.4, 2.1 Hz), 1.77 – 1.70 (m, 
3H), 1.63 (d, 3H, J =  12.6 Hz), 1.22 (qt, 2H, J = 12.9, 3.3 Hz), 1.12 – 0.95 (m, 3H) ppm. 13C 
NMR (101 MHz, CDCl3) δ 180.6, 126.7, 125.7, 51.8, 45.9, 27.6, 26.6, 26.5, 26.3 ppm. EI MS, 








































1-isobutylcyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure and workup 
outlined above with benzoic acid (2.06 g, 16.89 mmol) and 1-iodo-2-methylpropane (3.60 mL,  
mmol). 2.87 g (94%) of an orange oil was isolated. 1H NMR (400 MHz, CDCl3) δ 5.89 (dtd, 2H, 
J = 10.5, 3.3, 1.7 Hz), 5.78 (dp, 2H, J = 10.5, 1.9 Hz), 2.66 (ttd, 2H, J = 3.1, 2.0, 0.8 Hz, 2H), 
1.76 – 1.65 (m, 3H), 0.89 (d, 6H, J = 6.4 Hz) ppm.13C (101 MHz, CDCl3) 181.3, 127.4, 125.6, 
48.2, 47.7, 26.1, 24.8, 24.2 ppm. Spectral data were in accordance with the literature.9 EI MS, 









































1-(methoxymethyl)cyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure and 
workup outlined above with benzoic acid (3.02 g, 24.76 mmol).  3.74 g (90%) of a white solid 
was isolated. m.p.= 66.9-70.5˚C. 1H NMR (400 MHz, CDCl3) δ 6.01 – 5.93 (m, 2H), 5.84 (dt, 
2H, J = 10.5, 2.0 Hz), 3.52 (s, 2H), 3.37 (s, 3H), 2.71 (m, 2H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 178.2, 127.2, 124.4, 78.7, 59.5, 49.2, 26.3 ppm. Spectral data were in accordance with 










































1-(naphthalen-1-ylmethyl)cyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure 
and workup outlined above with 1-(chloromethyl)napthalene (2.28 g, 18.7 mmol). 4.43 g (90%) 
of a light-yellow solid was isolated. m.p. = 130.5-133.8. 1H NMR (400 MHz, CDCl3) δ 8.09 
(ddd, 1H, J = 7.2, 2.8, 1.6 Hz), 7.82 (dd, 1H, J = 7.8, 1.8 Hz), 7.76 – 7.70 (m, 1H), 7.46 (tdt, 2H, 
J = 10.6, 6.8, 3.5 Hz), 7.39 – 7.34 (m, 2H), 5.87 (dt, 2H, J = 10.5, 1.9 Hz), 5.79 (dt, 2H, J = 10.3, 
3.2 Hz), 3.56 (s, 2H), 2.54 (dheptd, 1H, J = 13.0, 1.8 Hz), 2.36 (dhept, 1H, J = 13.1, 1.8 Hz) 
ppm. 13C NMR (101 MHz, CDCl3) δ 179.8, 133.7, 132.7, 128.6, 128.6, 127.5, 126.8, 126.2, 
125.5, 125.3, 125.1, 124.8, 49.3, 41.7, 26.0 ppm. EI MS, m/z: 218 (100), 202 (35), 189 (8), 163 
(2), 152 (2), 141 (13), 115 (8), 108 (8), 91 (4), 65 (3). 



































Figure 92: 13C NMR of compound 37 
 
 
1-(but-3-en-1-yl)cyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure and 
workup outlined above with benzoic acid (3.19 g, 26.08 mmol). 4.12 g (89%) of a dark yellow 
free flowing oil was isolated. 1H NMR (400 MHz, CDCl3) δ 5.93 (dtd, 2H, J = 10.6, 3.4, 1.8 Hz), 
5.86 – 5.71 (m, 3H), 5.00 (dq, 1H, J = 17.1, 1.7 Hz), 4.94 (dq, 1H, J = 10.2, 1.5 Hz), 2.66 (dtt, 
2H, J = 4.3, 3.3, 2.1 Hz), 2.00 (dddd, 2H, J = 12.7, 6.4, 3.2, 1.6 Hz), 1.84 – 1.75 (m, 2H) ppm. 
13C NMR (101 MHz, CDCl3) δ 181.0, 138.1, 133.8, 130.2, 128.5, 126.5, 126.4, 114.7, 47.6, 38.4, 
28.6, 26.2 ppm. EI MS, m/z: 177 (1), 160 (3), 133 (11), 123 (5), 115 (1), 105 (6), 91 (100), 79 



















































1-(but-3-yn-1-yl)cyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure and 
workup outlined above with benzoic acid (2.05 g, 16.8 mmol). 2.88 g (89%) of a tan solid was 
isolated. 1H NMR (400 MHz, CDCl3) δ 6.02 – 5.92 (m, 2H), 5.70 (dp, 3H, J = 10.6, 2.0 Hz), 
2.76 – 2.56 (m, 2H), 2.16 – 1.91 (m, 7H) ppm. 13C NMR (101 MHz, CDCl3) δ 156.5, 127.3, 
125.5, 83.9, 68.6, 47.4, 37.6, 26.1, 13.8 ppm. EI MS, m/z: 176 (1), 131 (68), 123 (5), 116 (10), 


























Figure 96: 13C NMR of compound 39 
 
 
1-(sec-butyl)cyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure and workup 
outlined above with benzoic acid (2.06 g, 16.9 mmol). 2.82 g (93%) of an orange oil was 
isolated. 1H NMR (400 MHz, CDCl3) δ 5.97-5.91 (m, 2H), 5.74-5.70 (m, 2H), (2.76-2.56 (m, 
2H), 1.86-1.78 (m, 1H), 1.53-1.43 (m, 2H), 0.88 (dd, 8H, J = 16.3, 7.2 Hz) ppm. 13C NMR (101 
MHz, CDCl3) δ 181.4, 127.0, 126.6, 125.7, 125.6, 52.5, 42.6, 26.5, 24.4, 13.6, 12.4 ppm. EI MS, 
















































1-(2-amino-2-oxoethyl)cyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure and 
workup outlined above with benzoic acid (2.10 g, 17.2 mmol) and 2-chloroacetamide (3.21 g, 
34.3 mmol). 1.71 g (55%) of a light-yellow oil was isolated. 1H NMR (400 MHz, CDCl3) δ 5.93 
(ddq, 2H, J = 10.4, 3.3, 1.9 Hz), 5.84 (ddt, 1H, J = 10.4, 3.7, 2.0 Hz), 2.71 (dqt, 1H,  J = 9.2, 3.5, 
2.0 Hz), 2.41 (m, 1H), 2.22-2.16 (m, 1H) ppm.  
GCMS had benzoic acid peak only. Proton NMR has product peaks, however, there is still a lot 
































1-(2,2,2-trifluoroethyl)cyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure 
and workup outlined above with benzoic acid (3.02 g, 24.7 mmol) and 1,1,1-trifluoro-2-
iodoethane (4.87 mL, 49.4 mmol). 3.05 g of a crude solid was isolated. The NMR contained 














Figure 100: 1H NMR of compound 42 
 
Ammonium 1-((1H-benzo[d][1,2,3]triazol-1-yl)methyl)cyclohexa-2,5-diene-1-carboxylate: 
Using the general procedure and workup outlined above with benzoic acid (2.08 g, 17.0 mmol) 
and 1-(chloromethyl)-1H-benzotriazole. 6.42 g (>100%) of a white solid was isolated. No 




concentrating the solution in vacuo to produce a white solid. 1H NMR (400 MHz, CD3OD) δ  
7.88 (d, 1H, J = 7.9 Hz), 7.83 (d, 1H, J = 8.4 Hz), 7.48 (ddd, 1H,  J = 8.2, 6.9, 1.0 Hz), 7.36 
(ddd, 1H, J = 8.1, 6.8, 1.0 Hz), 5.96 (dt, 2H, J = 10.5, 2.0 Hz), 5.60 (dt, 1H, J = 10.5, 3.4 Hz), 














Figure 101: 1H NMR of compound 43 
 
 
1-methylcyclohexa-2,5-diene-1-carboxylic acid: Using the general procedure and workup 
outlined above with benzoic acid (3.02 g, 24.7 mmol) and iodomethane (3.08 mL, 49.5 mmol). 
3.15 g (92%) of a white solid was isolated. 1H NMR (400 MHz, CDCl3) δ 5.87-5.83 (m, 2H), 
5.78 (dt, 2H, J = 10.4, 1.9 Hz), 2.74-2.59 (m, 2H), 1.37 (s, 3H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 181.6, 128.1, 125.0, 43.7, 27.2, 25.9 ppm. Spectral data were in accordance with the 








































6.3.2 Benzamide General Procedures and Data 
 
 
Scheme 32: Benzamide general procedure 
General Acid Chloride synthesis procedure: 
In a round bottom flask with a stir bar, oxalyl chloride (2.2 eq) was dissolved in DCM. Then a 
catalytic amount of DMF (1.38 μL/mmol) was added. The Birch product (1.0 mmol) was dissolved in 
DCM and added dropwise to the flask. The reaction was refluxed under Argon for an hour until it 
turned deep yellow. Once completed, the reaction was concentrated under vacuum to remove excess 
oxalyl chloride and taken immediately to the next step without further characterization of these 
intermediates.  
Benzamide synthesis procedure: 
In a round bottom flask with a stir bar, purified 2-(methylamino) phenol or 2-aminophenol or 2-
bromoaniline (1.3-1.6 eq) was dissolved in DCM and cooled to 0°C. Triethylamine (2.5 eq) was 
added dropwise and after a few minutes, the acid chloride in DCM was added. The mixture was 
allowed to warm to room temperature and react overnight. The reaction mixture was diluted with 
DCM and washed with NaHCO3, 1N HCl, water, brine and dried with MgSO4. The product was 
then concentrated under vacuum. NMRs were taken in (CD3)2SO and were heated to 100˚C. Heat 
was needed to coalesce the peaks due to atropisomers that formed in the reaction.  
 
 
1-benzyl-N-(2-hydroxyphenyl)cyclohexa-2,5-diene-1-carboxamide: Using the general 
procedure  and workup outlined above, (0.216 g, 0.93 mmol) of the acid chloride was used. This 
reaction yielded 0.248 (87%) of an orange solid. 1H NMR (400 MHz, CDCl3): δ 8.84 (s, 1H), 7.71 
(s, 1H), 7.26-7.17 (m, 5H), 7.11 (ddd, 1H, J = 8.8, 6.3, 2.6 Hz), 7.01 (d, 1H, J = 7.6 Hz), 6.85-6.79 
(m, 2H), 6.00 (dt, 2H, J = 10.4, 3.4 Hz), 5.83 (dt, 2H, J = 10.4, 2.0 Hz), 3.19 (s, 2H), 2.70 (dp, 1H, 
J = 23.5, 3.0 Hz), 2.57 (dh, 1H, J = 23.5, 1.7 Hz) ppm. 13C (100 MHz, CDCl3): δ 174.3, 148.9, 

















































N-(2-hydroxyphenyl)-1-isobutylcyclohexa-2,5-diene-1-carboxamide: Using the general 
procedure and workup outlined above, (0.229 g, 1.20 mmol) of the acid chloride was used. This 
reaction yielded 0.315 g (99%) of a dark orange solid. 1H NMR (400 MHz, CDCl3): δ 7.82 (s, 1H), 
7.17-7.15 (m, 1H), 7.11 (td, 1H, J = 7.7, 1.6 Hz), 6.98 (dd, 1H, J = 8.2, 1.5 Hz), 6.87 (td, 1H, J = 
7.6 ,1.4 Hz), 6.31-6.26 (m, 2H), 5.84 (dt, 2H, J = 10.4, 2.1 Hz), 3.01-2.83 (m, 4H) ppm. 13C (100 
MHz, CDCl3): δ 171.3, 147.9, 130.5, 127.2, 125.1, 124.7, 121.9, 120.8, 119.2, 117.1, 47.4, 27.1, 
26.1 ppm. EI MS, m/z: 209 (15), 196 (62), 136 (67), 117 (32), 105 (23), 92 (100), 77 (25), 65 (18), 





































Figure 107: 13C NMR of compound 46 
 
1-benzyl-N-(2-bromophenyl)cyclohexa-2,5-diene-1-carboxamide: Using the general procedure 
and workup outlined above, (0.550 g, 2.36 mmol) of the acid chloride was used. 0.819g (94%) of 
a red/tan solid was isolated. 1H NMR (400 MHz, CDCl3): δ 8.43 (dd, 1H, J = 8.2, 1.6 Hz), 8.31 
(s, 1H), 7.48 (dd, 1H, J = 8.0, 1.4 Hz), 7.33-7.29 (m, 1H), 7.25-7.16 (m, 5H), 6.95 (td, 1H, J = 
7.7, 1.6 Hz), 5.99 (dt, 2H, J = 10.2, 3.4 Hz), 5.82 (dt, 2H, J = 10.4, 2.0 Hz), 3.21 (s, 2H), 2.73 
(dp, 1H, J = 23.4, 3.0 Hz), 2.56 (dh, 1H, J = 23.4, 1.8 Hz) ppm. 13C (100 MHz, CDCl3): δ ppm. 
EI MS, m/z: 367 (9), 276 (18), 262 (3), 196 (30), 170 (14), 152 (4), 120 (4), 105 (30), 91 (100), 










































1-benzyl-N-(2-hydroxyphenyl)-N-methylcyclohexa-2,5-diene-1-carboxamide: Using the general 
procedure and workup outlined above, (5.36g, 23.0 mmol) of the acid chloride was used. This 
reaction yielded >100% of a light brown solid. IR (neat):3164, 3027, 1616,1582, 1494, 1450, 1414, 
1289, 1135, 1063, 1031, 798, 756, 695, 674, 630, 586, 508, 476 cm-1. 1H NMR (400 MHz, DMSO-
d6): δ 9.08 (s, 1H), 7.08 (m, 6H), 6.85 (dd, 1H, J =7.7, 1.5 Hz), 6.75 (d, 1H, J= 8.0 Hz), 6.60 (t, 
1H, J=7.6 Hz), 5.46 (d, 2H, J=9.5 Hz), 5.22 (d, 2H, J= 6.0 Hz), 3.04 (s, 3H), 2.99 (s, 2H), 1.91 (q, 
2H, J=23 Hz)   ppm. 13C (100 MHz, DMSO-d6): δ 138.1, 131.4, 129.2, 127.5, 126.1, 119.1, 116.2, 
50.5, 46.4, 39.0, 26.0 ppm.  EI MS, m/z: 319 (9), 227 (23), 210 (7), 196 (13), 167 (51), 150 (59), 








































1-(cyanomethyl)-N-(2-hydroxyphenyl)-N-methylcyclohexa-2,5-diene-1-carboxamide: Using the 
general procedure outlined above with 1-(cyanomethyl)cyclohexa-2,5-diene-1-carbonyl chloride 
(1.1228, 6.18 mmol), 1.5938 g (96%) of a dark yellow/brown oil was isolated. 1H NMR (400 
MHz, DMSO-d6 100 degrees): 9.24 (s, 1H), 7.08 (td, 1H, J= 8.0, 1.6 Hz), 7.00 (dd, 1H, J= 
8.0,1.6 Hz), 6.80 (dd, 1H, J=8.2, 1.1 Hz), 6.66 (td, 1H, J=7.6, 1.1 Hz), 5.56 (s, 4H), 3.05 (s, 3H), 
2.73 (s, 2H), 2.38 (d, 1H, J=24.0 Hz), 2.02 (d, 1H, J=24 Hz) ppm. 13C (100 MHz, DMSO-d6): 
170.1, 154.1, 153.1, 137.1, 130.8, 129.9, 129.6, 129.0, 127.9, 127.3, 127.0, 125.5, 124.1, 119.8, 
119.2, 119.0, 116.8, 116.4, 47.4, 46.2, 38.9, 30.2, 26.3 ppm. EI MS, m/z: 268 (14), 150 (100), 












































N-(2-hydroxyphenyl)-N-methyl-[1,1'-bi(cyclohexane)]-2,5-diene-1-carboxamide: Using the 
general procedure outlined above with [1,1'-bi(cyclohexane)]-2,5-diene-1-carbonyl chloride 
(1.61 g, 7.16 mmol), 2.16 g (97%) of a light brown solid was isolated. 1H NMR (400 MHz, 
DMSO-d6 100 degrees): 9.10 (s, 1H), 7.07 (td, 1H, J = 7.9, 1.6 Hz), 13.8 (dd, 1H, J = 7.8, 1.5 
Hz), 6.79 (dd, 1H, J = 8.2, 1.5 Hz), 6.64 (td, 1H, J = 7.4, 1.2 Hz), 5.34 (s, 4H), 3.00 (s, 3H), 2.23 
(q, 2H, J = 23.0 Hz), 1.93 (tt, J = 12.0, 3.2 Hz, 1H), 1.61 (dd, 6H, J = 37.6, 11.6 Hz), 1.15 (qt, 
3H, J = 12.8, 3.3 Hz), 0.98 (qt, 1H, J = 12.7, 3.4 Hz), 0.83 (qd, 2H, J = 12.5, 3.0 Hz) ppm. 13C 
(100 MHz, DMSO-d6): 176.5, 152.0, 129.4, 128.6, 126.9, 125.8, 125.3, 120.7, 111.2, 54.0, 46.2, 
39.6, 27.8, 26.7, 26.6, 26.5 ppm. EI MS, m/z: 311 (5), 228 (15), 210 (1), 196 (2), 151 (21), 135 






































N-(2-hydroxyphenyl)-1-isobutyl-N-methylcyclohexa-2,5-diene-1-carboxamide: Using the 
general procedure outlined above with 1-isobutylcyclohexa-2,5-diene-1-carbonyl chloride (1.18 
g, 5.93 mmol), 1.68 g (99%) of a tan solid was isolated. 1H NMR (400 MHz, DMSO-d6 100 
degrees): 9.11 (s, 1H), 7.07 (td, 1H, J = 7.7, 1.6 Hz), 6.95 (dd, 1H, J = 7.8, 1.6 Hz), 6.79 (d, 1H, 
J = 8.1), 6.65 (td, 1H, J = 7.5, 1.2 Hz), 5.44 (d, 2H, J = 9.4 Hz), 5.31 (d, 2H, J = 7.5 Hz), 3.00 (s, 
3H), 2.33 (d, 1H, J = 22.8 Hz), 2.12 (d, 1H, J = 22.8 Hz), 1.62-1.52 (m, 3H), 0.81 (d, 6H, J = 6.5 
Hz) ppm. 13C (100 MHz, DMSO-d6): 174.0, 154.1, 130.2, 129.7, 128.9, 123.1, 119.4, 116.7, 













































Using the general procedure outlined above with 1-(methoxymethyl)cyclohexa-2,5-diene-1-
carbonyl chloride (2.30 g, 12.31 mmol), 3.04 g (90%) of a light brown solid was isolated. 1H 
NMR (400 MHz, DMSO-d6 100 degrees): 9.11 (s, 1H), 7.07 (td, 1H, J = 7.8, 1.6 Hz), 6.96 (dd, 
1H, J = 7.8, 1.6 Hz), 6.79 (d, 1H, J = 8.1 Hz), 6.65 (td, 1H, J = 7.4, 1.3 Hz), 5.49 (d, 2H, J = 9.4 
Hz), 5.37 (s, 2H), 3.42 (s, 2H), 3.18 (s, 3H), 3.01 (s, 3H), 2.33 (d, 1H, J = 22.8 Hz), 2.12 (d, 1H, 
J = 22.9 Hz) ppm. 13C (100 MHz, DMSO-d6): 154.0, 130.3, 129.2, 127.9, 127.3, 126.1, 125.9, 
119.2, 116.3, 80.0, 59.0, 50.3, 38.6, 26.4 ppm. EI MS, m/z: 273 (5), 242 (3), 228 (4), 210 (3), 


































Figure 119:  13C NMR of compound 52 
 
N-(2-hydroxyphenyl)-N-methyl-1-(naphthalen-1-ylmethyl)cyclohexa-2,5-diene-1-carboxamide: 
Using the general procedure and workup outlined above with 1-(chloromethyl)napthalene (2.17 
g, 7.69 mmol). 2.68 g (94%) of a light-yellow solid was isolated. 1H NMR (400 MHz, CDCl3): 
8.10-8.07 (m, 1H), 7.83-7.80 (m, 1H), 7.73 (t, 1H, J = 4.0), 7.49-7.41 (m, 2H), 7.38-7.36 (m, 
2H), 5.87 (dt, 2H, J = 10.5,1.6 Hz), 5.79 (dt, 2H, J = 10.5, 3.2 Hz), 3.56 (s, 2H), 2.54 (dsept, 1H, 
J = 23.2,1.6 Hz), 2.36 (dquint, 1H, J = 23.1, 2.0 Hz) ppm. 13C (100 MHz, CDCl3) 179.8, 133.7, 
133.1, 132.7, 128.6, 128.5, 127.5, 126.8, 126.2, 125.5, 125.3, 125.1, 124.8, 49.3, 41.7, 30.0 ppm. 












































1-(but-3-en-1-yl)-N-(2-hydroxyphenyl)-N-methylcyclohexa-2,5-diene-1-carboxamide: Using the 
general procedure and workup outlined above with 1-(but-3-en-1-yl)cyclohexa-2,5-diene-1-
carbonyl chloride (1.28 g, 6.51 mmol). 1.82 g (99%) of a dark red/brown oil was isolated. 1H 
NMR (400 MHz, DMSO-d6 100 degrees): 9.10 (s, 1H), 7.07 (td, 1H, J = 8.0, 1.7 Hz), 6.96 (dd, 
1H, J = 7.8, 1.6 Hz), 6.79 (dd, 1H, J = 8.1, 1.2 Hz), 6.65 (td, 1H, J = 7.6, 1.3 Hz), 5.76 (ddt, 4H, 
J = 16.9, 10.3, 6.4 Hz), 5.44-5.36 (m, 4H), 4.94-4.89 (m, 1H), 4.87-4.84 (m, 1H), 3.01 (s, 3H), 
2.31 (d, 1H, J = 22.9 Hz), 2.10 (d, 1H, J = 21.7 Hz), 1.88-1.83 (m, 2H), 1.74-1.69 (m, 2H) ppm. 
13C (100 MHz, DMSO-d6): 173.6, 154.1, 139.7, 130.3, 128.9, 123.9, 119.4, 116.7, 114.3, 49.4, 
38.9, 28.6, 26.3 pm. EI MS, m/z: 283 (1), 228 (1), 192 (3), 150 (25), 134 (3), 123 (5), 105 (11), 









































the general procedure and workup outlined above with 1-(but-3-yn-1-yl)cyclohexa-2,5-diene-1-
carbonyl chloride (2.88 g, 14.8 mmol). 5.15 g (>100%) of an oil was isolated. 1H NMR (400 MHz, 
CDCl3): 7.18 (dt, 1H, J = 7.8, 1.6 Hz), 7.05 (dd, 1H, J = 7.8, 1.4 Hz), 6.90 (d, 1H, J = 7.8 Hz), 
6.81 (t, 1H, J = 7.6 Hz), 5.58 (s, 2H), 5.49 (d, 2H, J = 20.6 Hz), 3.19 (s, 3H), 2.36 (d, 1H), 2.05 (d, 
5H, J = 7.2), 1.91 (t, 1H, J = 2.4 Hz) ppm. 13C (100 MHz, CDCl3): 126.3, 120.8, 84.8, 68.2, 53.4, 
49.3, 39.6, 38.2, 26.2, 13.7 ppm. EI MS, m/z: 281 (9), 264 (15), 251 (1), 228 (1), 176 (2), 160 (1), 







































1-(sec-butyl)-N-(2-hydroxyphenyl)-N-methylcyclohexa-2,5-diene-1-carboxamide: Using the 
general procedure and workup outlined above with 1-(sec-butyl)cyclohexa-2,5-diene-1-carbonyl 
chloride (1.66 g, 8.35 mmol). 2.31 g (99%) of a light brown solid. 1H NMR (400 MHz, CDCl3): 
7.18 (td, 1H, J = 7.8, 1.6 Hz), 7.02 (dd, 1H, J = 7.8, 1.5 Hz), 6.88 (dd, 1H, J = 8.2, 0.9 Hz), 6.78 
(td, 1H, J = 7.6, 1.1 Hz), 5.48-5.35 (m, 4H),3.16 (s, 3H), 2.39 (d, 1H, J = 23.4 Hz), 2.26-2.13 (m, 
2H), 1.42-1.37 (m,1H), 0.97-0.69 (m, 9H) ppm. 13C (100 MHz, CDCl3): 129.4, 125.6, 125.3, 
120.7, 54.7, 42.8, 39.6, 26.6, 13.8, 12.7 ppm. EI MS, m/z: 285 (7), 256 (1), 228 (28), 151 (44), 



































Figure 127: 13C NMR of compound 56 
 
N-(2-hydroxyphenyl)-N,1-dimethylcyclohexa-2,5-diene-1-carboxamide: Using the general 
procedure and workup outlined above with 1-methylcyclohexa-2,5-diene-1-carbonyl chloride 
(2.34 g, 14.96 mmol). 3.41 g (94%) of a tan solid. 1H NMR (400 MHz, CDCl3): 7.17 (td, 1H, J = 
7.7, 1.6 Hz), 7.08 (dd, 1H, J = 7.8, 1.5 Hz), 6.91 (d, 1H, J = 7.7 Hz), 6.83 (t, 1H, J = 7.6 Hz), 
5.60 (s, 2H), 5.50 (s, 2H), 3.22 (s, 3H), 2.43 (s, 1H), 2.10 (s, 1H), 1.35 (s, 3H) ppm. 13C (100 
MHz, CDCl3): 154.0, 130.6, 130.4, 129.4, 128.9, 127.8, 127.7, 122.4, 119.4, 116.8, 45.6, 38.8, 








































6.3.3 Triflation General Procedures and Data 
 
 
Scheme 33: Triflation general procedure 
The procedure was adapted from Darses and co-workers.11 A flame-dried flask with a stir bar, 
under argon, was charged with benzamide (1.0 eq) which was dissolved in DCM (2.5 mL/mmoL). 
Pyridine (2.0 eq) was added and the solution was stirred at -20˚C (70:30, H2O:MeOH dry ice bath) 
for 10 minutes. Tf2O (3.0 eq) was added slowly in a dropwise manner and stirred for a few minutes 
before the bath was removed and the reaction was allowed to warm to room temperature with the 
total reaction time being 1 hour. The reaction was worked up by adding saturated sodium 
bicarbonate and was extracted with DCM. The organic layers were washed with 1 N HCl. The 







1-benzyl-N-(2-hydroxyphenyl)cyclohexa-2,5-diene-1-carboxamide: Using the general 
procedure outlined above with 1-benzyl-N-(2-hydroxyphenyl)cyclohexa-2,5-diene-1-
carboxamide (0.315 g, 0.66 mmol), the crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 90% hexanes/ 10% ethyl acetate (Rf = 0.26) and 0.202 g 
(70%) of a yellow viscous oil was isolated. 1H NMR (400 MHz, CDCl3) δ 8.37 (dd, 1H,J = 8.3, 
1.7 Hz), 7.97 (s, 1H), 7.37 (ddd, 1H, J = 8.5, 7.5, 1.5 Hz), 7.29 – 7.10 (m, 8H), 5.99 (dt, 2H, J = 
10.3, 3.4 Hz), 5.78 (dt, 2H, J = 10.4, 2.0 Hz), 3.19 (s, 2H), 2.70 (dp, 1H, J = 12.7, 3.0 Hz), 2.51 
(dhept, 1H, J = 12.9, 1.9 Hz) ppm. 13C NMR (101 MHz, CDCl3) δ 172.4, 139.0, 137.2, 130.8, 
130.7, 129.0, 128.2, 127.8, 127.1, 126.3, 124.9, 123.2, 121.3, 118.4 (CF3, q, J = 320.3 Hz) 51.2, 
43.5, 26.0 ppm. 19F NMR (376 MHz, DMSO) δ -73.30 (s) ppm. EI MS, m/z: 437 (9), 346 (28), 



































































Figure 132: 19F NMR of compound 58 
 
 
2-(1-(cyanomethyl)cyclohexa-2,5-diene-1-carboxamido)phenyl trifluoromethanesulfonate: Using 
the general procedure outlined above with 1-(cyanomethyl)-N-(2-hydroxyphenyl)cyclohexa-2,5-
diene-1-carboxamide (2.23 g, 8.77 mmol) ), the crude reaction mixture was purified using 
column flash chromatography (silica gel, 60Å) with 70% hexanes/ 30% ethyl acetate (Rf = 0.37) 
and 1.94 g (57%) of a light yellow oil was isolated. 1H NMR (400 MHz, CDCl3) δ 8.27 (dd, 1H, 
J = 8.3, 1.6 Hz), 7.94 (s, 1H), 7.39 (ddd, 1H, J = 8.8, 7.4, 1.5 Hz), 7.28 (dd, 1H, J = 8.3, 1.5 Hz), 
7.19 (ddd, 1H, J = 8.4, 7.4, 1.6 Hz), 6.32 – 6.25 (m, 2H), 5.79 (dt, 3H, J = 10.4, 2.1 Hz), 2.95 – 
2.90 (m, 2H), 2.89 (s, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 169.9, 139.0, 130.8, 130.3, 
129.2, 125.6, 124.2, 123.3, 121.5, 118.5 (d, J=322 Hz), 117.3, 48.0, 26.9, 26.0 ppm. 19F NMR 
(376 MHz, DMSO) δ -73.17 (s) ppm EI MS, m/z: 386 (0.1), 269 (2), 241 (3), 196 (2), 135 (15), 












































































Figure 135: 19F NMR of compound 59 
  
2-(1-benzyl-N-methylcyclohexa-2,5-diene-1-carboxamido)phenyl trifluoromethanesulfonate: 
using the general procedure outlined above with 1-benzyl-N-(2-hydroxyphenyl)-N-
methylcyclohexa-2,5-diene-1-carboxamide (2.3075 g, 7.22 mmol), the crude reaction mixture 
was purified using column flash chromatography (silica gel, 60Å) with 1% triethylamine/ 79% 
hexanes/ 20% ethyl acetate (Rf = 0.38) and 2.7401 g (84%) of a yellow oil was isolated. FTIR-
ATR: 3029, 2925, 1647, 1494, 1418, 1348, 1247, 1207, 1136, 1078, 979, 946, 896, 766, 704, 
672, 628, 592, 571, 495, 473 cm-1. 1H NMR (400 MHz, DMSO) δ 7.47 – 7.32 (m, 4H), 7.17 – 
7.10 (m, 3H), 7.05 (dd, 2H, J = 7.6, 1.8 Hz), 5.55-5.46 (m, 4H), 3.20 (s, 3H), 3.01 (s, 2H), 2.14 
(d, 1H, J = 23.2 Hz), 1.97 (d, 1H, J = 23.2 Hz) ppm. 13C NMR (101 MHz, DMSO) δ 173.1, 
145.6, 137.7, 131.4, 130.0, 129.6, 127.9, 127.5, 126.2, 125.4, 121.7, 118.6 (d, J=322 Hz), 50.9, 
46.5, 39.9, 25.9 ppm. 19F NMR (376 MHz, DMSO) δ -73.61 (s) ppm. EI MS, m/z: 451 (1), 360 



















































Figure 138: 19F NMR of compound 60 
 
2-(1-(cyanomethyl)-N-methylcyclohexa-2,5-diene-1-carboxamido)phenyl 
trifluoromethanesulfonate: Using the general procedure outlined above using 1-(cyanomethyl)-
N-(2-hydroxyphenyl)-N-methylcyclohexa-2,5-diene-1-carboxamide (0.9828 g, 3.66 mmol), the 
crude reaction mixture was purified using column flash chromatography (silica gel, 60Å) with 
30% ethyl acetate/70% hexanes (Rf = 0.34) and 0.9434 g (64%) of an yellow viscous oil was 
isolated. FTIR-ATR:  3028, 1648, 1494, 1416, 1358, 1247, 1207, 1135, 1077, 890, 830, 799, 
755, 737, 672, 627, 591, 571, 518, 465 cm-1.  1H (400 MHz, DMSO, 100°C): 7.52-7.44 (m, 3H), 
7.40-7.38 (m, 1H), 5.85 (s, 2H), 5.66 (d, 2H, J =9.4), 3.23 (s, 3H), 2.77 (s, 2H), 2.62 (d, 1H, 
22.9), 2.35 (d, 1H, J = 22.2 Hz) ppm. 13C (100 MHz, CDCl3): 170.6, 170.3, 145.1, 138.2, 133.4, 
131.3, 130.7, 130.3, 130.1, 129.8, 129.6, 128.8, 127.5, 127.3, 126.1, 124.6, 124.3, 123.2, 122.1, 
120.0, 118.6, 116.9, 47.0, 39.1, 30.1, 29.8, 26.4, 25.9 ppm. 19F NMR (376 MHz, DMSO) δ -
73.49 (s) ppm. EI MS, m/z: 400 (1), 360 (1), 331 (1), 282 (11), 255 (2), 239 (1), 218 (19), 203 





















































Using the general procedure outlined above using N-(2-hydroxyphenyl)-N-methyl-[1,1'-
bi(cyclohexane)]-2,5-diene-1-carboxamide (1.38 g, 4.42 mmol) , the crude reaction mixture was 
purified using column flash chromatography (silica gel, 60Å) with 20% ethyl acetate/80% 
hexanes (Rf = 0.0.41) and 1.10 g (56%) of a white solidified oil was isolated. m.p. = 45.2-48.3˚C. 
1H NMR (400 MHz, DMSO) δ 7.50-7.35 (m, 4H), 5.55 (d, 2H, J = 8.5 Hz), 5.38 (d, 2H, J = 9.8 
Hz), 3.15 (s, 3H), 2.41 (d, 1H, J = 23.6 Hz), 2.26 (d, 1H, J = 22.7 Hz), 1.98 (t, 1H, J = 12.0 Hz), 
1.62 (dd, 5H, J = 32.7, 11.1 Hz), 1.18 (q, 2H, J =25.5, 12.8 Hz), 1.00 (q, 1H, J = 25.2, 12.4 Hz), 
0.86 (q, 2H, J = 24.4, 12.0 Hz) ppm. 13C NMR (101 MHz, DMSO) δ 173.6, 145.7, 137.9, 131.5, 
130.0, 129.6, 127.2, 125.5, 121.7, 118.6 (d, J = 322 Hz), 53.8, 46.9, 39.9, 34.4, 27.7, 26.9, 26.7, 
26.5 ppm. 19F NMR (376 MHz, DMSO) δ -73.65 (s) ppm. EI MS, m/z: 443 (3) 360 (77), 284 
































































Figure 144: 19F NMR of compound 62 
 
2-(1-isobutyl-N-methylcyclohexa-2,5-diene-1-carboxamido)phenyl trifluoromethanesulfonate: 
Using the general procedure outlined above using N-(2-hydroxyphenyl)-1-isobutyl-N-
methylcyclohexa-2,5-diene-1-carboxamide (1.11 g, 3.88 mmol), the crude reaction mixture was 
purified using column flash chromatography (silica gel, 60Å) with 20% ethyl acetate/80% 
hexanes (Rf = 0.40) and 0.9720 g (60%) of an light yellow oil was isolated. 1H (400 MHz, 
DMSO, 100°C): 7.50-7.36 (m, 4H), 5.55 (dd, 4H, J = 30.4, 10.0 Hz), 3.18 (s, 3H), 2.51 (d, 1H, J 
= 24.0 Hz), 2.30 (d, 1H, J = 24.0 Hz), 1.59 (m, 3H), 0.83 (d, 6H, J = 6.4 Hz) ppm. 13C NMR 
(101 MHz, CDCl3) δ 173.4, 145.6, 138.0, 131.5, 129.9, 129.7, 128.8, 124.8, 121.7, 118.6 (d, J= 
322 Hz), 49.9, 49.7, 39.8, 26.2, 24.9, 24.2 ppm. 19F NMR (376 MHz, DMSO) δ -73.62 (s) ppm. 






































































trifluoromethanesulfonate: Using the general procedure outlined above using N-(2-
hydroxyphenyl)-1-(methoxymethyl)-N-methylcyclohexa-2,5-diene-1-carboxamide (2.14 g, 7.85 
mmol), the crude reaction mixture was purified using column flash chromatography (silica gel, 
60Å) with 30% ethyl acetate/70% hexanes (Rf = 0.28) and 1.66 g (52%) of a white solid was 
isolated. m.p. = 55.7-58.0˚C. 1H NMR (400 MHz, DMSO) δ 7.52 – 7.39 (m, 3H), 7.37 (d, 1H, J 
= 7.9 Hz), 5.61 (d, 2H, J = 10.6 Hz), 5.58 – 5.50 (m, 2H), 3.46 (s, 1H), 3.19 (d, 6H, J = 8.8 Hz), 
2.49 (d, 1H, J = 23.6 Hz), 2.30 (d, 1H, J = 23.6 Hz) ppm. 13C (100 MHz, CDCl3) 171.9, 145.7, 
137.4, 131.6, 130.0, 129.6, 126.3, 126.0, 121.7, 118.6 (d, J = 326 Hz), 79.7, 59.3, 51.0, 39.6, 
26.2 ppm. 19F NMR (376 MHz, DMSO) δ -73.58 (s) ppm. EI MS, m/z: 405 (10), 375 (8), 360 
(39), 314 (3), 284 (11), 268 (6), 242 (1), 227 (5), 210 (22), 182 (1), 166 (1), 149 (89), 122 (25), 








































































6(5H)-one: Using the general procedure outlined above using N-(2-hydroxyphenyl)-N-methyl-1-
(naphthalen-1-ylmethyl)cyclohexa-2,5-diene-1-carboxamide (0.96 g, 2.61 mmol), the crude 
reaction mixture was purified using column flash chromatography (silica gel, 60Å) with 20% 
ethyl acetate/80% hexanes (Rf = 0.31) and 0.81 g (62%) of a yellow viscous oil was isolated. 
1H 
NMR (400 MHz, DMSO) δ 8.05 – 7.96 (m, 1H), 7.80 (dd, 1H, J = 6.7, 4.0 Hz), 7.70 (d, 1H, J = 
7.4 Hz), 7.46 – 7.28 (m, 8H), 5.59 (d, 2H, J = 10.0 Hz), 5.33 (d, 4H, J = 9.9 Hz), 3.57 (s, 2H), 
3.22 (s, 3H), 2.06 (d, 1H, J = 23.2 Hz), 1.80 (dp, 1H, J = 23.3, 2.4 Hz) ppm. 13C NMR (101 
MHz, DMSO) δ 173.4, 145.7, 137.8, 134.1, 133.8, 133.7, 131.4, 130.0, 129.6, 129.4, 128.7, 
128.0, 127.1, 125.5, 125.4, 125.3, 125.2, 125.1, 121.7, 118.7 (CF3, q, J = 322.1 Hz), 51.5, 41.5, 
40.0, 25.8. ppm. 19F NMR (376 MHz, DMSO) δ -73.58 ppm. EI MS, m/z: 210 (45), 141 (33), 
















































Figure 153: 19F NMR of compound 65 
 
2-(1-(3-cyanobenzyl)-N-methylcyclohexa-2,5-diene-1-carboxamido)phenyl 
trifluoromethanesulfonate: Using the general procedure outlined above using 1-(but-3-en-1-yl)-
N-(2-hydroxyphenyl)-N-methylcyclohexa-2,5-diene-1-carboxamide (0.93 g, 3.27 mmol), the 
crude reaction mixture was purified using column flash chromatography (silica gel, 60Å) with 
20% ethyl acetate/80% hexanes (Rf = 0.35) yielding 1.09 g (80%) of an orange solid. m.p. = 
51.7-52.9˚C. 1H NMR (400 MHz, DMSO) δ 7.52 – 7.45 (m, 3H), 7.40 (d, 1H, J = 7.2 Hz), 5.80 
(ddt, 1H, J = 17.0, 10.4, 6.4 Hz), 5.68 (d, 2H, J = 9.8 Hz), 5.54 (d, 2H, J = 10.3 Hz), 4.96 (dd, 
1H, J = 17.2, 1.6 Hz), 4.90 (dd, 1H, J = 10.2, 1.2 Hz), 3.24 (s, 3H), 2.55 (d, 1H, J = 23.3 Hz), 
2.36 (d, 1H, J = 23.3 Hz), 1.96 – 1.84 (m, 2H), 1.80 – 1.76 (m, 2H) ppm. 13C NMR (101 MHz, 
DMSO) δ 170.1, 145.6, 139.4, 137.9, 131.4, 129.9, 129.7, 127.8, 125.5, 121.7, 118.6 (q, J = 322 
Hz), 114.5 ppm. 19F NMR (376 MHz, DMSO) δ -73.60 (s) ppm. EI MS, m/z: 414 (1), 360 (3), 



























































trifluoromethanesulfonate: Using the general procedure outlined above using 1-(sec-butyl)-N-
(2-hydroxyphenyl)-N-methylcyclohexa-2,5-diene-1-carboxamide (0.71 g, 2.50 mmol) ), the 
crude reaction mixture was purified using column flash chromatography (silica gel, 60Å) with 
20% ethyl acetate/80% hexanes (Rf = 0.41) yielding 0.40 g (38%) of a yellow oil. 
1H NMR (400 
MHz, DMSO) δ 7.50-7.36 (m, 4H), 5.53 (s, 2H), 5.38 (s, 2H), 3.16 (s, 3H), 2.43 (d, 1H, J = 22.4 
Hz), 2.25 (d, 1H, J = 22.8 Hz), 2.09-2.02 (m, 1H), 1.45-1.38 (m, 1H), 0.86-0.82 (m, 4H), 0.73 (d, 
3H, J = 6.7 Hz) ppm. 13C NMR (101 MHz, DMSO) δ 173.8, 145.7, 137.9, 131.5, 130.0, 129.7, 
127.3, 126.9, 125.8, 125.4, 121.7, 118.6 (d, J = 311 Hz) 54.6, 43.3, 40.0, 26.5, 24.8, 14.1, 12.9 
ppm. 19F NMR (376 MHz, DMSO) δ -73.63 (s) ppm. EI MS, m/z: 417 (4), 360 (74), 284 (61), 



















































Figure 159: 19F NMR of compound 67 
 
2-(1-(but-3-yn-1-yl)-N-methylcyclohexa-2,5-diene-1-carboxamido)phenyl 
trifluoromethanesulfonate: Using the general procedure and workup outlined above with 1-(but-
3-yn-1-yl)-N-(2-hydroxyphenyl)-N-methylcyclohexa-2,5-diene-1-carboxamide (0.13 g, 0.32 
mmol), the crude reaction mixture was purified using column flash chromatography (silica gel, 
60Å) with 20% ethyl acetate/80% hexanes (Rf = 0.39) and 0.74 g (12%) of a yellow solid was 
isolated. 1H NMR (400 MHz, DMSO) δ 7.36-7.28 (m, 4H), 6.06-5.26 (m, 4H), 3.29 (s, 3H), 
2.84-2.27 (m, 2H), 2.07 (s, 4H) ppm. EI MS, m/z: 412 (3), 360 (3), 308 (5), 284 (35), 264 (8), 
218 (7), 176 (1), 149 (53), 131 (30), 115 (8), 91 (100), 65 (9). 
-C13CPD was too dilute. This data was taken prior to the discovery that DMSO and elevated 




















Figure 160: 1H NMR of compound 68 
 
2-(N,1-dimethylcyclohexa-2,5-diene-1-carboxamido)phenyl trifluoromethanesulfonate: Using 
the general procedure and workup outlined above with N-(2-hydroxyphenyl)-N,1-
dimethylcyclohexa-2,5-diene-1-carboxamide (3.07 g, 12.61 mmol), the crude reaction mixture 
was purified using column flash chromatography (silica gel, 60Å) with 20% ethyl acetate/80% 
hexanes (Rf = 0.24) and 4.16 g (88%) of an orange solid was isolated. m.p. = 60.2-65.4˚C. 
1H 
NMR (400 MHz, DMSO) δ 7.54-7.49 (m, 3H), 7.42 (d, 1H, J = 7.8 Hz), 5.88 (s, 2H), 5.69 (d, 
2H, J = 8.5 Hz), 3.25 (s, 3H), 2.80 (s, 3H), 2.65 (d, 1H, J = 22.2 Hz), 2.37 (d, 1H, J = 21.6 Hz) 
ppm. 13C NMR (101 MHz, DMSO) δ 173.3, 145.6, 131.3, 129.8, 129.7, 129.6, 124.0, 121.7, 
117.1, 45.7, 39.6, 29.2, 25.9 ppm. 19F NMR (376 MHz, DMSO) δ -73.61 (s) ppm. EI MS, m/z: 



























































Figure 163: 13C NMR of compound 69 
6.3.4 Mizoroki-Heck Reaction General procedures and data 
 
 
Scheme 34: Palladium catalyzed Mizoroki-Heck general procedure 
A flame dried vial under argon was charged with aryl triflate diene (1.0 eq) which was 
dissolved in DMF. In a separate flame dried vial with a stir bar, under argon, Pd(OAc)2 (0.2 eq) 
and (R or racemic) BINAP (0.24 eq) was dissolved in DMF and stirred for 1 hour. To the 
palladium mixture, Cy2NMe (2.0 eq) was added and the solution was stirred for an additional 10 
minutes. The aryl triflate diene was then added to the Pd/Cy2NMe vial via syringe. Finally, 
lithium acetate (2.0 eq) was added to the vial. The vial was capped with a pressure relief cap and 
stirred at 80˚C. Upon completion the reaction mixture was filtered using a pipet pack with 




compound off the celite and silica gel. The organic layer was concentrated in vacuo and 
columned on silica gel. 
 
 
6a-benzyl-5-methyl-6a,10a-dihydrophenanthridin-6(5H)-one: Using the general procedure 
outlined above with 2-(1-benzyl-N-methylcyclohexa-2,5-diene-1-carboxamido)phenyl 
trifluoromethanesulfonate (0.0741 g, 0.16 mmol), the crude reaction mixture was purified using 
column flash chromatography (silica gel, 60Å) using a gradient solvent from 0% to 20% ethyl 
acetate in hexanes (Rf = 0.30) and 0.0402 g (92%) of a yellow cloudy oil was isolated.  1H NMR 
(400 MHz, CDCl3) δ 7.30 (dtd, J = 945.6, 7.8, 1.7 Hz, 1H), 7.28 – 7.14 (m, 4H), 7.10 (td, 1H, J = 
7.4, 1.1 Hz), 7.00 (ddd, 3H, J = 10.7, 8.3, 1.4 Hz), 6.11 – 5.99 (m, 2H), 5.95 (dddd, 1H, J = 9.2, 
4.5, 2.8, 1.4 Hz), 5.55 (ddt, 1H, J = 9.3, 3.1, 1.0 Hz), 3.60 (t, 1H, J = 3.0 Hz), 3.38 (s, 3H), 2.95 
(d, 1H, J = 13.3 Hz), 2.83 (d, 1H, J = 13.4 Hz) ppm. 13C NMR (101 MHz, CDCl3) δ 172.6, 
139.2, 136.6, 130.6, 130.5, 128.6, 128.3, 128.2, 127.8, 126.7, 126.2, 125.0, 124.7, 123.5, 114.3, 
46.7, 41.3, 40.1, 30.0 ppm. EI MS, m/z: 301 (1), 210 (100), 195 (27), 180 (9), 167 (11), 152 (11), 
139 (2), 127 (2), 115 (3), 91 (11), 77 (2), 65 (4), 51 (1). HPLC: CHIRALCEL OD-H 4.6mm x 
250 mm, 5μm column, 20 μL injection, 97.5: 2.5 Hex:IPA, 1mL/min, 30 min, 210 nm VWD 





Figure 164: R-BINAP HPLC data for compound 69 
Racemic BINAP: 97% yield yellow cloudy oil 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 
Hex:IPA, 1mL/min, 30 min, 210 nm VWD UV. tR1 =12.57 min., Area (mAU) = 5476.50; tR2 = 






Figure 165: Racemic BINAP HPLC data for compound 69 
R-BINAP data using Pd(TFA)2: 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 
Hex:IPA, 1mL/min, 30 min, 210 nm VWD UV. tR1 =11.68 min., Area (mAU) = 5639.12; tR2 = 
19.507 min., Area (mAU) =56940.2; er = 1:10 
 
 
# Time Area 
1 11.675 5639.1 
2 19.507 56940.2 


























































3-((5-methyl-6-oxo-5,10a-dihydrophenanthridin-6a(6H)-yl)methyl)benzonitrile: Using the 
general procedure and workup outlined above with 2-(1-(3-cyanobenzyl)-N-methylcyclohexa-
2,5-diene-1-carboxamido)phenyl trifluoromethanesulfonate (0.084 g, 0.18 mmol), the crude 
reaction mixture was purified using column flash chromatography (silica gel, 60Å) using a 
gradient solvent from 0% to 30% ethyl acetate in hexanes (Rf = 0.30) and 0.034 g (58%) of 
a cloudy white solidified oil was isolated. m.p. = 60.2-63.9˚C. 1H NMR (400 MHz, CDCl3) δ 
7.47 (dt, 1H, J = 7.5, 1.5 Hz), 7.36 – 7.26 (m, 4H), 7.18 (dd, 1H, J = 7.5, 1.7 Hz), 7.11 (td, 1H, J 
= 7.4, 1.1 Hz), 6.94 (dd, 1H,  J = 8.2, 1.1 Hz), 6.11 (dd, 1H, J = 9.4, 5.1 Hz), 6.03 (dddd, 1H, J = 
8.9, 5.2, 2.6, 1.0 Hz), 5.92 (dd, 1H, J = 9.4, 0.9 Hz), 5.66 (dd, 1H, J = 9.4, 3.5 Hz), 3.50 (t, 1H, J 
= 3.0 Hz), 3.36 (s, 3H), 2.97 (q, 2H, J = 13.4 Hz) ppm. 13C NMR (101 MHz, CDCl3) δ 171.6, 
139.0, 138.2, 134.9, 133.9, 130.5, 129.7, 128.9, 128.2, 128.1, 127.9, 125.6, 125.5, 125.0, 123.7, 
118.8, 114.3, 112.2, 46.7, 41.0, 39.9, 30.1 ppm. EI MS, m/z: 326 (4), 210 (100), 195 (25), 180 
(11), 167 (11), 152 (13), 139 (3), 116 (6), 89 (4), 77 (2), 63 (2), 51 (1). HPLC: CHIRALCEL 
OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 Hex:IPA, 1mL/min, 30 min, 
210 nm VWD UV. tR1 = 10.677 min., Area (mAU) = 9330; tR2 = 11.735 min., Area (mAU) = 883; 






Figure 169: R-BINAP HPLC data for compound 70 
 
 
Racemic BINAP: 57% of a white solid was isolated. m.p. = 145.2-148.8˚C. 
 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 
2.5 Hex:IPA, 1mL/min, 20 min, 210 nm VWD UV. tR1 = 11.063 min., Area (mAU) 
















































Figure 172: 13C NMR of compound 70 
 
 
2-(5-methyl-6-oxo-5,10a-dihydrophenantridin-6a(6H)-yl)acetonitrile: Using the general 
procedure outlined above using 2-(1-(cyanomethyl)-N-methylcyclohexa-2,5-diene-1-
carboxamido)phenyl trifluoromethanesulfonate (0.282 g, 0.70 mmol) and no lithium acetate, the 
crude reaction mixture was purified using an automated column flash chromatography system 
(Biotage column) with 30% ethyl acetate/ 70% hexanes (Rf= 0.23) and 0.170 g (97%) of a 
yellow opaque oil was isolated. FTIR-ATR: 3042, 3012, 2928, 2853, 2247, 1659, 1598, 1498, 
1472, 1498, 1457, 1416, 1365, 1308, 1268, 1076, 1044, 750, 710, 681, 608, 543, 474, 457. 1H 
NMR (400 MHz, CDCl3): 7.34-7.26 (m, 2H), 7.09 (td, 1H, J=7.5, 0.8 Hz), 6.99 (d, 1H, J= 8.1 
Hz), 6.19-6.12 (m, 2H), 6.07 (dd, 1H, J= 9.1, 4.8 Hz), 5.70 (d, 1H, J=9.0 Hz), 3.93 (d, 1H, J=4.8 
Hz), 3.41 (s, 3H), 2.91 (d, 1H, J =16.3 Hz), 2.67 (d, 1H, J=16.3 Hz) ppm. 13C (100 MHz, CDCl3) 
169.3, 139.0, 128.4, 127.8, 127.0, 126.9, 126.5, 125.2, 124.4, 123.8, 117.1, 114.4, 44.6, 38.4, 




152 (12), 139, (4), 127 (2), 115 (3), 104 (3), 89 (2), 77 (4), 63 (3), 51 (2). HPLC: CHIRALCEL 
OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 Hex:IPA, 1mL/min, 60 min, 
210 nm VWD UV. tR1 =44.77 min., Area (mAU) = 7213; tR2 = 53.53 min., Area (mAU) = 68196; 
er = 1:9 
 
 
Figure 173: R-BINAP HPLC data for compound 71 
 
 
Racemic BINAP: 83% of a light yellow oily solid was isolated. m.p. = 118.3-121.8°C. 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 
Hex:IPA, 1mL/min, 60 min, 210 nm VWD UV. tR1 =45.94 min., Area (mAU) = 23396; tR2 = 



























































6a-isobutyl-5-methyl-6a,10a-dihydrophenanthridin-6(5H)-one: Using the general procedure 
outlined above using 2-(1-isobutyl-N-methylcyclohexa-2,5-diene-1-carboxamido)phenyl 
trifluoromethanesulfonate (0.111 g, 0.27 mmol), the crude reaction mixture was purified using an 
automated column flash chromatography system with 20% ethyl acetate/ 80% hexanes (Rf= 
0.33) and 0.0591 g (83%) of a light yellow opaque oil was isolated. 1H NMR (400 MHz, CDCl3) 
δ 7.30 (d, 1H, J = 7.9 Hz), 7.20 (dd, 1H, J = 7.4, 1.6 Hz), 7.08 (td, 1H, J = 7.4, 1.1 Hz), 6.97 (d, 
1H, J = 7.0 Hz), 6.12 (dd, 1H, J = 9.3, 5.3 Hz), 6.02 – 5.96 (m, 2H), 5.53 (ddt, 1H, J = 9.3, 2.3, 
1.1 Hz), 3.68 (t, 1H, J = 2.8 Hz), 3.34 (s, 3H), 1.83 (ddt, 1H, J = 13.4, 11.4, 6.7 Hz), 1.42 (qd, 
2H, J = 14.1, 5.9 Hz), 0.84 (dd, 6H, J = 14.4, 6.7 Hz) ppm. 13C (100 MHz, CDCl3) 173.1, 139.1, 
131.7, 128.6, 128.5, 127.8, 126.7, 125.1, 124.0, 123.3, 114.2, 44.7, 43.8, 41.9, 29.8, 24.7, 24.4, 
23.8 ppm. EI MS, m/z: 266 (25), 250 (1), 224 (10), 210 (100), 195 (17), 180 (12), 167 (10), 152 
(8), 141 (1), 131 (2), 115 (2), 104 (1), 91 (1), 77 (2), 63 (1). HPLC: CHIRALCEL OD-H 4.6mm 
x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 Hex:IPA, 1mL/min, 30 min, 210 nm VWD 
UV. tR1 =7.30 min., Area (mAU) = 9110; tR2 = 8.00 min., Area (mAU) = 1266; er = 7:1 
 
 
Figure 177: R-BINAP HPLC data for compound 72 
 
Racemic BINAP: 68% of a light-yellow solidified oil was isolated.  
 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 
Hex:IPA, 1mL/min, 20 min, 210 nm VWD UV. tR1 =7.25 min., Area (mAU) = 6500; tR2 = 7.92 
















































Figure 180: 13C NMR of compound 72 
 
6a-cyclohexyl-5-methyl-6a,10a-dihydrophenanthridin-6(5H)-one: Using the general procedure 
and workup outlined above with 2-(N-methyl-[1,1'-bi(cyclohexane)]-2,5-diene-1-
carboxamido)phenyl trifluoromethanesulfonate (0.064 g, 0.15 mmol), the crude reaction mixture 
was purified using an automated column flash chromatography system with 20% ethyl acetate/ 
80% hexanes (Rf= 0.35) and 0.064 g (59%) of a cloudy oil was isolated. 1H NMR (400 MHz, 
CDCl3) δ 7.30 (td, 1HJ = 7.9, 1.7 Hz,), 7.19 (dd, 1H, J = 7.4, 1.6 Hz), 7.07 (td, 1H, J = 7.4, 1.1 
Hz), 6.97 (dd, 1H, J = 8.1, 1.1 Hz), 6.15 (dd, 1H, J = 9.6, 5.1 Hz), 6.02 – 5.93 (m, 2H), 5.48 (dd, 
1H, J = 9.5, 2.2 Hz), 3.85 (s, 1H), 3.35 (s, 3H), 1.76 – 1.63 (m, 2H), 1.55 (s, 6H), 1.49 – 1.24 (m, 
4H), 1.12 – 0.79 (m, 4H) ppm. 13C NMR (101 MHz, CDCl3) δ 172.4, 139.3, 129.2, 128.6, 128.4, 
127.7, 127.0, 124.9, 124.6, 123.3, 114.2, 48.7, 40.5, 40.2, 29.8, 28.7, 28.3, 26.8, 26.4, 26.2 ppm. 
EI MS, m/z: 293 (7), 210 (100), 195 (11), 180 (4), 167 (6), 152 (4), 139 (1), 115 (1), 91 (1), 77 




2.5 Hex:IPA, 1mL/min, 20 min, 210 nm VWD UV. tR1 = 8.445 min., Area (mAU) = 13749; tR2 =  






Figure 181: R-BINAP HPLC data for compound 73 
 
Racemic BINAP: 57% of a cloudy oil was isolated. 
 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 
Hex:IPA, 1mL/min, 20 min, 210 nm VWD UV. tR1 = 8.434 min., Area (mAU) = 8127; tR2 = 
















































6a-(methoxymethyl)-5-methyl-6a,10a-dihydrophenanthridin-6(5H)-one: Using the general 
procedure and workup outlined above with 2-(1-(methoxymethyl)-N-methylcyclohexa-2,5-
diene-1-carboxamido)phenyl trifluoromethanesulfonate (0.084 g, 0.21 mmol), the crude reaction 
mixture was purified using an automated column flash chromatography system with 30% ethyl 
acetate/ 70% hexanes (Rf= 0.35) and 0.047 g (88%) of a yellow cloudy oil was isolated. 1H 
NMR (400 MHz, CDCl3) δ 7.33 – 7.22 (m, 2H), 7.07 (td, 1H, J = 7.5, 1.1 Hz), 6.96 (d, 1H, J = 
8.1 Hz), 6.14 – 6.08 (m, 1H), 6.05 (dddd, 1H, J = 8.8, 5.1, 2.3, 1.1 Hz), 5.84 – 5.75 (m, 2H), 3.97 
(t, 1H, J = 3.2 Hz), 3.52 (d, 1H, J = 8.8 Hz), 3.42 (d, 1H, J = 8.8 Hz), 3.37 (s, 3H), 3.31 (s, 3H) 
ppm. 13C NMR (101 MHz, CDCl3) δ 170.7, 139.1, 128.1, 127.7, 127.6, 127.4, 126.1, 125.7, 
124.6, 123.3, 114.1, 73.3, 59.4, 47.3, 36.7, 30.1 ppm. HPLC: CHIRALCEL OD-H 4.6mm x 250 
mm, 5μm column, 20 μL injection, 97.5: 2.5 Hex:IPA, 1mL/min, 30 min, 210 nm VWD UV. tR1 




Figure 185: R-BINAP HPLC data for compound 74 
 
Racemic BINAP: 77% of a yellow cloudy oil was isolated. 
 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 
Hex:IPA, 1mL/min, 30 min, 210 nm VWD UV. tR1 = 18.661 min., Area (mAU) =7062; tR2 =  





















































Figure 188: 13C NMR of compound 74 
 
5-methyl-6a-(naphthalen-1-ylmethyl)-6a,10a-dihydrophenanthridin-6(5H)-one: Using the 
general procedure and workup outlined above with 2-(N-methyl-1-(naphthalen-1-
ylmethyl)cyclohexa-2,5-diene-1-carboxamido)phenyl trifluoromethanesulfonate (0.066 g, 0.13 
mmol) , the crude reaction mixture was purified using an automated column flash 
chromatography system with 20% ethyl acetate/ 80% hexanes (Rf= 0.21) and 0.030 g (65%) of a 
cloudy oil was isolated. 1H NMR (400 MHz, CDCl3) δ 7.74 (dd, 2H, J = 29.1, 8.0 Hz), 7.65 (d, 
1H, J = 9.3 Hz), 7.41 (d, 2H, J = 5.5 Hz), 7.32 (t, 1H, J = 7.0 Hz), 7.27 – 7.18 (m, 4H), 7.06 (d, 
1H, J = 7.0 Hz), 6.99 (t, 1H, J = 7.4 Hz), 6.86 (d, 1H, J = 9.2 Hz), 6.13 (d, 1H, J = 10.4 Hz), 6.02 
(d, 1H, J = 9.0 Hz), 5.95 (d, 1H, J = 8.3 Hz), 5.48 (d, 1H, J = 9.2 Hz), 3.75 (s, 1H), 3.46 (d, 1H, J 




138.9, 133.8, 132.9, 132.7, 130.2, 129.0, 128.7, 128.7, 128.7, 127.7, 127.7, 126.4, 125.5, 125.3, 
125.0, 124.5, 124.2, 124.1, 123.3, 114.0, 46.7, 41.7, 38.1, 30.0 ppm. EI MS, m/z: 209 (100), 178 
(23), 166 (4), 152 (16), 141 (51), 127 (2), 115 (16), 104 (4), 90 (4), 76 (5), 63 (5), 51 (3). HPLC: 
CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 Hex:IPA, 
1mL/min, 30 min, 210 nm VWD UV. tR1 = 19.651 min., Area (mAU) = 1650; tR2 =  24.085 min., 
Area (mAU) = 13818; e.r. = 1:8 
 
- GCMS will not show the correct mass for the product due to degradation of the 




Figure 189: R-BINAP HPLC data for compound 75 
Racemic BINAP: 0.030 g (57%) of a cloudy white oil was isolated. 
 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 
Hex:IPA, 1mL/min, 30 min, 210 nm VWD UV. tR1 = 19.543 min., Area (mAU) = 6211; tR2 = 


























































6a-(but-3-en-1-yl)-5-methyl-6a,10a-dihydrophenanthridin-6(5H)-one: Using the general 
procedure and workup outlined above with 2-(1-(3-cyanobenzyl)-N-methylcyclohexa-2,5-diene-
1-carboxamido)phenyl trifluoromethanesulfonate (0.060 g, 0.14 mmol), the crude reaction 
mixture was purified using an automated column flash chromatography system with 20% ethyl 
acetate/ 80% hexanes (Rf= 0.36) and 0.021 g (55%) of a clear colorless oil was isolated. 1H 
NMR (400 MHz, CDCl3) δ 7.26 (dt, 1H, J = 7.8, 1.6 Hz), 7.22 (dd, 1H, J = 7.4, 1.4 Hz), 7.08 (td, 
1H, J = 7.4, 1.0 Hz), 6.98 (d, 1H, J = 8.2 Hz), 6.15 (dd, 1H, J = 9.5, 5.2 Hz), 6.01 (dddd, 1H, J = 
9.3, 5.2, 3.1, 1.0 Hz), 5.95 (dd, 1H, J = 9.5, 0.8 Hz), 5.67 (ddt, 1H, J = 17.0, 10.3, 6.4 Hz), 5.54 
(dd, 1H, J = 9.2, 2.6 Hz), 4.96-4.87 (m, 2H), 3.67 (s, 1H), 3.35 (s, 3H), 2.16 – 1.97 (m, 2H), 1.70 
– 1.62 (m, 1H), 1.59 – 1.48 (m, 5H) ppm. 13C NMR (101 MHz, CDCl3) δ 160.1, 139.0, 137.8, 
130.2, 128.7, 128.6, 127.9, 126.3, 125.1, 124.9, 123.4, 114.9, 114.3, 44.7, 41.5, 34.2, 29.9, 29.0 
ppm. EI MS, m/z: 265 (19), 248 (5), 236 (15), 224 (14), 210 (100), 195 (25), 180 (23), 167 (16), 
152 (14), 139 (3), 128 (3), 115 (4), 104 (1), 91 (2), 77 (4), 63 (1), 51 (1). HPLC: CHIRALCEL 
OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 Hex:IPA, 1mL/min, 30 min, 
210 nm VWD UV. tR1 = 9.032 min., Area (mAU) = 1755.4; tR2 = 9.697 min., Area (mAU) = 
144.3; er = 12:1 
 
 
Figure 193: R-BINAP HPLC data for compound 76 
 
Racemic BINAP: 67% of a yellow cloudy oil was isolated. 
 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 
Hex:IPA, 1mL/min, 15 min, 210 nm VWD UV. tR1 = 8.93 min., Area (mAU) = 4715; tR2 = 9.49 























































Figure 196: 13C NMR of compound 76 
 
8-methyl-4-methylene-3a,4,5,6,8,12b-hexahydrocyclopenta[h]phenanthridin-7(1H)-one: 0.0056 
g (14%) of a white solidified oil was isolated. 1H NMR (400 MHz, CDCl3) δ 7.28 (td, 1H, J = 
7.8, 4.0 Hz), 7.16 (dd, 1H, J = 7.3, 1.5 Hz), 7.03 (dt, 1H, J = 7.4,1.0 Hz), 6.99 (d, 1H, J = 8.1 
Hz), 6.06- 6.02 (m, 1H), 5.70 (qt, 1H, J = 5.2, 2.0 Hz), 4.98-4.96 (m, 1H), 4.88 (q, 1H, J = 2.4 
Hz), 3.93 (s, 1H), 3.39 (s, 3H), 2.76 (dd, 1H, J = 11.5, 5.7 Hz), 2.54-2.39 (m, 2H), 2.18 (dt, 1H, J 
= 17.9, 5.2 Hz), 2.01 (qq, 1H, J= 11.5, 2.4 Hz), 1.70-1.58 (m, 2H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 154.0, 139.0, 129.2, 128.3, 127.6, 127.3, 124.4, 123.0, 114.8, 106.9, 50.1, 44.6, 36.9, 
31.2, 30.1, 30.0, 29.9 ppm. EI MS, m/z: 265 (100), 250 (58), 236 (29), 222 (9), 210 (5), 194 (6), 
184 (9), 172 (13), 159 (6), 144 (15), 130 (6), 115 (9), 103 (4), 91 (9), 77 (10), 65 (3), 51 (3). 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 
Hex:IPA, 1mL/min, 15 min, 210 nm VWD UV. tR1 = 5.165 min., Area (mAU) = 539; tR2 = 5.344 






Figure 197: R-BINAP HPLC data for compound 77 
 
Racemic BINAP: 14% of a white solidified oil was isolated. 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 
Hex:IPA, 1mL/min, 15 min, 210 nm VWD UV. tR1 = 7.78 min., Area (mAU) = 2430; tR2 = 8.03 


































































Figure 201: COSY NMR of compound 77 
 




















Figure 202: COSY NMR of compound 77 
 
X-ray crystallography of compound 77: 
Crystals were grown by crystallizing the sample by dissolving 4.6 mg of compound 82 in 110 μL 
acetonitrile in a small vial. This vial was placed in a larger vial filled with hexanes (110 μL) and 
was left until crystals were formed. The crystals were long thin and colorless and were stacked in 

























Volume 1406.86(15) 1406.86(15) 
Space group P 21 21 21 P 21 21 21 
Hall group P 2ac 2ab P 2ac 2ab 
Moiety formula C18 H19 N O C18 H19 N O 
Sum formula C18 H19 N O C18 H19 N O 
Mr 265.34 265.34 
Dx,g cm-3 1.253 1.253 
Z 4 4 
Mu (mm-1) 0.599 0.599 
F000 568.0 568.0 
F000’ 569.54  
h,k,lmax 8,15,20 8,15,20 
Nref 2909[ 1692] 2889 
Tmin,Tmax 0.944,0.965 0.701,0.754 
Tmin’ 0.880  
 
Correction method= # Reported T Limits: Tmin=0.701 Tmax=0.754 
AbsCorr = MULTI-SCAN 
 
Data completeness= 1.71/0.99 Theta(max)= 75.265 
R(reflections)= 0.0288( 2770) wR2(reflections)= 0.0738( 2889) 





The following ALERTS were generated. Each ALERT has the format 
test-name_ALERT_alert-type_alert-level. 
Click on the hyperlinks for more details of the test. 
 
Alert level C 
PLAT089_ALERT_3_C Poor Data / Parameter Ratio (Zmax < 18) ........ 6.56 Note 
PLAT911_ALERT_3_C Missing FCF Refl Between Thmin & STh/L= 0.600  2 Report 
 
Alert level G 
PLAT791_ALERT_4_G Model has Chirality at C2 (Sohnke SpGr) R Verify 
 
Author Response: On close inspection of the connectivity and application of CIP rules, 
C2=S, C3=R, C13=R. 
 
PLAT791_ALERT_4_G Model has Chirality at C3 (Sohnke SpGr) R Verify 
 
Author Response: On close inspection of the connectivity and application of CIP rules, 
C2=S, C3=R, C13=R. 
 
PLAT791_ALERT_4_G Model has Chirality at C13 (Sohnke SpGr) R Verify 
 
Author Response: On close inspection of the connectivity and application of CIP rules, 
C2=S, C3=R, C13=R. 
 
PLAT912_ALERT_4_G Missing # of FCF Reflections Above STh/L= 0.600 5 Note 
PLAT913_ALERT_3_G Missing # of Very Strong Reflections in FCF .... 1 Note 
PLAT933_ALERT_2_G Number of OMIT Records in Embedded .res File ... 3 Note 
PLAT978_ALERT_2_G Number C-C Bonds with Positive Residual Density. 9 Info 
 
0 ALERT level A = Most likely a serious problem - resolve or explain 
0 ALERT level B = A potentially serious problem, consider carefully 
2 ALERT level C = Check. Ensure it is not caused by an omission or oversight 





0 ALERT type 1 CIF construction/syntax error, inconsistent or missing data 
2 ALERT type 2 Indicator that the structure model may be wrong or deficient 
3 ALERT type 3 Indicator that the structure quality may be low 
4 ALERT type 4 Improvement, methodology, query or suggestion 
0 ALERT type 5 Informative message, check 
  
 

















6a-(sec-butyl)-5-methyl-6a,10a-dihydrophenanthridin-6(5H)-one:  Using the general procedure 
and workup outlined above with 2-(1-(sec-butyl)-N-methylcyclohexa-2,5-diene-1-
carboxamido)phenyl trifluoromethanesulfonate (0.15 g, 0.36 mmol). The crude reaction mixture 
was purified using column flash chromatography (silica gel, 60Å) with 80% hexanes/ 20% ethyl 
acetate (Rf = 0.31) and 0.0253 g (26%) of a cloudy yellow oil was isolated.  1H NMR (400 MHz, 
CDCl3) δ 7.30 (tt, 1H, J = 7.5, 1.8 Hz), 7.19 (ddd, 1H, J = 7.3, 3.2, 1.6 Hz), 7.07 (tdd, 1H, J = 
7.3, 2.9, 1.1 Hz), 6.97 (dt, 1H, J = 8.2, 1.6 Hz), 6.17 (td, 1H, J = 9.2, 4.9 Hz), 5.99 (dddd, 1H, J = 
10.8, 6.0, 2.3, 1.0 Hz), 5.94 (dt, 1H, J = 9.7, 1.2 Hz), 5.49 (dtd, 1H, J = 9.4, 2.6, 1.0 Hz), 3.88 (s, 
1H), 3.36 (d, J = 1.0 Hz, 4H), 1.56 – 1.33 (m, 1H), 0.99 – 0.81 (m, 3H), 0.86 – 0.72 (m, 4H) 
ppm. 13C NMR (101 MHz, CDCl3) δ129.2, 128.4, 128.3, 128.2, 128.0, 127.8, 127.7, 127.0, 
125.3, 125.1, 125.0, 124.8, 123.3, 114.2, 114.2, 41.1, 40.7, 37.4, 36.9, 29.9, 29.8, 25.0, 24.5, 
14.8, 14.2, 12.6, 12.5. EI MS, m/z: 267 (1), 238 (2), 210 (100), 195 (18), 180 (8), 167 (9), 152 
(7), 139 (2), 127 (1), 115 (2), 77 (2). HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm 
column, 20 μL injection, 97.5: 2.5 Hex:IPA, 1mL/min, 20 min, 210 nm VWD UV. tR1 = 7.778 




Figure 205: R-BINAP HPLC data for compound 78 
 
 
Racemic BINAP: 0.0403 g (47%) of a cloudy white oil was isolated. 
 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 
2.5 Hex:IPA, 1mL/min, 20 min, 210 nm VWD UV. tR1 = 7.734 min., Area (mAU) = 3391; tR2 = 

































Figure 208: 13C NMR of compound 78 
 
6.3.5 MOM Protection of Secondary Benzamides General Procedures and Data 
 
Scheme 35: MOM protection procedure 
Unwashed NaH (60% dispersion in mineral oil) (1.10 eq) was added to a flame 
dried roundbottom flask in the glovebox and a septum was added to seal the flask. The 
roundbottom flask was removed from the glovebox and was placed in an ice bath. Anhydrous 
THF from the still was then added to the roundbottom flask and the solution was stirred for 1 h. 
Then, methylchloromethyl ether (2.0 eq) was added slowly at 0˚C. After a few minutes of 
stirring, the flask was removed from the bath and and the mixture was stirred overnight at room 






carboxamido)phenyl trifluoromethanesulfonate: Using the general procedure and workup 
outlined above with 2-(1-benzylcyclohexa-2,5-diene-1-
carboxamido)phenyl trifluoromethanesulfonate (1.55 g, 3.53 mmol), the crude reaction mixture 
was purified using an automated column flash chromatography system with 20% ethyl acetate/ 
80% hexanes (Rf= 0.36) and  0.96 g (56%) of a white solidified oil was isolated. 1H NMR (400 
MHz, DMSO) δ 7.52 – 7.46 (m, 1H), 7.41 – 7.29 (m, 3H), 7.13 (td, 3H, J = 5.8, 2.8 Hz), 7.06 – 
7.04 (m, 2H), 5.55 (d, 2H, J = 10.0 Hz), 5.46 (d, 2H, J = 10.0 Hz), 4.90 (s, 1H), 3.23 (s, 3H), 
3.02 (s, 2H), 2.11 (d, 1H, J = 23.5 Hz), 1.95 (d, 1H, J = 23.0 Hz) ppm. 13C NMR (101 MHz, 
DMSO) δ 174.0, 146.0, 137.5, 132.9, 131.5, 130.4, 129.1, 128.0, 127.6, 126.3, 125.4, 121.3, 
81.2, 56.5, 46.5, 25.8 ppm. 19F NMR (376 MHz, DMSO) δ -73.63 (s). EI MS, m/z: 481 (0.1), 
449 (3), 389 (2), 358 (7), 314 (2), 282 (5), 253 (15), 196 (3), 168 (23), 134 (1), 105 (100), 77 (1), 






















































carboxamido)phenyl trifluoromethanesulfonate: Using the general procedure and workup 
outlined above with 2-(1-(cyanomethyl)cyclohexa-2,5-diene-1-
carboxamido)phenyl trifluoromethanesulfonate (1.52 g, 3.94 mmol).  1.02g (60%) of a cloudy 
yellow oil was isolated. 1H NMR (400 MHz, DMSO) δ 7.55 – 7.39 (m, 4H), 5.81 (s, 2H), 5.67 
(d, 2H, J = 9.8 Hz), 4.88 (s, 2H), 3.24 (s, 3H), 2.79 (s, 2H), 2.60 (d, 1H, J = 23.4 Hz), 2.30 
(d, 1H, J = 23.5 Hz) ppm. 13C NMR (101 MHz, DMSO) δ 171.8, 145.9, 133.9, 133.1, 130.8, 
129.2, 127.9, 125.3, 121.4, 118.6 (d, J = 322), 117.9, 81.2, 56.5, 48.2, 30.1, 26.2 ppm. 19F NMR 
(376 MHz, DMSO) δ -73.55 (s) ppm. EI MS, m/z: 399.1 (1), 270 (1), 253 (38), 196 (1), 164 
























































6.3.6 MOM Protected Mizoroki Heck Reaction General Procedures and Data 
 
 
Scheme 36: MOM Heck reaction general procedure 
A flame dried vial under argon was charged with aryl triflate diene (1.0 eq) which was dissolved 
in DMF. In a separate flame dried vial with a stir bar, under argon, Pd(OAc)2 (0.2 eq) and (R or 
racemic) BINAP (0.24 eq) was dissolved in DMF and stirred for 1 hour. To the palladium 
mixture, Cy2NMe (2.0 eq) was added and the solution was stirred for an additional 10 minutes. 
The aryl triflate diene was then added to the Pd/Cy2NMe vial via syringe. Finally, lithium 
acetate (2.0 eq) was added to the vial for the benzyl derivative only. The vial was capped with a 
pressure relief cap and stirred at 80˚C. Upon completion the reaction mixture was filtered using a 
pipet pack with cotton, followed by silica gel, and topped with celite. Excess EtOAc was used to 
rinse any compound off the celite and silica gel. The organic layer was concentrated in vacuo 
and columned on silica gel. 
  
6a-benzyl-5-(methoxymethyl)-6a,10a-dihydrophenanthridin-6(5H)-one: Using the general 
procedure and workup outlined above with 2-(1-benzyl-N-(methoxymethyl)cyclohexa-2,5-diene-
1-carboxamido)phenyl trifluoromethanesulfonate (0.12 g, 0.24 mmol). The crude reaction 
mixture was purified using column flash chromatography (silica gel, 60Å) with 80% hexanes/ 
20% ethyl acetate (Rf = 0.38) and 0.065 g (81%) of a cloudy white oil was isolated. 1H NMR 
(400 MHz, CDCl3) δ 7.35 – 7.13 (m, 7H), 7.03 – 7.01 (m, 2H), 6.11 – 6.04 (m, 2H), 5.94 
(dddd, 1H, J = 9.2, 4.6, 3.0, 1.4 Hz), 5.59 (d, 1H, J = 10.6 Hz), 5.55 (dd, 1H, J = 9.4, 2.9 Hz), 
5.18 (d, 1H, J = 10.6 Hz), 3.59 (t, 1H, J = 3.0 Hz), 3.39 (s, 3H), 3.01 (d, 1H, J = 13.3 Hz), 2.86 
(d, 1H, J = 13.4 Hz) ppm. 13C NMR (101 MHz, CDCl3) δ 174.1, 137.9, 136.3, 130.7, 130.2, 
128.7, 128.4, 128.3, 128.1, 126.8, 125.9, 125.3, 124.7, 124.2, 115.6, 74.0, 56.4, 46.8, 40.9, 
40.2 ppm. EI MS, m/z: 331 (0.1), 300 (2), 284 (1), 270 (1), 254 (1), 239 (10), 224 (19), 208 
(100), 196 (16), 178 (29), 165 (6), 152 (8), 139 (3), 127 (1), 115 (2), 91 (49), 77 (3), 65 (5), 51 
(1). HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 
2.5 Hex:IPA, 1mL/min, 20 min, 210 nm VWD UV. tR1 = 8.753 min., Area (mAU) = 8981; tR2 = 







   




Racemic BINAP: 0.0778 g (79%) of a cloudy white oil was isolated. 
 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 
2.5 Hex:IPA, 1mL/min, 40 min, 210 nm VWD UV. tR1 = 8.651 min., Area (mAU) = 2578; tR2 = 
























































2-(5-(methoxymethyl)-6-oxo-5,10a-dihydrophenanthridin-6a(6H)-yl)acetonitrile: Using the 
general procedure and workup outlined above with 2-(1-(cyanomethyl)-N-
(methoxymethyl)cyclohexa-2,5-diene-1-
carboxamido)phenyl trifluoromethanesulfonate (0.062 g, 0.14 mmol).  The crude reaction 
mixture was purified using column flash chromatography (silica gel, 60Å) with 70% hexanes/ 
30% ethyl acetate (Rf = 0.31) and 0.030 g (73%) of a cloudy yellow oil was isolated. 1H NMR 
(400 MHz, DMSO) δ 7.33-7.26 (m, 3H), 7.12 (td, 1H, J = 6.4, 1.6 Hz), 6.20-6.16 (m, 2H), 3.92 
(d, 1H, J = 4.7 Hz), 3.40 (s, 3H), 2.90 (d, 1H, J = 16.4 Hz), 2.69 (d, 1H, J = 16.4 Hz) ppm. 13C 
NMR (101 MHz, DMSO) δ 170.6, 137.7, 128.6, 127.9, 127.3, 127.2, 126.2, 125.2, 124.4, 124.0, 
116.9, 115.7, 74.4, 56.5, 44.7, 38.7, 22.9 ppm. EI MS, m/z: 280 (35), 248 (32), 234 (35), 219 (7), 
208 (79), 192 (100), 180 (73), 165 (41), 152 (24), 139 (9), 127 (4), 115 (5), 102 (2), 90 (15), 77 
(10), 63 (7), 51 (5). HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 
20 μL injection, 97.5: 2.5 Hex:IPA, 1mL/min, 60 min, 210 nm VWD UV. tR1 = 36.55 min., Area 





Figure 219: R-BINAP HPLC data for compound 82 
 
 
Racemic BINAP: 68% of a yellow cloudy oil was isolated. 
 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 
2.5 Hex:IPA, 1mL/min, 60 min, 210 nm VWD UV. tR1 =36.99 min., Area (mAU) = 

















































Figure 222: 13C NMR of compound 82 
 





Scheme 37: MOM deprotection procedure 
Procedure adapted from Fukuyama and Liu.12 To a solution of (Heck Product) in acetonitrile at 
0˚C was added TMS-I (4.6 eq). Then, the mixture was stirred at 0˚C for 1hr. The reaction was 
quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The organic layers were 
combined, washed with brine, dried over magnesium sulfate and concentrated.  The resulting 
crude product was used in the next step. To a solution of crude product in MeOH at room 




reactor. After cooling to room temperature, the reaction was quenched in saturated aq. 
Ammonium chloride and hexane/EtOAc (1:1 mixture) was added. The organic layer was 
separated and the aqueous layer was extracted with hexane. The organic layers were combined, 
washed with brine, dried over magnesium sulfate, and concentrated.   
 
  
6a-benzyl-6a,10a-dihydrophenanthridin-6(5H)-one: Using the general procedure and workup 
outlined above with 6a-benzyl-5-(methoxymethyl)-6a,10a-dihydrophenanthridin-6(5H)-one 
(0.031 g, 0.94 mmol), the crude reaction mixture was purified using an automated column flash 
chromatography system with 20% ethyl acetate/ 80% hexanes (Rf= 0.43) and 0.0156 g (58%) of 
a white solid was isolated. m.p. = 76.4-81.5˚C. 1H NMR (400 MHz, CDCl3) δ 8.45 (s, 1H), 7.27-
7.17 (m, 5H), 7.11-7.04 (m, 3H), 6.76 (d, 1H, J = 7.8 Hz), 6.10 (dd, 1H, J = 9.5, 4.0 Hz), 6.01-
5.97 (m, 2H), 5.63 (dd, J = 9.5, 2.9 Hz, 1H), 3.65 (t, 1H, J = 2.8 Hz), 3.00 (s, 2H) ppm. 13C NMR 
(101 MHz, CDCl3) δ 173.8, 136.5, 136.0, 130.6, 129.3, 128.3, 128.2, 128.1, 127.8, 126.8, 125.4, 
124.6, 124.5, 123.8, 115.1, 46.9, 40.9, 39.9 ppm. EI MS, m/z: 289 (15), 208 (2), 196 (100), 178 
(44), 167 (21), 152 (12), 139 (6), 128 (5), 115 (6), 91 (39), 77 (4), 65 (5), 51 (2). HPLC: 
CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 2.5 Hex:IPA, 
1mL/min, 40 min, 210 nm VWD UV. tR1 = 19.631 min., Area (mAU) = 792; tR2 = 31.14 min., 














Racemic BINAP: 0.014 g (52%) of a clear oil was isolated. 
 
HPLC: CHIRALCEL OD-H 4.6mm x 250 mm, 5μm column, 20 μL injection, 97.5: 
2.5 Hex:IPA, 1mL/min, 40 min, 210 nm VWD UV. tR1 = 19.590 min., Area (mAU) 





























































Figure 226: 13C NMR of compound 83 
 
 
5,6a-dimethyl-6a,10a-dihydrophenanthridin-6(5H)-one: Using the general procedure and workup 
outlined above with N-(2-bromophenyl)-N,1-dimethylcyclohexa-2,5-diene-1-carboxamide 
(0.103 g, 0.33 mmol). The crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 80% hexanes/ 20% ethyl acetate (Rf = 0.27) and 0.003 g 
(4%) of a cloudy oil was isolated. 1H NMR (400 MHz, CDCl3) δ 7.30 (td, 1H, J = 7.8, 1.6 Hz), 
7.23 (dd, 1H, J = 7.4, 1.4 Hz), 7.08 (td, 1H, J = 7.4, 1.1 Hz), 6.99 (d, 1H, J = 8.1 Hz), 6.09 (dd, 
1H, J = 9.2, 5.0 Hz), 6.02 (dddd, 1H, J = 9.2, 5.1, 2.9, 1.0 Hz), 5.89 (dd, 1H, J = 9.3, 0.9 Hz), 
5.58 (dd, 1H, J = 9.3, 2.8 Hz), 3.48 (t, 1H, J = 2.8 Hz), 3.35 (s, 3H), 1.23 (s, 3H) ppm. 13C NMR 
(101 MHz, CDCl3) δ 173.4, 139.0, 131.8, 128.6, 127.8, 126.6, 125.2, 124.2, 123.3, 114.3, 44.3, 
40.8, 29.9, 23.4 ppm. EI MS, m/z: 224 (80), 210 (100), 195 (22), 182 (25), 167 (27), 152 (12), 
139 (5), 128 (4), 115 (7), 104 (3), 91 (5), 77 (6), 63 (5), 51 (4). Spectal data were in accordance 




20 μL injection, 97.5: 2.5 Hex:IPA, 1mL/min, 40 min, 210 nm VWD UV. tR1 = 9.626 min., Area 










































































5,6a-dimethyl-6a,9,10,10a-tetrahydrophenanthridin-6(5H)-one: Using the general procedure and 
workup outlined above with N-(2-bromophenyl)-N,1-dimethylcyclohexa-2,5-diene-1-
carboxamide (0.103 g, 0.33 mmol). The crude reaction mixture was purified using column flash 
chromatography (silica gel, 60Å) with 80% hexanes/ 20% ethyl acetate (Rf = 0.40) and 0.0163 g 
(21%) of an oil was isolated. 1H NMR (400 MHz, CDCl3) δ 7.26 (td, 1H, J = 8.0, 1.6 Hz), 7.17 
(dd, 1H, J = 7.4, 1.5 Hz), 7.03 (td, 1H, J = 7.4, 1.1 Hz), 6.98 (d, 1H, J = 8.1 Hz), 5.74-5.69 (m, 
1H), 5.65-5.60 (m, 1H), 3.37 (s, 3H), 2.96 (dddt, 1H, J = 18.0, 5.0, 2.6, 1.3 Hz), 2.80 (dd, 1H, J = 
10.3, 6.2 Hz), 2.30-2.22 (m, 1H), 2.08-1.98 (m, 1H), 1.91-1.83 (m, 1H), 1.05 (s, 3H) ppm. 13C 
NMR (101 MHz, CDCl3) δ 173.9, 139.0, 129.9, 128.9, 127.4, 127.3, 126.1, 126.1, 124.4, 123.0, 
114.5, 41.6, 40.0, 32.7, 30.0, 29.9, 24.3ppm. EI MS, m/z: 227 (100), 212 (47), 198 (11), 182 (7), 
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